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1 Background
The traditional approach to release of biopharmaceutical products relies on quality-by-
testing, where a series of analytical assays typically measuring quality attributes related 
to product safety and efficacy (i.e. identity, purity, potency, stability) are tested after 
the manufacturing process is completed. The list of disadvantages of this approach is 
long, from limited understanding of the manufacturing processes and consequences of 
deviations on product quality, to extensive documentation and to long lead times for 
product release post-manufacturing (1). To improve this sub-optimal situation, the FDA 
launched several guidelines inviting the (bio)pharmaceutical industry to shift its quality 
paradigm towards the use of Process Analytical Technology (PAT) principles and towards 
implementation of Quality by Design (QbD) rather than quality by testing (2, 3). The 
aim is to increase the level of control of their manufacturing processes and ultimately to 
ensure consistent and high product quality.
Although PAT was launched over a decade ago, biotechnological companies have 
not all embraced this concept and PAT is not always applied to all process steps that 
form the complex train of operation units for the manufacturing of drugs or vaccines. 
In this context, the research described in this thesis has been initiated to apply PAT 
principles to a perfusion PER.C6® cell cultivation process, which is an operation unit 
of a viral vaccine production. This process aims at expanding PER.C6® cultures to high 
cell densities in perfusion mode, to seed the next process step of virus production. The 
quality of the cells used as a substrate for virus propagation was hypothesized to be 
critical for the performance of the virus production process. This thesis therefore focused 
on understanding the critical quality features of PER.C6® cells used for virus production, 
and on identifying an appropriate process monitoring strategy using the PAT principles. 
This research was conducted in collaboration between Crucell (a Janssen Pharmaceutical 
company) and Wageningen University. The structured and systematic application of PAT 
principles has led to the development of new analytical methods and data analysis tools 
used to increase the scientific understanding of the perfusion PER.C6® cultivation process. 
This work is the basis for the design of improved process control strategies.
2 PAT for biopharmaceutical processes
PAT was defined by the FDA as “a system for designing, analyzing, and controlling 
manufacturing through timely measurements (i.e., during processing) of critical quality 
and performance attributes of raw and in-process materials and processes, with the goal 
of ensuring final product quality” (3). PAT is therefore a toolbox for process monitoring, 
control and continuous improvement. QbD is a broader concept stating that the quality 
of a product is built into its production process in order to ensure consistent high product 
quality during manufacturing (2, 4). The basis of QbD is that the product is designed 
to meet the patient’s needs and the process is designed to yield consistent high level of 
product quality, by controlling all critical sources of process variation. In practice, QbD 
starts with the identification of the critical process parameters (CPPs) that affect the critical 
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quality attributes (CQAs) of the product during manufacturing. Ultimately, QbD yields the 
definition of a process design space, in which the variations of CPPs have demonstrated 
to provide high product quality. In this context, PAT is therefore a QbD enabler that aims 
at improving operational systems and risk management on manufacturing processes.
The PAT implementation path can be summarized in three major steps (Figure 1). Firstly, 
the process design phase focuses on identifying the product CQAs the CPPs. The way in 
which the CPPs and possibly their interactions affect the CQAs should also be characterized. 
Secondly, appropriate analytical tools need to be implemented to capture all relevant 
information on the CPPs or on the CQAs if the relations between the CQAs and CPPs are not 
clearly understood. In order to make the fullest use of the data collected by these analyzers, 
the analytical results must be available in a frame-frame that enables real-time decision 
making. Indeed, the third step is to use the combination of the process understanding gained 
during the process design phase and the data collected by the process analyzers, to achieve 
real-time process control. The ultimate process control strategy should ensure consistent 
process performance and more importantly product quality, while the process is running. 
This implementation exercise is a circle as new information and understanding gained on the 
process should be used to continuously improve the process design and its control strategy. 
Figure 1. The three major steps for implementation of PAT during the development life cycle of a 
biopharmaceutical process. Modified from Rathore et al. (2010).
3 PER.C6® cell line and its applications
PER.C6® is a human immortalized cell line which was developed in the late ‘90s (5). 
These cells are derived from embryonic retinoblast cells obtained from an aborted fetus 
and were immortalized by transformation with the E1A and E1B-encoding sequences of 
Adenovirus 5 (5, 6). Expression of E1A stimulates the cells to enter the S phase of the 
cell cycle by disabling their ability to enter the quiescent G0 phase (7, 8). This way, cell 
proliferation is stimulated. To ensure cell integrity (e.g. number of chromosomes and 
accuracy of DNA replication), apoptotic cell death is initiated upon expression of E1A 
(9, 10). Expression of E1B results in two proteins E1B 55-kDa and E1B 19-kDa (11). E1B 
55-kDa blocks of the function of the tumor-suppressor protein p53. E1B 19-kDa is a 
homolog of the anti-apoptotic protein Bcl2 (10, 12). These two proteins contribute to down 
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regulating apoptosis induction in the cells. The co-expression of E1B therefore prevents 
the defensive apoptosis induction caused by E1A (13, 14). Overall, immortalization of 
the PER.C6® cell line lead to proliferation at high rates and regulation of apoptosis.
PER.C6® is a safe and cost-effective production cell line for biopharmaceutical 
production (6, 15-18). These cells can grow in suspension in fully animal-derived 
component free and chemically defined medium. High cell densities of PER.C6® can 
be reached in continuous perfusion processes (19). Additionally, the immortalization 
technique used for PER.C6® makes these cells especially suited for complementing and 
propagating replication-incompetent Adenoviruses. PER.C6® is therefore an excellent 
platform to replicate Adenoviruses (20-23) and other types of viruses such as Influenza 
(16, 24, 25) and poliovirus (26). High productivities of immunoglobulin G (IgG) 
and IgM in PER.C6® cells have also been reported (27, 28), making it an all-round 
biopharmaceutical production platform. Several products produced using PER.C6® are 
currently in different stages of pre-clinical and clinical development (25, 29-31).
PER.C6® is used as a basis in a vaccine production platform based on intensified 
technology, which aims at maximizing process yield (Figure 2). A large volume and high 
density cell bank of PER.C6® is used to inoculate a wave-rocking bioreactor (Cultibag) 
for cell recovery post-thawing and seed train expansion. The following two steps are 
performed in perfusion bioreactors using an alternating tangential flow (ATF) filtration 
system for cell retention. The PER.C6® cultures are first further expanded and grown 
to high cell densities, to inoculate the subsequent intensified virus production process. 
PER.C6® cultures are infected with a virus seed and process conditions are adapted 
depending on the virus type to produce (e.g. Adenovirus, Influenza or Poliovirus). 
Figure 2. Schematic of a pilot-scale PER.C6®-based vaccine production platform from cell bank to 
virus production. Pictures on courtesy of Sartorius, Hyclone and Refine.
4 Research aim and thesis outline
The quality of cell substrate is critical for performance of a virus production process. 
Variation in performance of the virus production process is hypothesized to be caused 
by the quality of the cells. The characteristics, or CQAs, of mammalian cells used 
as a substrate for virus propagation are largely unknown. The relation between the 
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CQAs of these cells and virus attachment, infection, and propagation are also not fully 
understood. The objective of this thesis is to apply PAT principles to the perfusion PER.
C6® cell expansion process. This thesis focuses therefore first on identifying the CQAs 
of the PER.C6® cells used for virus production and second on the implementation of the 
most appropriate analytical tools for optimal process monitoring. 
The PER.C6® perfusion cell cultivation process studied in this thesis has been originally 
developed in 2008-2009 at Crucell. This process is the basis for the development of several 
vaccine development programs, which are mostly in early clinical development phases. The 
first step to implement PAT on this process is to extract the most relevant process information 
from the large and elaborate datasets typically generated from these processes. Multivariate 
data analysis (MVDA) is a statistical method of choice for this purpose. Chapter 2 discusses 
the importance of MVDA for industrial bioprocess data and presents recent studies on MVDA 
as a PAT tool to analyze data from biopharmaceutical cultivation processes. In Chapter 
3, MVDA was applied to historical data on the PER.C6® perfusion cultivation process. 
Although the data available from early development contain gaps and are not generated 
from statistically designed experimental sets, a thorough multivariate analysis expanded 
understanding on the process and revealed its sensitivity to scale and input materials. 
Subsequently, the research focuses on the quality of the PER.C6® cells during the 
expansion process. To identify the CQAs of the PER.C6® cells used for virus propagation, 
biological and cellular parameters that are expected to reflect the cell’s suitability 
for virus attachment, infection and replication, are studied. Firstly, in Chapter 4, the 
dynamics of PER.C6® cell growth and cell death are measured throughout the perfusion 
process and compared to those of batch cultures. Flow cytometry-based assays are used 
to measure apoptosis in the different cultures, targeting three steps of the apoptosis 
cascade. Secondly, in Chapter 5, a novel assay is developed to measure the cell’s 
infectability for adenoviruses, or in other words their ability to be infected by viruses 
and to replicate viruses. Kinetics of infection and of virus production are compared 
for exponentially growing and high viability cultures and for cells sampled from the 
perfusion process within normal operating conditions and under suboptimal cultivation 
conditions, as well as on PER.C6® batch cultures exposed to various stresses. 
The main aim of Chapters 4 and 5 is to study the robustness of the PER.C6® cells 
in the perfusion process, and to assess whether variation in cell quality occurred over 
process time. On the one hand, apoptosis is found to be maintained at a constant 
low level during the entire perfusion process (Chapter 4), and one the other hand, 
infectability of PER.C6® cultures with adenoviruses shows to be very robust throughout 
the perfusion cultivation and under suboptimal process conditions (Chapter 5). Overall, 
these studies demonstrate the robustness of the PER.C6® cell line cultivated in perfusion 
and suggests that PER.C6® cell quality for virus propagation can be sufficiently assessed 
by the measurement of culture viability. 
The next step focuses on the online PAT tools that are the most relevant to monitor 
and ultimately control the perfusion PER.C6® cultivation process. These PAT tools should 
capture information on the culture viability, which is the PER.C6® cells’ CQA defined in the 
previous chapters, as well as the key performance attributes of the perfusion cultivation 
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process. The business capacity of this process is reflected in the cell specific growth rate, 
as the time to reach the cell density required to inoculate the virus production phase 
should ideally be reached as fast as possible. In Chapter 6, a combination of dielectric 
spectroscopy (DS) and near infrared spectroscopy (NIRS) is shown to be complementary 
to monitor the product CQA and the key performance attributes of the perfusion PER.C6® 
cultivation process. Using either simple linear regressions or more complex multivariate 
models, data from DS and NIRS are used for accurate online predictions of viable cell 
density as well as of glucose and lactate concentrations.
Finally, Chapter 7 summarizes the results presented in this thesis and discusses the 
PAT application presented here in the context of the current and prospective efforts to 
implement PAT and QbD for continuous cell cultivation processes. 
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Chapter 2
Multivariate PAT solutions  
for biopharmaceutical cultivation:  
current progress and limitations
Abstract
Increasingly elaborate and voluminous datasets are generated by the (bio)
pharmaceutical industry and are a major challenge for application of PAT and QbD 
principles. Multivariate data analysis (MVDA) is required to delineate relevant process 
information from large multi-factorial and multi-collinear datasets. Here the key role 
of MVDA for industrial (bio)process data is discussed, with a focus on progress and 
limitations of MVDA as a PAT solution for biopharmaceutical cultivation processes. 
MVDA based models were proven useful and should be routinely implemented for 
bioprocesses. It is concluded that although the highest level of PAT with process control 
within its design space in real-time during manufacturing is not reached yet, MVDA will 
be central to reach this ultimate objective for cell cultivations.
Sarah M. Merciera 
Bas Diepenbroeka 
René H. Wijffelsb 
Mathieu Streeflandb
a Crucell Holland BV, Process Development Department,  
Archimedesweg 4-6, 2333 CN Leiden, The Netherlands 
b Wageningen University, Bioprocess Engineering,  
P.O. Box 16, 6700 AA Wageningen, The Netherlands
Trends in Biotechnology 32(6):329-36
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Glossary
Design of experiments (DoE) (1): DoE is a rigorous, structured and systematic approach 
to designing statistically relevant experimental set where the data generated ensures 
sound conclusions and decision making. DoE aims at generating the most informative 
results by eliminating experimental error while minimizing runs, time and resources.
Design space (2):  Design space is “the multidimensional combination and interaction 
of input variables (e.g., material attributes) and process parameters that have been 
demonstrated to provide assurance of quality”. Operation of a process within its 
established design space is not considered as a change, as product quality is ensured 
within the entire design space.
Critical process parameter (CPP) (2): CPP is “a process parameter whose variability has 
an impact on a critical quality attribute and therefore should be monitored or controlled 
to ensure the process produces the desired quality”. Any measurable input material 
attribute, operating parameter and process state variable of a process step affecting 
product quality or consistency of process performance is a potential CPP.
Critical quality attribute (CQA) (2): CQAs are “physical, chemical, biological or 
microbiological properties or characteristics that should be within an appropriate limit, 
range, or distribution to ensure the desired product quality”. In QbD, CQAs are related 
to safety, efficacy and stability of the drug product or drug substance and must be 
directly or indirectly controlled throughout the manufacturing process.
Multivariate data analysis (MVDA) (3): MVDA makes use of statistical techniques 
to analyze datasets composed of more than one variable or more than one type of 
variable. With MVDA, variables are analyzed simultaneously to perform exploratory, 
regression or classification studies.
Partial least square (PLS) (4): PLS is a MVDA technique using projections and linear 
regressions to study relations and interactions among variables. Predictive models 
can be made using PLS when variables are highly collinear and when several input 
parameters correlated to one or more output parameters. 
Principal component analysis (PCA) (5): PCA is a MVDA technique using orthogonal 
projections of the original dataset into new uncorrelated (latent) variables called principal 
components to study underlying structure of the dataset. Main trends or clusters among 
batches or data points can be identified using PCA.
1 Quality by Design and Process analytical technology  
for bioprocesses
Quality by Design (QbD) and Process Analytical Technology (PAT) are guiding principles 
stimulating the biopharmaceutical industry to improve understanding and control of 
their manufacturing processes, and to ultimately build product quality into the process 
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(Box1) (2,6-12). To date, classical chemical pharmaceutical production has achieved 
significant advances regarding QbD and PAT (13). For unit operations such as mixing, 
milling, crystallization or drying, process parameters affecting quality attributes are very 
well defined and PAT analyzers are widely used to control product quality and process 
performance (14-16). Implementation of QbD and PAT is however slower and more 
challenging for bioprocesses due to their distinct complexity. Biopharmaceuticals such 
as monoclonal antibodies or viruses are highly complex products because of their large 
size and biological nature and they are known for being sensitive to their manufacturing 
processes (17). Consortia of leading biotech companies and FDA officials gave an 
important impetus to QbD and PAT for biological processes in the A-Mab and AVAX 
case studies, paving the road with concrete examples for practical implementation 
(http://www.casss.org/associations/9165/files/A-Mab_Case_Study_Version_2-1.pdf 
and http://www.pda.org/HomePageContent/CMC-VWG-A-VAX.aspx). 
Several PAT applications have been published on unit operations of downstream 
biprocessing such as protein refolding or chromatography (18,19). The main challenges facing 
PAT in this part of bioprocesses are the short execution time of these unit operations and their 
interdependency, which reduce the possibilities of real-time process control based on on-line 
monitoring (20). Similarly, efforts towards implementation of PAT to cell cultivations have been 
developed using a combination of data analysis systems, analytical tools and quality control 
principles (21-23). However, PAT applications on this unit operation are restrained by its 
unique complexity. Cells themselves have a sophisticated metabolism and product expression 
is a result of many elaborate and interacting cellular mechanisms often described as black 
boxes (24). Additionally, cultivation medium and feed typically have a complex composition 
with many nutrients, vitamins and co-factors each consumed at different rates (25). Finally, 
process control systems use cascade controllers for numerous process parameters such as 
aeration, agitation, pH and temperature. In most processes, cells therefore need to adapt 
to a continuously changing environment. All these dynamic parameters are monitored to 
varying extent and resolution, resulting in complex and elaborate datasets.
A multivariate approach is needed for the analysis of these multidimensional 
datasets from cell cultivations (26,27). Multivariate data analysis (MVDA) can translate 
the large amount of data recorded during bioprocesses into relevant, understandable 
information. MVDA is therefore largely recognized as essential for successful PAT and 
QbD implementations (Figure 1). 
We discuss the increasing importance of MVDA for industrial bioprocess data in general 
and recent studies on MVDA as a PAT tool to analyze data from biopharmaceutical cultivation 
processes. We focus on current progress and challenges to reaching the highest level of PAT 
with MVDA-based models and on-line analyzers fully exploring the process design space. 
2 MVDA for industrial bioprocess data
Linear statistical techniques are widely used to analyze most industrial datasets. However, 
when applied to multi-dimensional and multi-collinear data, univariate analyses or even 
22
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Box 1. PAT and QbD principles for biopharmaceuticals
Process analytical technology (PAT) is concept introduced by the American 
Food and Drug Administration (FDA) to encourage the pharmaceutical and 
biopharmaceutical industries to increase the efficiency and the control of the 
production of biopharmaceuticals (6). The goal of PAT is to monitor and control 
all critical process parameters (CPPs) that affect one or more of the critical quality 
attributes (CQAs) of the final product, preferably on-line, to ensure consistent and 
adequate product quality during manufacturing.
PAT is a key enabler of Quality by Design (QbD), the modern approach to 
quality which is also promoted by the FDA  (7). Traditionally, the biopharmaceutical 
industry relies on the quality-by-testing paradigm, where product release is based 
on post-manufacturing testing. QbD oppositely promotes the use of thorough 
scientific understanding of the product and its manufacturing process, together 
with risk-based approaches, to build quality into the process, rather than quality 
being a variable output (2,8,9). Implementation of QbD and PAT for bioprocesses 
starts with the definition of the target product profile and results in a production 
process that routinely runs within a defined design space that has been proven to 
yield the specified product quality (10,12).
Similar quality principles based on improving analysis, monitoring and 
control of processes have been implemented for decades in many industries 
such as automotive, tobacco or petrochemical production (27). There, relations 
between end product and manufacturing processes are rather straight forward 
and can be defined very rigorously. Products from the biopharmaceutical 
industry are of particular complexity as their quality features (CQAs) must be 
linked to safety and specific therapeutic effects in humans, before they can be 
related to critical parameters of the manufacturing process (CPPs). In the early 
2000’s, it became apparent that the lack of understanding (both mechanistic 
and statistic) of the manufacturing processes of biopharmaceuticals contributed 
to a long list of industrial and business drawbacks including inability to predict, 
analyze and understand root causes for process failure, dependency on intense 
post-manufacturing quality testing for product release, limited flexibility for post-
approval process changes, high number of batch rejects and recalls and heavy 
and long review times by the regulation authorities (11). The launch of the PAT 
and QbD initiatives by the regulation authorities was essentially driven by this 
situation of the biopharmaceutical industry regarded as sub-optimal by both the 
industry and the regulatory authorities.
23
bivariate regressions can lead to misinterpretation of data and to misleading conclusions 
(28). MVDA offers solutions to handle large datasets containing measurement errors and 
missing data (29). When a deviation is detected with a univariate approach, each process 
variable has to be analyzed and its contribution to the root cause has to be evaluated 
individually (Figure 2). This can be challenging especially when deviations result from 
an interaction of parameters. However, when the relations among process variables are 
studied upfront by using multivariate batch modeling and structured experimentation, the 
root cause of a process deviation can be readily identified (Figure 2).
Multivariate analysis methodologies for continuous and batch process monitoring were 
first proposed in the early 1990’s (30). Among the panel of MVDA tools, multi-way principal 
component analysis (PCA) and multi-way partial least squares (PLS) regression have been 
successfully applied to visualize the non-linear dynamics of batch processes (4,5,31). Both 
are projection methods that reduce the original multidimensional dataset into a lower 
number of uncorrelated variables explaining most of the variance contained in the original 
data. PCA aims at identifying patterns and main trends within the dataset, whereas PLS 
analyses the covariance between the process variables and the process output.
MVDA has been widely accepted and is common practice in several industries, with 
focuses ranging from polymers to semi-conductors, food or the environment (32-34). The 
aim for MVDA in these industries is to maximize the exploitation of process data in order 
to deepen understanding of the processes and to improve the level of process control. 
The interest of the pharmaceutical industry in MVDA techniques largely increased after 
the launch of the PAT and QbD guidelines, where MVDA was explicitly recommended 
by the regulators as a key enabling tool for PAT and QbD. Applications were primarily 
on classical, small molecule pharmaceutical products, for which production steps are 
rather simple and very well defined. In this field, the use of spectroscopic tools for 
process monitoring increased the need for MVDA applications (35,36). An example 
of the importance of MVDA to support QbD for drug development was published by 
Figure 1. Typical approach for QbD and PAT implementation in bioprocess development and role of 
MVDA in this process.
24
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Figure 2. Comparison of classical univariate analysis (left) and advanced multivariate analysis (right) 
for bioprocess data. A multivariate approach helps to identify variables causing process deviations as 
the interactions and relations among process variables are known and used to build multivariate batch 
models. Conversely, with a univariate approach, process variables have to be analyzed individually 
in order to identify root causes for process deviations. 
Huang et al. (37). An integrated multivariate approach was used in a QbD application 
for a pharmaceutical product, where statistically designed experiments and MVDA were 
applied during development to establish a process design.
Because the biopharmaceutical industry generates the most complex datasets, it 
has also greatly beneficiated from MVDA as shown in several reviews on this topic 
(3,26,27,38). Applications have been published in the past decade both on upstream 
and downstream unit operations. The use of MVDA on upstream cell cultivation data 
will be discussed in detail in the next section. In the field of downstream bioprocessing, 
examples relate mainly to chromatographic purification to characterize the effect of 
process conditions on process performance and robustness (39,40). 
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Furthermore, technological advances more frequently used for the innovation and 
production of biopharmaceuticals contribute greatly to increasing the amount of data 
to be modeled and interpreted. Systems biology and the omics technologies (genomics, 
transcriptomics, metabolomics, proteomics) support the development of a holistic 
methodology to investigate the complex interactions within biological systems, shifting 
from the current vision where cells are black boxes to systems in which cells define 
the product (41,42). Additionally, high-throughput, small-scale, automated systems 
were developed to facilitate parallel testing and screening to meet the demand for both 
low-cost development and extensive experiments required to understand processes and 
define design spaces (43). These innovative improvements are obvious QbD enablers as 
they make increased experiment throughput possible and they enhance understanding 
of biological processes. The future needs for MVDA in this field will therefore keep 
increasing together with the size of the datasets, especially for cultivation processes. 
3 MVDA as a PAT tool for cell cultivation data 
The use of MVDA as a PAT tool for biopharmaceutical cell cultivation steps has greatly 
increased over the last decade. The aim is often to exploit available datasets mostly 
originating from pilot or manufacturing plants, in order to find correlations pointing 
to causes for bioprocess variation and to improve bioprocess understanding. Since the 
launch of the PAT Initiative, there have been a variety of studies published on MVDA 
application to datasets originating from both microbial and mammalian cell cultivation 
processes. These studies range widely in complexity and scope, from exploration 
of early development runs to the complete mapping of a process design space. We 
propose to classify these studies into 3 different PAT levels (Table 1), depending on the 
level of statistical structure in the experimental design, the use of additional advanced 
multivariate process analyzers, and the resolution of the measurements (i.e. on-line or 
off-line). The PAT levels are defined as follows:
1. Datasets containing classical process variables for explorative studies;
2. Datasets containing process variables and basic off-line critical quality attributes 
(CQA) assessments for process development and scale up;
Table 1. Classification of PAT levels for cell cultivation processes, based on experimental designs, 
process analyzers and data resolution.
PAT level Stage of process life-cycle Data recorded
Level 1 Proof of concept,  
process capacity exploration 
Basic process monitoring  
(pH, temperature, DO, etc.) 
Level 2 Process optimization, scale-up,  
using small experimental sets 
Same as level 1 + off-line  
CQA assessments 
Level 3 Process characterization,  
using full statistical designs
Same as level 2 + on-line PAT tools  
and biological assessments of CQAs
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3. Datasets containing the abovementioned and additional on-line PAT tools capturing 
relevant information related to the CQAs for predictive process modeling studies 
and basic design space exploration.
The structure of the datasets of these studies is described through the scale and origin 
of the batches, the process variables that are monitored, the use of PAT tools and the 
method of MVDA application (Table 2). It is important to note that to date no studies 
report the implementation of a design space model at manufacturing scale.
Level 1: MVDA on datasets containing classical bioprocess data
Two studies are limited to using basic readily available process variables in relatively 
simple applications and were therefore classified at Level 1 (Table 1). Gunther et al. (44) 
applied PCA to a pilot-scale industrial fed-batch cell culture process. A similar study 
was performed by Nucci and co-workers (45) on a Bacillus production of penicillin G 
acylase, where MVDA was used to generate on-line multivariate control charts. In these 
examples, each dataset contained information exclusively related to the process. MVDA 
models therefore only assessed quality of technical execution of the process, enabling 
detection of process faults or deviations. This is relevant for process monitoring in a 
manufacturing setting, for example. However, because no biological responses were 
captured to measure product quality or even process performance, the relations and 
interactions between process parameters and process performance or product quality 
remain unknown. Corrective actions in case of a deviation are difficult to implement 
when understanding of these relations is lacking. These studies can therefore be 
considered as the first, most basic level of MVDA and PAT.
Level 2: MVDA on datasets containing process variables  
and basic offline CQA assessments
In 7 studies simple off-line measurements of process performance or product quality 
(namely cell density, viability, end product concentration or purity) were used in addition 
to standard on-line data from the bioreactor control system, to create more elaborate 
multivariate models. With these analyses, the level of PAT increased because process 
performance was linked to actual product quality attributes (Table 1). 
Within this second level of PAT, a first group of 4 studies focused on using raw 
unprocessed offline data to build explorative MVDA models. Kirdar et al. (46) used 
a set of off-line output variables to model a cell cultivation process at two different 
scales. A second study from the same group used similar off-line measurements and 
additional on-line monitoring of process variables to identify process parameters 
and their interactions that adversely impacted process performance (47). Similarly, 
Thomassen et al. (48) applied MVDA to exploit available data of an inactivated polio 
vaccine manufacturing process run at commercial scale. More recently, Mercier et al. 
(49) used a set of unstructured runs from early development and demonstrated that 
MVDA can even provide valuable handholds for further development. 
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Table 2. Applications of MVDA on cell cultivation processes with analysis of PAT level and of structure 
of the datasets.
PAT 
level
Dataset Dataset
MVDA application and outcome RefsBatches Process variables PAT tool Process responses
1 23 pilot scale batches On-line process parameters  
(e.g. agitation, temperature, gas flows, etc., 
and controller outputs)
None None Fault detection and diagnosis in industrial fed-batch cell culture.
Identification of deviating batches and of the root  
cause for each deviation; findings matched 
 observations from process engineers.
[44]
1 6 small scale batches On-line process parameters (agitation, pH, 
temperature, dissolved oxygen, and gas flows) 
None None On-line detection of abnormal bacterial cultivation  behavior [45]
2 14 small scale batches
11 pilot scale batches
Off-line metabolites  
and cell growth measurements
None Off-line viable cell density, 
viability, osmolality  
and product purity
Application of MVDA to support  
key cell culture process activities.
Gain of process information related to scale-up, process 
comparability, process characterization and fault diagnosis.
[46]
2 152 small scale batches
14 pilot scale batches
5 commercial scale 
batches
On-line process parameters  
(pH, dissolve oxygen and temperature)
Off-line gas levels, metabolites  
and cell growth measurements 
None Off-line product yield Identification of process parameters and their interactions 
adversely impacting process performance. 
Design of experimental work to confirm  
and correct the root cause.
[47]
2 50 batches at two  
commercial scales
On-line process parameters  
(e.g. agitation, pH, temperature, gas flows, 
etc. and controller outputs) 
Off-line metabolites concentration and cell 
growth measurements
None Off-line cell concentration   
and product yield
Exploitation of historical data to gain  
understanding on the process.
Identification of known outliers using MVDA.
[48]
2 17 small scale batches On-line process parameters (e.g. agitation, pH, 
temperature, dissolved oxygen, and gas flows) 
Off-line metabolites and gas concentrations, 
osmolality and cell growth measurements
None Off-line culture viability  
and growth rate 
Increased understanding of cell cultivation process.
Identification of causes for batch deviations and of process 
differences among batches scale.
[49]
2 20 sets of seed data at 
pilot scale
75 sets of seed and 
main fermentation data 
at commercial scale
On-line process parameters (e.g. agitation, 
pH, temperature, gas flows, etc.) 
Calculation of carbon dioxide evolution rate 
and oxygen uptake rate
None Off-line mycelial volume  
and pH for seed
Off-line product yield  
for main fermentation
Assessment of seed quality and influence on productivity of 
an industrial antibiotic production process.
Relation of final productivity at both pilot and production 
scales to seed fermentation quality.
[50]
2 1081 and 2432 batches 
including inoculation 
and production data at 
various scales
On-line process parameters (e.g. agitation, 
pH, temperature, dissolved oxygen, gas 
flows, etc. and controller outputs) 
Off-line metabolites concentration and cell 
growth measurements
None Off-line product concentration Prediction of process production performance days prior  
to harvest using cell culture stage-specific models.1
Identification of hidden relations between process outcome 
and process parameters.2
[51]1 
[52]2
3 16 pilot scale batches On-line process parameters (carbon dioxide 
and oxygen concentration in the exhaust 
gases and dissolved oxygen in the broth) 
Calculation of carbon dioxide evolution rate 
and oxygen uptake rate
On-line DS  
measuring 
capacitance  
and conductance
Off-line product concentration Detection of dissimilarities among batches, prediction  
of final product concentration and identification  
of variables influencing process productivity. 
Improvement of knowledge  
on industrial fermentation process. 
[56]
3 small scale batches  
(number not available)
None On-line multi-
wavelength 
fluorescence
Off-line biomass and glucose  
concentration and carbon  
dioxide production rate
Prediction of process responses from fluorescence  
data in batch cultivations.
Decrease in prediction accuracy when models calibrated  
with batch data were applied to fed-batch data, 
demonstrating that proper calibration of PLS  
models is critical for accurate predictions.
[57]
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Table 2. Applications of MVDA on cell cultivation processes with analysis of PAT level and of structure 
of the datasets.
PAT 
level
Dataset Dataset
MVDA application and outcome RefsBatches Process variables PAT tool Process responses
1 23 pilot scale batches On-line process parameters  
(e.g. agitation, temperature, gas flows, etc., 
and controller outputs)
None None Fault detection and diagnosis in industrial fed-batch cell culture.
Identification of deviating batches and of the root  
cause for each deviation; findings matched 
 observations from process engineers.
[44]
1 6 small scale batches On-line process parameters (agitation, pH, 
temperature, dissolved oxygen, and gas flows) 
None None On-line detection of abnormal bacterial cultivation  behavior [45]
2 14 small scale batches
11 pilot scale batches
Off-line metabolites  
and cell growth measurements
None Off-line viable cell density, 
viability, osmolality  
and product purity
Application of MVDA to support  
key cell culture process activities.
Gain of process information related to scale-up, process 
comparability, process characterization and fault diagnosis.
[46]
2 152 small scale batches
14 pilot scale batches
5 commercial scale 
batches
On-line process parameters  
(pH, dissolve oxygen and temperature)
Off-line gas levels, metabolites  
and cell growth measurements 
None Off-line product yield Identification of process parameters and their interactions 
adversely impacting process performance. 
Design of experimental work to confirm  
and correct the root cause.
[47]
2 50 batches at two  
commercial scales
On-line process parameters  
(e.g. agitation, pH, temperature, gas flows, 
etc. and controller outputs) 
Off-line metabolites concentration and cell 
growth measurements
None Off-line cell concentration   
and product yield
Exploitation of historical data to gain  
understanding on the process.
Identification of known outliers using MVDA.
[48]
2 17 small scale batches On-line process parameters (e.g. agitation, pH, 
temperature, dissolved oxygen, and gas flows) 
Off-line metabolites and gas concentrations, 
osmolality and cell growth measurements
None Off-line culture viability  
and growth rate 
Increased understanding of cell cultivation process.
Identification of causes for batch deviations and of process 
differences among batches scale.
[49]
2 20 sets of seed data at 
pilot scale
75 sets of seed and 
main fermentation data 
at commercial scale
On-line process parameters (e.g. agitation, 
pH, temperature, gas flows, etc.) 
Calculation of carbon dioxide evolution rate 
and oxygen uptake rate
None Off-line mycelial volume  
and pH for seed
Off-line product yield  
for main fermentation
Assessment of seed quality and influence on productivity of 
an industrial antibiotic production process.
Relation of final productivity at both pilot and production 
scales to seed fermentation quality.
[50]
2 1081 and 2432 batches 
including inoculation 
and production data at 
various scales
On-line process parameters (e.g. agitation, 
pH, temperature, dissolved oxygen, gas 
flows, etc. and controller outputs) 
Off-line metabolites concentration and cell 
growth measurements
None Off-line product concentration Prediction of process production performance days prior  
to harvest using cell culture stage-specific models.1
Identification of hidden relations between process outcome 
and process parameters.2
[51]1 
[52]2
3 16 pilot scale batches On-line process parameters (carbon dioxide 
and oxygen concentration in the exhaust 
gases and dissolved oxygen in the broth) 
Calculation of carbon dioxide evolution rate 
and oxygen uptake rate
On-line DS  
measuring 
capacitance  
and conductance
Off-line product concentration Detection of dissimilarities among batches, prediction  
of final product concentration and identification  
of variables influencing process productivity. 
Improvement of knowledge  
on industrial fermentation process. 
[56]
3 small scale batches  
(number not available)
None On-line multi-
wavelength 
fluorescence
Off-line biomass and glucose  
concentration and carbon  
dioxide production rate
Prediction of process responses from fluorescence  
data in batch cultivations.
Decrease in prediction accuracy when models calibrated  
with batch data were applied to fed-batch data, 
demonstrating that proper calibration of PLS  
models is critical for accurate predictions.
[57]
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Table 2. Continued
PAT 
level
Dataset Dataset
MVDA application and outcome RefsBatches Process variables PAT tool Process responses
3 4 large scale batches None On-line Raman 
spectroscopy
Off-line viable and total  
cell densities, and main  
metabolites concentrations  
(glucose, glutamine, glutamate, 
lactate and ammonium)
Demonstration that prediction models for cell density  
and main metabolites concentrations based on Raman 
spectra can be used for on-line process monitoring.
[58]
3 5 small scale batches Off-line metabolites  
and cell growth measurements
On-line NIRs Off-line viable cell density Modeling of near-infrared spectroscopy data  
for monitoring of an antibody production process.
Identification of outliers and detection of a contamination.
[59]
3 On-line process parameters  
(e.g. agitation, pH, temperature, gas flows, etc.) 
Off-line metabolites concentration  
(glucose and acetate)
On-line NIRs
In-line electronic  
noise mapping
Off-line biomass  
and product concentration
Prediction of key process responses  
during bacterial cultivation process.
Detection of abnormal cultivations and of contamination.
Use of on-line biomass prediction to control cultivation feed.
[60]
3 10 commercial  
scale batches
Off-line glucose concentration  
and osmolality
On-line NIRs Off-line cell density, culture 
viability, packed cell volume 
and product concentration
Detection of abnormal cell cultivation batches.
Monitoring and accurate in-line prediction  
of seven cell culture parameters using control charts.
[63]
3 12 small scale 
batches, designed 
using DoE 
methodology
On-line process parameters  
(pH, dissolve oxygen and temperature)
Off-line metabolites and bacteria  
density measurements 
On-line NIRs
Off-line microarray for 
determination of RNA 
expression profile
Off-line product quality score Exploration and modeling of the design space  
of a bacterial vaccine cultivation process.
Fingerprinting of process based on on-line measurements, 
modeling of the design space within the ranges studied.
[64]
Additional relevant information can be extracted from standard on-line monitoring 
tools available for cell culture processes. Raw datasets can be complemented with new 
information that better reflect the biological features of the processes. Cunha et al. (50) 
added carbon dioxide evolution rate and oxygen uptake rate to their dataset initially 
consisting of main on-line process variables and a basic assessment of seed quality for 
a bacterial fermentation. These new computed variables encompassed the biological 
mechanisms taking place during cell growth better than the raw measurements in the 
multivariate models and this was achieved without additional analytical tools. 
Classical measurements can also be used to yield predictive models for process 
performance. These applications go beyond process exploration and enable predictive 
modeling from raw material quality or process execution data. Examples are shown in two 
studies that used MVDA on manufacturing cell culture data from Genentech, Inc. (51,52). 
The authors did not use the typical PCA and PLS multivariate tools but rather support vector 
machines, which are supervised learning models for pattern classification and regression 
analysis (53). Charaniya et al. (52) first used several algorithms to integrate the large set 
of data and then showed that run performance can be reliably predicted several days 
before culture harvest. Le et al. (51) built models predicting the final concentrations of 
antibody and of lactate using data from the early phase of the production process.
In all the studies classified in the second PAT level, MVDA is useful for increasing 
understanding of cell cultivation unit operations a posteriori, meaning after the 
batches are terminated. However, when only off-line, classical and simple (univariate) 
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Table 2. Continued
PAT 
level
Dataset Dataset
MVDA application and outcome RefsBatches Process variables PAT tool Process responses
3 4 large scale batches None On-line Raman 
spectroscopy
Off-line viable and total  
cell densities, and main  
metabolites concentrations  
(glucose, glutamine, glutamate, 
lactate and ammonium)
Demonstration that prediction models for cell density  
and main metabolites concentrations based on Raman 
spectra can be used for on-line process monitoring.
[58]
3 5 small scale batches Off-line metabolites  
and cell growth measurements
On-line NIRs Off-line viable cell density Modeling of near-infrared spectroscopy data  
for monitoring of an antibody production process.
Identification of outliers and detection of a contamination.
[59]
3 On-line process parameters  
(e.g. agitation, pH, temperature, gas flows, etc.) 
Off-line metabolites concentration  
(glucose and acetate)
On-line NIRs
In-line electronic  
noise mapping
Off-line biomass  
and product concentration
Prediction of key process responses  
during bacterial cultivation process.
Detection of abnormal cultivations and of contamination.
Use of on-line biomass prediction to control cultivation feed.
[60]
3 10 commercial  
scale batches
Off-line glucose concentration  
and osmolality
On-line NIRs Off-line cell density, culture 
viability, packed cell volume 
and product concentration
Detection of abnormal cell cultivation batches.
Monitoring and accurate in-line prediction  
of seven cell culture parameters using control charts.
[63]
3 12 small scale 
batches, designed 
using DoE 
methodology
On-line process parameters  
(pH, dissolve oxygen and temperature)
Off-line metabolites and bacteria  
density measurements 
On-line NIRs
Off-line microarray for 
determination of RNA 
expression profile
Off-line product quality score Exploration and modeling of the design space  
of a bacterial vaccine cultivation process.
Fingerprinting of process based on on-line measurements, 
modeling of the design space within the ranges studied.
[64]
measurements of process responses are available, the totality of the process parameters 
impacting process performance or product quality cannot always be fully captured and 
predictions on product quality cannot be reached.
Level 3: MVDA on datasets containing data from advanced  
and on-line process monitoring tools
Implementation of on-line or at-line measurements of CPPs or directly of CQAs enables 
data analysis and process modeling in real-time. This facilitates, for example, early 
fault detection at a time where corrective actions can be taken, maximizing both 
process success rate and probability of obtaining the desired end product quality (54). 
Five examples of MVDA applications illustrate this stage where complementary and 
advanced analytical data related to the CQAs were collected (Table 2), which makes 
them a distinctly more advanced PAT level.
Several on-line PAT tools capture information related to cellular features of cultivations, or 
cell state (23,55). Ferreira et al. (56) modeled on-line capacitance and conductance measured 
with dielectric spectroscopy (DS) on an industrial fermentation process, in combination with 
on-line dissolved oxygen and composition of the outlet gas stream data, to predict final 
product concentration and to identify faults influencing process productivity. Jain et al. (57) 
developed calibration models with on-line multi-wavelength fluorescence spectroscopy data 
from a batch Escherichia coli cultivation process to predict key process responses. 
31
Efforts are also directed towards using broad spectroscopic techniques to fingerprint 
the complex matrix of cell cultures. These techniques capture all information related 
to the many interacting process parameters, at a high frequency. MVDA is ideal to 
translate the massive amount of data generated into relevant process information, 
which is the main challenge associated with these analyzers. Abu-Absi et al. (58) used 
Raman spectroscopy for simultaneous and accurate prediction of main cultivation 
parameters in large scale bioreactors. Henriques et al. (59) modeled on-line Near-
infrared spectroscopy (NIRs) data for monitoring mammalian cell cultures producing a 
monoclonal antibody to identify batch deviation and to predict cell density and main 
cultivation metabolites. In another study, accurate calibration models linked data from 
on-line NIRs to very subtle process changes to generate robust process control (60). A 
major objective of PAT was achieved in this example, as process understanding was 
used to build accurate models from advanced on-line data, not only to monitor the 
process but most importantly to control it in real-time. 
NIRs techniques outnumber other advanced PAT tools for cell cultivation, as four of 
the seven papers in this third PAT level used NIRs (Table 2). NIR and Raman are both 
vibrational spectroscopy techniques yielding very large datasets as each spectrum consists 
of more than 2000 points and measurement frequency can be as high as every few seconds 
(61,62). Raman enables more accurate identification of chemical compounds in small 
molecules applications and NIRs prevails for bioprocess fingerprinting. Of course these 
complex tools are relevant for PAT only when information related to product quality (or 
process performance) have been proven to link to or be contained in the signal from these 
analyzers. This needs to be established experimentally prior to implementing these tools.
All applications examined so far were conducted in laboratory or pilot plant settings. 
A manufacturing scale application of MVDA and PAT tools was published by a group 
at Hoffmann-La Roche (63), in which NIRs measurements were acquired in a Good 
Manufacturing Practices (GMP) compliant set up. Multidimensional control charts linked 
off-line information on cell growth, culture viability and protein concentration to the 
on-line NIRs signal. This study is a proof of concept of PAT and QbD application to 
existing processes. In such an approach, routine manufacturing data consisting of both 
the on-line control system data and results from the off-line test panel (e.g. release tests) 
can be used together with data from failed or rejected runs to map the process design 
space and to build on-line process control. However, when “retrofitting” a design space 
model to an existing process, the exact borders of the design space cannot be accurately 
defined, as the process is typically run at set-point.
The goal and highest level of PAT and QbD requires strong scientific and mechanistic 
understanding of the process gained during process development, before manufacturing 
(Figure 1). Such a comprehensive and structured approach was found only in one study. 
Streefland et al. (64) generated a hierarchical process fingerprint model from DNA 
microarray data, used as a biological measurement of a  bacterial suspension’s quality, 
and from a combination of on-line NIRs data and on-line measurements of classical 
process variables. A design of experiments (DoE) was used to explore ranges of process 
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parameters and a single model was developed, describing the process in the domain of 
the experimental design. Such models can be used to assess if the process is executed 
within the investigated design space, to push a deviating process back into the design 
space, and to make real-time release decisions when the investigated design space is 
validated to ensure desired product quality. The scope of this study was extensive but 
it lacked validation of the design space model and scalability testing scalability in a 
manufacturing setting. Nevertheless, the approach of first developing highly structured 
datasets and then hierarchical models to define a process design space as well as the 
strong emphasize given to the assessment of product quality and its link to process 
control clearly tends towards the highest level of PAT and QbD, where quality of the end 
product is built in the process design.
4 Concluding remarks and future perspectives 
Addressing PAT and QbD for cell cultures is challenging, partly due to the many varying 
parameters and thus the complex analyzers necessary to capture all bioprocess variance 
and also to the resulting complex datasets. MVDA is therefore essential for PAT and QbD 
implementation on these bioprocesses.
We have highlighted the strong link between the nature and features of the bioprocess 
datasets, the necessity for MVDA approaches, and the level of the PAT implementation. 
The most powerful applications of MVDA are typically obtained when applied to highly 
structured datasets that comprise most of the process design space and include both 
data from on-line fingerprinting tools as well and data on product quality and process 
performance. MVDA models based on these datasets will allow highly accurate control 
of product quality in real-time, reducing failure and rework and thus reducing cost 
while increasing safety for the patient. However, this highest level of PAT and QbD 
has not been reached yet, probably because these studies typically take place in later 
process development and are therefore not disclosed because of company strategy. A 
QbD-based design space submitted by Genentech/Roche has been approved by the 
FDA at the end of 2013, but no PAT elements were included. To our knowledge, although 
a lot of applications are published during process development, there has never been a 
filing of a formal PAT/QbD based cell culture process to regulatory agencies. 
Overall, given all the limitations underlined in this paper, we expect that full PAT 
and QbD implementations for cell cultivation will not be achieved in a near future. 
Nonetheless there is a clearly growing interest in exploring and modeling data to 
increase process understanding and control. Progress has been made in early stages of 
process development, where multivariate analyses are becoming common. Structured 
and statistical approaches (DoE for instance) are also being more frequently used during 
process characterization or late stage of process development. 
Considering MVDA applications for cell culture only, this technique is not a “one-size fits 
all” solution, but rather an enabling tool that generates unique models to address defined 
questions or issues on a specific process. With a continuous rise in scientific understanding 
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of bioprocesses and more researchers learning the power of MVDA for bioprocess data, 
we expect that more advanced MVDA examples will be published in the future. 
The next step to reach full PAT and QbD implementation for cell cultures will be 
to build complex hierarchical MVDA models for establishing process control strategies 
from multivariate PAT tools. Inputs and outputs of all process steps should be considered 
in these models, from seed expansion to production cultivation, possibly even including 
downstream processing. Efforts will need to focus on validation and confirmation of 
these models. In the end, release decisions of intermediate and final products should be 
based on these models, immediately after completion of a process step. The question 
remains how fast this rather high-tech approach to manufacturing will be implemented 
in an industry that traditionally sticks to technology that has been proven over decades.
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Chapter 3
Multivariate data analysis as a PAT tool  
for early bioprocess development data
Abstract
Early development datasets are typically unstructured, incomplete and truncated, 
yet they are readily available and contain relevant process information which is not 
extracted using classical data analysis techniques. In this paper, we illustrate the power 
of multivariate data analysis (MVDA) as a Process Analytical Technology tool to analyze 
early development data of a PER.C6® cell cultivation process. 
MVDA increased our understanding of the process studied. Principal component 
analysis enabled a thorough exploration of the dataset, identifying causes for batch 
deviations and revealing sensitivity of the process to scale. These findings were previously 
undetected using traditional univariate analysis. The lack of structure and gaps in the 
early development datasets made it impossible to fit them to more advanced partial least 
square regression models. This paper clearly shows that MVDA should be routinely used 
to analyze early development data to reveal relevant information for later development 
and scale-up. The value of these early development runs can be greatly enhanced if 
the experiments are well-structured and accompanied with full process analytics. This 
up-front investment will result in shorter and more efficient process development paths, 
resulting in lower overall development costs for new biopharmaceutical products.  
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ATF  Alternating tangential flow
CPP  Critical process parameter
CQA  Critical process attribute
DO  Dissolved oxygen
DoE  Design of experiment
FDA  Food and drug administration
MFCS  Multi-fermentation control system
MVDA  Multivariate data analysis
PAT  Process analytical technology
PC  Principal component
PCA  Principal component analysis
PDT  Population doubling time
PID  Proportional-integral-derivative
PLS  Partial least square
QbD  Quality by design
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1 Introduction
Upstream processes for production of biopharmaceuticals, such as mammalian cell 
cultivation, are among the most complex industrial processes because of the very sensitive 
relation between the manufacturing process and the complex large biomolecules 
produced. The more complex the process, the more elaborate the dataset. Full analysis 
of these highly elaborate datasets is time consuming and difficult. However, analysis of 
bioprocess data is key for building the solid understanding of the production process 
required for commercialization of a biopharmaceutical product.
The Process Analytical Technology (PAT) initiative, launched by the United States Food 
and Drug Administration (FDA) in 2004, encourages biopharmaceutical companies 
to develop “a system for designing, analyzing and controlling manufacturing through 
timely measurements of critical quality and performance attributes ... with the goal of 
ensuring final product quality” (1). The aim of PAT is to monitor and control all critical 
process parameters (CPPs) that affect process performance or critical quality attributes 
(CQAs) of the final product, to ensure consistent and adequate product quality during 
manufacturing (2). Ultimately, PAT implementation leads to obtaining new information, 
which is used to make (real-time) process control decisions. To reach this aim, PAT relies 
on implementation of adequate data analysis systems, as well as on development of 
new analytical tools and on application of process quality control principles (3). Efforts to 
implement PAT on cell cultivation processes range from characterization and screening 
of complex raw materials (4,5), and use of analytical tools for online monitoring of 
bioreactor cultivations (6,7), to application of multivariate analysis of data for online 
batch performance modeling and quality prediction (8). Quality-by-design (QbD) is a 
quality concept that makes use of scientific understanding of the manufacturing process 
to build quality in, instead of testing products’ quality post-manufacturing (2,9-11). 
Scientific understanding of a bioprocess typically includes two aspects. Firstly, statistical 
analyses should be applied in order to identify the relations and interactions among 
process parameters. 
Secondly, mechanistic principles underlying the biological process should be 
studied, in order to explain the mechanisms and principles behind these interactions, 
and to support the findings of the statistical analyses. This combination can be used 
to build sound process control systems with the required knowledge of the process, to 
ultimately ensure product quality and patients’ safety. In this context, PAT is therefore a 
tool enabling the implementation of QbD.
The initial steps for the implementation of PAT on an upstream bioprocess focus on 
gaining understanding of the process and on implementing appropriate analytical tools 
capturing relevant information on the end product and on the process dynamics, typically 
in the early phases of a process development (Figure 1). Statistical analyses on the 
complete dataset containing the additional information should lead to the identification 
of correlations between process parameters and product quality. The ultimate goal of 
QbD using PAT is to define the process design space, which is the “combination and 
interaction of input variables and process parameters that have been demonstrated to 
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provide assurance of quality” of the end product (11). The design space is typically 
explored with statistical experimental designs, during process characterization (late 
phase of a process development) (Figure 2).
Multivariate data analysis (MVDA) plays a key role in the implementation of PAT and 
QbD for biopharmaceuticals, as it enables the transformation of the enormous amount 
of data generated by process analyzers into relevant and crucial process information 
(12). Large amounts of data are generated during the (early) development phases of 
bioprocesses, in which parameters are intendedly or unintendedly varied in experiments 
for screening or optimizing process settings (Figure 2). In these early development datasets, 
statistical experimental design techniques like design of experiments are often not applied, 
and the data may be incomplete or not fully documented. MVDA on early development 
batches where unforeseen variations occur frequently would therefore likely reveal relevant 
information about the interactions between process input and output variables.
In this article, we present a detailed case study of MVDA applied to early development 
data of a biopharmaceutical cell cultivation process, as a preliminary step in the 
implementation of PAT on this process. The initial purpose of these runs was to develop 
a working process suitable to find failure limits and that can be a basis for further 
development. These runs are therefore feasibility studies and the preliminary steps in 
process development, where small experimental designs were performed testing side-
Figure 1. Proposed workflow to address initial steps of PAT and QbD: building process understanding 
and implementing analytical tools.
Figure 2. Biopharmaceutical development life cycle: phases of clinical and process development and 
associated process scale and experimental approaches. 
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by-side different conditions. The objective was to evaluate the strengths and limitations 
of MVDA for these unstructured, incomplete and truncated datasets. We successfully 
showed that MVDA of early development data enables the identification of gaps in 
process knowledge and of experimental shortcomings, which are crucial information to 
further develop a robust and well controlled bioprocess. 
2 Background
2.1 Features of bioprocess datasets
The many variables routinely recorded for biopharmaceutical cell cultivation processes 
can be divided into three categories (Figure 3): input variables (e.g. setpoints, raw 
materials), process variables (e.g. pH or DO trends) and output variables (e.g. sample 
analyses, product quality).
These bioprocess datasets are difficult to analyze for several reasons. Firstly, 
variation in input variables, such as quality of raw materials or viability of the preculture 
cells, causes poorly understood effects on process responses like cell growth rate or 
metabolic profiles (4,13,14). Secondly, most of the process variables recorded are 
dynamic. This time-related-variation can be very different for each variable, making 
the complete analysis of these process variables highly complex. Thirdly, the frequency 
of measurement and of data recording (online versus offline) can be considerably 
different from a variable to another. For instance, variables such as temperature or pH 
are typically recorded every second, while process responses such as cell density, culture 
viability or end product concentration are only measured once or twice per day, which 
results in a dataset with a complex structure. Fourthly, interactions and correlations 
between process variables (e.g. cell and main metabolite concentrations, gas demand, 
etc.) are inherent in such datasets because of the biological nature of these processes. 
Fifthly, quantity and quality of the end product of a bioprocess are the cumulative result 
of complex biological reactions taking place for up to several weeks, and can therefore 
vary substantially from batch to batch. 
Figure 3. Schematic representation of bioprocess datasets. Process input (e.g. raw material quality) 
typically contains variation in quality whereas processes are run at pre-determined, fixed and 
controlled set-points, which can lead to substantial variation in process output (quantity or quality).
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2.2 Multivariate analysis for bioprocess data
These large bioprocess datasets therefore require more advanced statistics to evaluate 
the quality of the process than the traditional linear principles based statistical process 
control charts (15). Classical linear techniques using univariate analyses or bivariate 
regressions applied to such complex datasets may result in misleading interpretations 
and conclusions (16). Indeed, with the use of univariate statistical control charts, several 
correlating parameters can be flagged as deviating in case of an abnormal batch 
behavior. In such a case, it is often difficult if not impossible to isolate or clearly identify 
the root cause of the deviation, since parameter dynamics and interactions are not 
considered in the analysis. 
Bioprocess data is therefore best analyzed using multi-variate techniques, as they 
address the multidimensionality nature of bioprocess datasets (12). Multi-way principal 
component analysis (PCA) and multi-way partial least squares (PLS) regression are two 
common MVDA techniques that have been proven useful in the biopharmaceutical field 
as they account for complex behavior and correlations in dynamic batch processes 
(17-19). PCA is typically used in a first step to study the structure of a dataset. After 
projection along different orthogonal axes, underlying structures (trends or clusters) 
in the dataset can be identified. PCA provides handholds for further investigations 
to identify previously unknown causes for structures in the dataset. In a second step, 
PLS can be used to capture and describe in a regression model the relations and 
interactions among process variables. On one hand, PLS enables the identification and 
understanding of the relations between process outcome and process variables. On the 
other hand, after proper calibration and validation, PLS models can be used to predict 
the evolution of process variables and process outcome in newly generated datasets. 
The use of MVDA as a PAT tool for biopharmaceutical processes has gained 
considerable interest over the last decade (12,20-22). The examples mostly use 
datasets originating from (large scale) pilot or manufacturing runs, which are typically 
complete yet poorly structured, meaning that the runs are intended to be identical 
and experiments are not designed to identify interactions among variables or explore 
process capabilities. Already on these datasets where batches are mostly similar, MVDA 
often reveals correlations that remained undiscovered using traditional linear statistics. 
3 Materials and methods
3.1 Bioreactor cell cultivation process
The dataset comprised 17 2L and 10 10L PER.C6® cell cultivation runs operated in 
perfusion. Human immortalized retinal PER.C6® cells (Crucell, Leiden, The Netherlands) 
were thawed and cultivated in Crucell’s proprietary and chemically defined PERMEXCIS® 
medium (Crucell, Leiden, The Netherlands), supplemented with 4mM L-Glutamine 
(Invitrogen, Paisley, UK). Cultures were expanded in roller bottles (Corning Costar Inc., 
Amsterdam, the Netherlands) or BIOSTAT® Cultibags RM (Sartorius Stedim Biotech, 
Aubagne, France) every 3-4 days before inoculation of either 2L or 10L autoclavable 
45
glass bioreactors (B. Braun Biotech, Melsungen, Germany). pH, DO, temperature and 
stirrer speed were controlled at constant levels. Online process variables were recorded 
using a multi-fermentation control system (MFCS/win, Sartorius, Goettingen, Germany). 
An alternating tangential flow (ATF) system (Refine, Pine Brook, NJ) with a 0.2 µm 
hollow fiber module was used for cell density driven perfusion with PERMEXCIS® based 
medium (Crucell, Leiden, The Netherlands). This perfusion process was designed to 
expand the PER.C6® culture to extremely high densities before viral infection. The cells 
were retained in the bioreactor vessel and only filtrate of waste medium was continuously 
extracted while fresh feed was supplied to keep a constant working volume. Samples 
from bioreactors were taken daily for the measurements described in table 1.
Table 1. Parameters measured on bioreactor samples and corresponding analyzers.
Parameter measured
Analyzer
Type Supplier
Cell concentration Viability CASY Roche Innovatis, Almere, The Netherlands
pH Bench pH meter WTW, Weilhem, Germany
pCO2
pO2
ABL5 Radiometer, Zoetermeer, the Netherlands
Ammonium Glucose
Glutamate 
Glutamine
Lactate
Potassium
Sodium
Bioprofile 400 NOVA Biomedical, Rödermark, Germany
Phosphate Vitros DT60 II Johnson & Johnson, Rochester, NY
Osmolality Fiske 210 Micro-sample Advanced Instruments Inc., Norwood, 
MA
3.2 Multivariate data analysis
3.2.1 Background on the techniques used
The two MVDA techniques used to analyze the available dataset were multi-way PCA 
and multiway PLS.  These techniques first unfold the three-way datasets (batches, 
process time interval and process variables, see Figure 4). PCA summarizes information 
of the original multidimensional dataset into a smaller set of uncorrelated variables 
called principal components (PC), by the mean of projections (23). The resulting models 
fit the data as closely as possible in the least squares sense, meaning that variance 
of the original data is maximized when projected onto the new coordinates, and the 
squared residual variance is minimized. PLS is a linear regression method based on 
the calculation of new variables as well. PLS models analyze the covariance between a 
matrix of process variables, and a matrix of process responses. The aim is to relate the 
variable matrix to the response matrix and to predict the latter (24).
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3.2.2 Software
Raw process data were first assembled in Excel (Microsoft, Redmont, WA), and then 
SIMCA-P+ 12 version 12.0.1 (Umetrics AB, Kinnelon, NJ) was used for MVDA.
3.2.3 Data collection
Datasets from 2L and 10L runs were assembled similarly. For each set, offline variables 
(e.g cell count, nutrients concentrations, osmolality, etc.) were recorded in a digital 
format. Online process variables recorded by MFCS were extracted from this data 
base and averaged every 30 minutes to reduce the size of the dataset. This averaging 
timescale was chosen as the biological reactions occurring during the process are rather 
slow (the process ran for at least 7 days), and the timescale of most of the process 
perturbations appeared to be higher than this time interval. Relevant information on 
incoming material (e.g. performance of seed, medium and additives lot numbers, 
etc.) and starting conditions (e.g. process set-points, equipments, operators, etc.) were 
collected and selected. Online variables, offline variables and initial conditions for all 
runs were finally assembled in an Excel spreadsheet and imported into SimcaP+ 12.
3.2.4 Data pre-processing and variables selection
Gas flow variables displayed spiky profiles since they were supplied on demand 
throughout the process as a response to the control loops feedback for dissolved oxygen 
and pH. Such noisy profiles caused disturbance when generating models. Online air, O2 
and CO2 flow data were therefore summed at each 30 minutes interval (i.e. smoothed) 
and cumulative gas production or consumption was considered. Additionally, every 
offline and gas related variable was normalized to bioreactor volume when necessary, 
thereby removing obvious dependency on bioreactor scale. 
Based on a priori process knowledge and iterative exploration, variables best 
representing process behavior were included in the models. The original and selected data 
sets of process variables are showed in table 2, where the unit for each variable and the 
rational for exclusion from multivariate models are detailed. During the variable selection 
process, the aim was to exclude variables with low impact and low reliability, and to avoid 
unnecessary redundancy caused by strong correlations among variables or by the fact that 
some variables are generated by direct calculations from measurements or control outputs. 
For each variable and each observation, up to 50% of missing values were tolerated 
and accounted for by SimcaP+, thanks to the projection methods used for the modeling. 
Below this default tolerance limit, variables or observations were excluded for the fit and 
prediction analyses.
The output variables, or process responses, selected to build the models were 
population doubling time (PDT) between inoculation and harvest and viability of the 
culture at the end of the runs. The ranges of the output variables contained in the 
dataset are given in table 3.
Batches included in this study were of different lengths. Two approaches were 
explored to overcome time alignment challenge (Figure 4). In one case, only batches 
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Table 2. Original and selected sets of process variables including units and rationale for exclusion from 
multivariate models.
Type of 
variables
Variable 
(underlined variables were 
included in multivariate models) Unit
Rationale for exclusion from multivariate 
models
Offline Total cell density Cell/mL Obtained from direct calculation using viable 
cell density and viability
Viable cell density Cell/mL
Viability % Process response
Cell diameter µm
Population doubling time hrs Process response
Feed rate mL/day Obtained from direct calculation using specific 
perfusion rate set-point and viable cell density
Total culture volume L Low impact, constant throughout process
Glutamine concentration mM Data not available for 56% of the batches
Glutamate concentration mM Data not available for 56% of the batches
Glucose concentration mM
Potassium concentration mM Data not available for 56% of the batches
Lactate concentration mM
Sodium concentration mM Data not available for 56% of the batches
Ammonium concentration mM Data not available for 56% of the batches
Phosphate concentration mM
pH -
Osmolality mOsm/kg
pCO2 mmHg Data not available for 56% of the batches
pO2 mmHg Data not available for 56% of the batches
Online Dissolved oxygen %
pH -
Temperature ºC
Actual air flow L/min Spiky profile causing disturbances in the models
Actual CO2 flow L/min Spiky profile causing disturbances in the models
Actual O2 flow L/min Spiky profile causing disturbances in the models
Normalized cumulative air demand * mL/L Low impact, controlled at set-point and did 
not vary from batch to batch
Normalized cumulative CO2 supply * mL/L
Normalized cumulative O2  supply * mL/L
Sodium bicarbonate pump totalizer mL Low reliability due to operating errors
Permeate pump totalizer mL Obtained from direct calculation using specific 
perfusion rate set-point and viable cell density
Feed pump totalizer mL Obtained from direct calculation using specific 
perfusion rate set-point and viable cell density
Bioreactor weight Kg Low impact, constant throughout process
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longer than 11 days were considered and the shorter batches were excluded. In the 
second case, all batches were truncated at 7 days of culture, which is the length of the 
shortest batch.
3.2.5 Multivariate analysis and modeling techniques
In order to keep as much information as possible for the explorative analysis of the 
large dataset available, online and offline data were analyzed separately. Indeed, data 
reduction needs to be applied when these data collected at different frequencies are 
combined, which may lead to a loss of information.
In the present study, the steps taken to analyze the data followed the complete and 
detailed descriptions of Kirdar et al. (25,26) (Figure 5), and are therefore only briefly 
explained here. 
First, the evolution of batches’ behavior over their duration was monitored using 
observation level modeling. At this stage, PLS was used to relate the process data to a response 
variable representing local batch time or run maturity, in order to explore run progression 
over time. Obvious outliers that deviated as a result from a priori known root-causes (e.g. 
technical or operating deviations) were identified and excluded from the analysis. 
Table 3. Range of the output variables contained in the dataset.
Output variable Population doubling time (h) Viability (%)
Range 29.1 – 92.6 70.2 – 86.3
Figure 4. Schematic representation of data multiway unfolding. In option 1, only batches longer than 
11 days were considered, the shortest batches are excluded. In option 2, all batches are truncated at 
7 days of culture. For both options, data excluded are shaded.
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Next, batch level modeling was developed, where batches were modeled as single 
units. PCA models were first developed to analyze overall batch behavior. Secondly, 
PLS models were developed to understand how process responses were influenced by 
process data or initial conditions. For both PCA and PLS, score plots were used to study 
the structure of the dataset: in short, batches plotted close to each other behaved similarly 
whereas batches plotted far away from each other behaved differently. Diagnosis using 
cluster or pattern identification was done. Outliers still present in the dataset were 
identified on the score plots if they fell outside the 95% Hotelling’s T2 ellipse (see Figure 
6), or if they were identified as outliers in the corresponding residuals model. Loadings 
were used to identify the variables having the greatest contribution to the variance of the 
data, therefore the greatest contribution to the models.
4 Results and discussion
4.1 PCA and evaluation of the structure of the dataset
The first step in applying MVDA on bioprocess data is to investigate the structure of the 
dataset using PCA. In this way, clusters of batches, process deviations or disturbances, 
and process trends can be identified. This analysis is necessary to exclude strongly 
deviating batches or to compensate for trends that would hamper further modeling (e.g. 
time alignment, variables scaling, etc.). 
Table 4 details the variance in the dataset captured by each principal component 
(PC), as well as the cumulative variance captured by the PCA models obtained from 
Figure 5. Overview of batch statistical process control via batch modeling. Figure adapted from 
Kirdar et al. 2008.
50
M
ultivariate data analysis as a PAT tool for early bioprocess developm
ent data
3
offline and online variables. Note that when models contain several PCs, most of the 
information generally lies in the projections on the first two or three PCs, but additional 
information may still remain in the other PCs. The choice of PCs represented in figure 6 
and figure 7 was made based on a systematic analysis of the score plots, to ensure that 
the selected plots display most of the relevant information. 
Figure 6 and figure 7 show PC1 and PC2 for the offline variables model, and PC1, 
PC2 and PC3 for the online variables model respectively. In these models, all batches 
were truncated after 7 days of cultivation (option 2 of Figure 4). Models generated from 
the analysis of the sub-set of batches lasting at least 11 days (option 1 of Figure 4) are 
not shown since no additional relevant information was gained compared to the data of 
the first 7 days only. This shows that the structured variance that is captured in the PCA 
models is present in the data collected from the early phase of the run. 
Clustering based on process scale was strong for the model of offline data (Figure 6) 
and was even more obvious for the models of online data (Figure 7), although batch 18, 
which is a 10L batch, is grouped with the 2L runs in the offline score plot (cause unknown). 
Process scale appears to cause a clear operational difference in process variables monitored 
both online and offline, despite the normalization to bioreactor working volume (Table 2). 
Analysis of raw online data suggested that O2 and CO2 demand throughout the process 
was greater for 2L cultures than for 10L cultures (P ≤ 0.01). The cell density and associated 
population doubling time profiles were comparable at 2L and 10L, therefore this observation 
is not imputable to a difference in performance of the batches at these two scales. After 
closely reviewing the scaling of the process, the most probable explanation was found in 
the aeration strategy which was not linearly scaled between the two bioreactor volumes: 
the constant air flow supplied per culture volume varied between the two systems, which 
Table 4. Variance captured in each principal component (PC) and cumulative variance captured by 
the PCA models for offline and online variables.
Type of variables 
used in model
PC Variance captured (%)
in each PC cumulative
Offline 1 21.5 21.5
2 15.3 36.8
3 11.7 48.6
4 10.5 59.1
5 7.7 66.8
6 6.6 73.4
Online 1 51.1 51.1
2 15.8 66.8
3 14.4 81.2
4 5.2 86.4
5 3.1 89.5
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Figure 6. PCA score scatter plot and 95% Hotelling’s T2 ellipse from offline variables of 2L (closed 
diamonds) and 10L (open diamonds) batches truncated after 7 days of culture. Circled batches are 
further analyzed in the text. 6 principal components explained 66% of the variation contained in the 
dataset. The dashed line separates the clusters based on process scale.
Figure 7. PCA score scatter plots and 95% Hotelling’s T2 ellipse of PC1 vs PC2 (a) and PC1 vs PC3 (b) 
from online variables of 2L (closed diamonds) and 10L (open diamonds)  batches truncated after 7 days 
of culture. Circled batches are further analyzed in the text. 5 principal components explained 89% of the 
variation contained in the dataset. Note that batch 26 is identified as an outlier due to high residuals.
was reflected in the cumulative gas demand throughout the process. In addition, detailed 
investigation of raw offline data revealed cell diameter on average 1.1 µm smaller for the 
10L cultivations than the 2L (P ≤ 0.01). Further analyses of the operating parameters of the 
ATF showed that the cross flows inside the fibers of the ATF module were different in the two 
bioreactor scales. The shear rates in the two systems were therefore different, which can 
have caused the observed difference in cell diameter. 
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Overall, PCA enabled to unveil technical process variations between 2L and 10L 
scales, which were previously not obvious, and for which the effect on process behavior 
were not known. 
Furthermore, batch diagnosis was performed from the PCA modeling. The batches 
presenting a different score on the PCA model than the main cluster of batches were 
further analyzed for individual investigation of the causes for these deviations. The 
process variables included in the models and contributing to the scores of these batches 
were used to identify the corresponding process deviations from the raw data. Table 5 
is an overview of process diagnosis achieved using PCA modeling. Batches of interest 
for diagnosis (batches 7, 8, 9 and 10 for offline model and batches 11, 16 and 24 for 
online model) are circled on the score plots in figure 6 and figure 7.
Sensitive changes in process behavior were caused by altered concentrations of 
additives in feed medium during the perfusion (this batch was part of an experiment 
where lower starting glucose and glutamine concentrations were tested), by an 
inoculation at twice the target cell density for the offline variables (operational error), 
and by a change in the procedure for medium preparation (powder lot of medium 
hydrated inhouse versus use of medium hydrated by the supplier) and by a deviation 
in DO probe calibration for the online variables (operational error). Note that for two 
batches deviating in the PCA models, no process deviation could be found. Overall, 
PCA enabled a fast and systematic analysis of the dataset and the identification of 
technical procedures which alter the process behavior.
Table 5. Overview of batch diagnosis from PCA models for offline and online variables: deviations 
observed in the models and corresponding process observations.
Variables 
used in model Batch Deviation in model Process observation
Offline 7-8 Score on first component; contribution 
of cell diameter and osmolality during 
second half of process
Altered concentration of additives in 
feed medium (lower starting glucose 
and glutamine concentrations)
9-10 Score on second component; 
contribution of viable cell density 
throughout process
Inoculation cell density twice the target
Online 11 Score on second component; 
contribution of pH throughout process
Powder medium hydrated in-house, 
whereas all other batches used liquid 
medium hydrated by the supplier
16 Score on second component; 
contribution of pH and CO2 
demand throughout process
No deviation identified
24 Score on third component; 
contribution of DO throughout 
process
Deviation in calibration of DO probe 
(calibration at 105% instead of 
100% at the start of the run)
26 Residuals larger than critical limit No deviation identified
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4.2  PLS modeling and analysis of relations between process 
parameters and process responses
The aim of PLS is to establish correlations between process parameters and process 
responses, and to identify parameters that influence the quality of process response. 
Process responses or product CQAs considered in this study were population doubling 
time (PDT) throughout the runs and viability at the end of the runs. These CQAs were 
chosen as the aim of the cell expansion process studied here is to produce a high viable 
cell density seed in a short time, to seed a larger scale virus production process. Based 
on previous knowledge, a batch was considered of high quality when viability at the end 
of the run was above 85% and when PDT was lower than 40h (note that high PDTs reflect 
low growth rates and vice versa). 
A preliminary analysis of the dataset showed that there was no significant difference 
in process performance between the 2L and 10L batches, for both PDT and viability 
(data not shown). However, due to the apparent effect of bioreactor scale on process 
behavior (Figure 6 and Figure 7), 2L and 10L runs were analyzed separately in this 
section. The main source of variation in the dataset was excluded in this way, to give the 
modeling a better chance to unveil more subtle sources of variation that would otherwise 
be obscured by the large scale effect.
The PLS models showed a poor fit and did not bring additional information on 
the process, therefore they are not shown. Relevance of models is typically expressed 
as the percentage of variation contained in the process variables dataset and used in 
the model, and as the percentage of variation in process responses explained by the 
model. In all the PLS models generated here, a limited part of variation in process 
variables (maximum of 55%) was modeled and used to explain up to 75% of variation 
in process responses. This means that on one hand, a lot of variation contained in 
the process variables dataset was not structured (e.g. not large, not redundant or very 
noisy) and could not be captured in the models. On the other hand, even if the portion 
of variation in process responses captured was relatively high in some models, further 
investigations of raw data did not lead to major information on interactions between 
process parameters and process responses. 
5 General discussion
Multi-variate analysis of available historical data of the cell expansion process described 
in this study highlighted new relevant information on the process. A thorough exploration 
of the dataset was done using PCA. The impact of changes of procedures for the batches 
preparation (medium preparation, probes calibration, bioreactor inoculation) was 
previously unknown and was clearly exposed using PCA. 
Additionally, PCA proved to be a valuable tool to pinpoint the sensitivity of the 
process to scale, whereas scale effects were previously not considered to be relevant 
between 2L and 10L. No significant difference in performance (for both viability and 
PDT) was observed between the batches operated at 2L and at 10L. This shows that the 
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technical deviations causing the clustering of the batches based on process scale do not 
affect process performance. The technical differences between 2L and 10L processes 
are therefore not critical for process outcome.
Moreover, the process deviations other than scale effect could not be related to 
process performance using PLS. This indicates that the process variables considered, 
and potentially the way they were measured or monitored (e.g. method, frequency), do 
not correlate with the CQAs as currently defined. A conclusion can be that the process is 
robust and that process responses are not affected by variations in process parameters. 
However, as mentioned above, this process is at the early phase of its development, 
which means that full optimization, characterization and investigation of full process 
operating ranges have not been performed yet (Figure 2). Only at the late stage of 
development, when all CPPs are identified and their optimal ranges to ensure good level 
of CQAs are known, can a process be considered robust.
Two other possible causes can explain the lack of fit of the PLS models obtained from 
the studied dataset. On one hand, process parameters were not varied in broad enough 
ranges to reveal their effect on CQAs. In other words the dataset lacks structure. On the 
other hand, the process variables currently monitored or the chosen process responses 
do not capture all the relevant information, either on the cells’ quality attributes side 
(intermediate product), on the process monitoring side, or on both sides. The implications 
of these issues for the use of MVDA to analyze early development data and for the use 
of PAT in early development are discussed below. 
5.1 The importance of dataset structuring for MVDA analysis
Common knowledge built on decades of experience in the field of cell culture typically 
identifies pH, temperature, DO and culture agitation as critical process parameters. 
These parameters were controlled at pre-defined set-points in the batches studied here 
and exhibited limited or no variance. As a consequence their effect on the CQAs could 
not be captured. This means that almost all variation in the dataset must have originated 
from other input variables, or starting materials, such as the medium (inoculation 
medium, feed and additives) and the cells (seed source and performance). 
When analyzing historical data or data from experiments done very early in the 
process development path, a structured approach is often not used or not in place 
yet. This case study showed that MVDA can still be used even on an unstructured 
experimental dataset, largely consisting of trial and error runs or one-factor-at-a-time 
experimental designs, to gain understanding on the process (e.g. sensitivity of the 
process to scale), and to identify relevant process steps which have been standardized 
(medium preparation, probes calibration). This information was previously not exposed 
using classical univariate analysis (i.e. trending), which shows that MVDA, which is a PAT 
tools commonly used in late process development or routine manufacturing stages, is a 
very useful tool for exploration of early development data.
Ideally, in order to identify the CPPs, and properly define the complete process design 
space and the corresponding safe operational ranges for the CPPs, the parameters 
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would have to be varied in a fully structured and designed way, for instance by using a 
full factorial Design of Experiments (DoE) approach. DoE is a methodology of choice to 
identify optimal process settings and interactions among process parameters (27,28). 
DoE leads to generating structured datasets, meaning datasets containing structured 
variation (29,30), which can be readily analyzed using multivariate techniques to 
build stable and robust models for the exploration of the process design space (31). 
Although this approach is usually an effort performed in later development stages, it 
is valuable to have structured data available in early development. Usually the most 
critical process parameters are known beforehand. By using fractional factorial designs 
or at least introduce structured variation for the most critical parameters, additional 
process understanding can be gained during early development. This understanding 
would already go beyond the typical yes-or-no information gained from simple one-
factor-at-a-time type of designs. 
5.2 Capturing all relevant process information
5.2.1 CQAs
At first sight, population doubling time and viability at the end of a run are obvious 
product quality attributes for this process, as the aim is to produce high densities of 
viable cells in a short time, to be able to seed a larger scale virus production process. 
However, since the cells produced in the process studied here are an intermediate 
product, quality requirements should be related to the subsequent process step. This 
means that the CQAs should be linked to the cells’ ability not only to grow, but also to 
bind virus particles and to replicate viruses, in short to the cell’s infectability. Biological 
features that characterize the best physiological conditions for cell infection are complex 
and not fully understood. Each stage of a viral infection process can be influenced by 
the physiological state of the cell (e.g. cell cycle, apoptosis, etc.). Therefore as a next 
step, additional measurements capturing biological features of the culture need to be 
investigated and related to the infectability of the host cells. For this, understanding 
of the mechanisms of cells’ infection and subsequent virus replication are needed 
to develop biological measurements capable of reflecting the cell’s infectability. For 
instance, analyses at the cellular or molecular level capturing the biochemical reactions 
taking place during cell’s infection are required. Such assays are essential to relate 
variation in process parameters to variation in this newly defined process outcome. This 
step of identification of “real” product CQAs is a prerequisite for the identification of the 
CPPs and the implementation of further (online) PAT tools.
5.2.2 CPPs
In this study, only classical measurements typically performed on bioreactor cultures 
were available: cell count, metabolites concentrations, pH, DO, temperature, etc. As 
these process variables did not correlate to the CQAs defined in this study, critical 
measurements are likely missing on the process monitoring side as well. To complement 
the classical univariate measurements done on bioprocesses, broad spectroscopic 
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analyzers such as near infrared or Raman spectroscopy could be used to capture process 
fingerprints (32,33). A process fingerprint describes the main patterns and trends 
occurring over the process time course and it typically yields qualitative information on 
the complete trajectory of a process. All information collected is not necessarily fully 
characterized and understood, but the use of multivariate techniques to build fingerprint 
models enables batch to batch comparison and detection of global process deviations 
(34). This approach is also supported by the comprehensive overview of applications 
of online monitoring to mammalian cell cultures, including associated MVDA methods 
provided by Teixeira et al. (35).
In this particular case, spectroscopic tools may therefore capture the relevant 
information related to the cell’s infectability in a single online measurement. Multi-
variate models can be used to assess whether this additional data captures information 
related to the CQAs directly, or related to surrogate process parameters which affect 
the CQAs, in other words related to the CPPs. The ultimate goal of PAT is to implement 
online analytical tools able to monitor the CPPs and which can eventually be used to 
control the CPPs in order to yield the desired level of quality of the CQAs.
6 Conclusions
Application of MVDA to early development of cell cultivation processes is rarely published, 
although all relevant process data is typically available. We demonstrated that systematic 
analysis of early development data using MVDA increased our understanding of the 
process studied. Deviating batches were identified in a more objective way using PCA 
than with classical approaches and PCA enabled targeted analysis of the causes of their 
deviation. Relevant steps in medium preparation, probe calibration and culture inoculation 
procedures have been optimized and standardized based on the outcome of this study. 
Moreover, PCA proved to be a valuable tool to reveal relevant features of the process, 
such as sensitivity of the process to scale. The scale effect between 2L and 10L processes 
were previously not considered to be relevant and this is now a topic for further research. 
MVDA is typically used on late development or manufacturing datasets. Despite the 
inherent shortcomings of datasets from early development, this study clearly shows the 
added value of using MVDA on these datasets as it helps to identify knowledge gaps, 
experimental flaws and uncontrolled variance. Gaining this information during early 
development is key to further develop robust and well controlled bioprocesses. 
In order to make full use of MVDA as a PAT tool throughout the entire process 
development path, MVDA should be routinely used and coupled with simple experimental 
designs providing the datasets with basic structure, with fundamental research on the 
process dynamics, and with the use of appropriate analytics. This strategy, which requires 
a larger investment up-front in the development path than classical approaches, will 
lead to shorter and more efficient process development and scale-up trajectories and 
will result in lower overall development costs for new biopharmaceutical products.
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Chapter 4
Characterization of apoptosis  
in PER.C6® batch and perfusion cultures
Abstract
Preventing or delaying cell death is a challenge in mammalian cell cultures for the 
development and optimization of production processes for biopharmaceuticals. Cell 
cultures need to be maintained highly viable for extended times in order to reach 
maximum production yields. Moreover, programmed cell death through apoptosis is 
often believed to occur without being detected by classical viability measurements. In 
this study, we characterized cell death in PER.C6® batch and perfusion cultures using 
three flow cytometry techniques measuring different steps of the apoptosis cascade: 
DNA fragmentation, caspases activation and phosphatidylserine externalization. We 
showed that apoptosis is the main pathway of PER.C6® cell death in batch cultures 
after depletion of main carbon sources. In high cell density perfusion cultures fed at 
a constant specific perfusion rate, both high viability and very limited apoptosis were 
observed. When extending this perfusion process far beyond standard operations, 
cultures were exposed to suboptimal process conditions, which resulted in an increase 
of apoptotic cell death. Moreover, we showed that the reference viability measurement 
using trypan blue exclusion properly assesses the level of cell death in PER.C6® cultures. 
This study is a first step in understanding the mechanisms of PER.C6® cell death, which 
will be helpful to support applications of the cell line. 
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1 Introduction
Understanding the mechanisms of cell growth and cell death in mammalian cell 
cultures is essential for the development and optimization of production processes for 
biopharmaceuticals. To reach maximum production yields (e.g. for monoclonal antibodies 
or more complex products such as viruses), cell cultures need to be maintained highly 
viable for extended times. Minimizing cell death is therefore an important challenge for 
industrial processes (1,2).
Cell death in mammalian cell cultures occurs in two ways: passive death called 
necrosis and programmed death called apoptosis. Necrosis occurs when cells are 
exposed to sudden and acute environmental stresses that cause irreversible damages 
to the cells. This results in cell swelling, loss of cell membrane integrity and finally 
uncontrolled release of cellular structures and organelles after cell disruption (3,4). In 
contrast, apoptosis is an actively regulated and genetically programmed way of cell 
death often referred to as cell suicide, which is triggered by either intrinsic or extrinsic 
stress or death signals (5). Specific morphological changes characterizing apoptosis 
include cell shrinkage, appearance of cytoplasmic blebs at the cell surface giving 
rise to apoptotic bodies, and condensation of chromatine followed by endonuclease 
fragmentation of nuclear DNA into 180-200 bp fragments (6). Cells that undergo 
apoptosis do not release their cellular content into the surrounding broth; they separate 
in small vesicles containing parts of the cell contents. Apoptosis and its mechanisms 
in mammalian cells are well understood and extensively described, as shown by the 
numerous elaborate reviews on this topic (6-8).
Several biochemical steps of the apoptotic cascade are of importance for the detection 
and measurement of apoptosis in cell cultures mostly using flow cytometry methods. 
Caspases (cysteine-aspartic proteases), which are expressed in an inactive form in healthy 
cells, are activated in cascade during apoptosis (6). Active caspases can be detected with 
labeled caspase substrates or inhibitors (9). During apoptosis, DNA is broken down into 
180-200 base pairs fragments by calcium and magnesium-dependent endonucleases 
(10). The free  3’OH nick ends of these DNA fragments can be detected by specific 
incorporation followed by straining of deoxyuridine triphosphate (11). Expression of cell 
surface markers is also widely used to detect apoptosis. For example, the translocation of 
phosphatidylserine from the inner- to the outer-layer of the cell membrane during apoptosis 
can be detected using specific binding proteins such as Annexin V. (12). Additionally, 
DNA staining with readily detectable dyes such as propidium iodide (PI), ethidium 
bromide, 7-Aminoactinomycin D (7-AAD) or Hoechst 33342 can also be used to detect 
either morphological changes such as chromatin condensation, or plasma membrane 
permeability to the dyes (13,14). With a combination of these flow cyotmetric methods, a 
detailed analysis and quantification of apoptosis in cell cultures is achieved (15).
While necrosis is usually triggered by acute stressors like shear or sudden high 
osmotic pressure, apoptosis is triggered by more gradual events such as depletion of 
nutrients, accumulation of metabolic by-products or damage of the central genome. 
During cultivation in a controlled bioreactor system, apoptosis is therefore more likely 
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to happen. The first evidence of apoptotic cell death in in vitro cultures of commercially 
relevant cell lines has been exposed in the 1990’s (16-18). Since then, dynamics, 
mechanisms and causes of cell death in cell cultivation processes have been widely 
studied for the cell lines commonly used by the biopharmaceutical industry. Several 
papers describe apoptosis in the well-known Chinese hamster ovary (CHO) cell line, 
which is commonly used for monoclonal antibody production (5,19-23). Studies on 
apoptosis in CHO cultures often aim to develop strategies to inhibit or delay cell death in 
cultivation processes by improving the extracellular environment either by supplementing 
cultivation media or optimizing process conditions (24-26). 
Another way to delay apoptosis is to alter natural apoptotic pathways by engineering 
cell lines with anti-apoptotic genes or by silencing the expression of apoptotic genes. 
These processes have been widely described for example for CHO (27-29) and for human 
embryonic kidney HEK-293 (30,31). Another example of a genetically immortalized 
cell line that is developed by introducing anti-apoptotic genes is the human PER.C6® 
cell line. PER.C6® cells are derived from embryonic retinoblast cells and immortalized 
similarly to HEK-293 by transformation with the E1A and E1B-encoding sequences of 
Adenovirus 5 (32,33). Briefly, expression of the E1A gene results in deregulation of 
the cell cycle: cells lose the ability to exit the cell cycle and enter the G0 or quiescent 
phase and they are stimulated to enter into the S phase and to proliferate (34). The E1A 
product also activates defense mechanisms that initiate apoptosis (35,36). E1B counters 
this apoptosis induction. E1B encodes two proteins that on the one hand inhibit the 
function of p53, a tumor suppressor protein, and on the other hand are homologous 
to Bcl-2, an anti-apoptotic protein, thereby negatively regulating several apoptosis 
induction pathways (36,37). The combined mechanisms of these two genes therefore 
lead to cell lines able to regulate and delay apoptosis and to proliferate at high rates.
Several biopharmaceutical PER.C6®-based products are current in (pre-)clinical 
development, including Adenovirus-based vaccines (38-40), of Influenza vaccine 
(41-43) and of Polio vaccine (44).  High level expression of IgGs and IgMs has also been 
reported in PER.C6® (45,46). To support these applications of the PER.C6® technology 
and to facilitate process optimization, fundamental studies of the cell line are required. 
The functions of apoptosis regulation of the E1 genes are well described in literature. 
However, the effect of this immortalization strategy on PER.C6® apoptotic cell death 
in industrial cell cultures has never been studied. Therefore in the present study, we 
describe and characterize the dynamics of cell growth and cell death in batch and high 
cell density perfusion cultures of suspension PER.C6® cells. Apoptosis was measured with 
three methods targeting different steps of the apoptosis cascade: phosphatidylserine 
externalization, caspases activation and DNA fragmentation. We show that although a 
low basal level of both apoptosis and necrosis is always measured, apoptosis is the main 
pathway for cell death at the end of batch cultures as well as at the end of perfusion 
cultures when suboptimal cultivation conditions are reached.
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2 Materials and methods
2.1 Cell line and growth condition
PER.C6® cells (Crucell, Leiden, the Netherlands) were thawed and cultivated in Crucell’s 
proprietary and chemically defined PERMEXCIS® medium (Lonza, Verviers, Belgium) 
supplemented with 4 mM L-Glutamine (Invitrogen, Paisley, UK). The parental PER.C6® 
cells used did not express proteins nor produced viruses in the processes studied, in 
order to be able to establish the basal apoptosis levels of the cell line as such. 
2.2 Batch cultures
Batch cultures were done in 250 mL disposable shaker flasks (Corning Costar Inc., 
Amsterdam, the Netherlands) with a working volume of 25 mL. Cultures were inoculated 
at 0.5 x 106 viable cells mL-1 and incubated in a humidified incubator at 37 ºC in 10% 
CO2 for up to 14 days. Agitation was set to 100 rpm on a IKA KS 260 shaker plateau 
(VWR International B.V., Amsterdam, the Netherlands).
2.3 Perfusion cultures
After expansion of PER.C6® seeds in roller bottles (Corning Costar Inc., Amsterdam, 
the Netherlands) or BIOSTAT® Cultibags RM (Sartorius Stedim Biotech, Aubagne, 
France), 13 L autoclavable bioreactor cultures (B. Braun Biotech, Melsungen, Germany) 
equipped with two marine impellers were inoculated at 0.8 x 106 viable cells mL-1 in a 
10L working volume. Temperature was maintained at 37°C by a heating blanket. The 
pH was controlled at 7.3 by addition of sodium bicarbonate or by adding CO2 to the gas 
inlet. Dissolved oxygen (DO) was controlled at 40% by sparging air and pure oxygen. 
Perfusion was run with an alternating tangential flow (ATF) system (Refine, Pine Brook, 
NJ, USA) and cells were continuously retained in the bioreactor due to the 0.2 µm hollow 
fiber module used (GE Healthcare, Breda, the Netherlands). Spent medium was extracted 
continuously while fresh medium was supplied to hold a constant working volume. The 
same medium was used for inoculation and feed. A constant specific perfusion rate (m3 
cell-1 s-1) was applied to maintain PER.C6® cultures in growth phase. Perfusion cultures 
were normally stopped on day 10, but in order to study the effect of process deviations 
encountered when extending the process, 3 perfusion cultures were prolonged until day 
14. Between day 10 and 11, when cell density exceeded 100 x 106 viable cells mL-1, the 
pumps supplying fresh medium and extracting spent medium reached their maximum 
output flow. From then and until the end of the runs, this maximum perfusion rate was 
maintained. Cultures were therefore no longer fed at the same specific perfusion rate 
and were thus exposed to suboptimal growth conditions. Samples were taken daily.
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2.4 Cell counting and reference viability measurements
Cell number and viability based on trypan blue exclusion were measured using a Vi-cell 
XR (Beckman Coulter Inc., Woerden, the Netherldands), according to manufacturer’s 
protocol. Cell specific growth rate between two sampling points was calculated as follows:
where µ represents cell specific growth rate, X1 and X2 representing total cell density of 
two samples (in x 106 cells mL-1) and t1 and t2 representing the time at which the two 
samples were taken.
2.5 Biochemical assays
Main metabolite concentrations (glucose, lactate, glutamine, glutamate and ammonia) 
were measured using a NOVA bioprofile 400 (LA Biosystems BV, Waalwijk, the 
Netherlands). pH was measured on a blood gas analyzer (ABL5, Radiometer, Zoetemeer, 
the Netherlands). Osmolality was determined using a Gonotech Osmomat 3000 
osmometer (Salm en Kipp BV, Breukelen, the Netherlands).
2.6 Flow cytometry
Three kits were used to measure the level of apoptosis in PER.C6® cultures using a Guava 
PCA Base flow cytometer (Merck Millipore, Amsterdam, the Netherlands). Externalization of 
phosphatidylserine (PS) was detected with Annexin V using the Nexin kit (Merck Chemicals 
BV, Amsterdam, the Netherlands). Activated caspases were labeled with a sulforhodamine-
valyl-alanyl-aspartyl-fluoromethyl-ketone (SR-VAD-FMK), a fluorochrome-conjugated 
inhibitor of caspases, in the MultiCaspases SR kit (Merck Chemicals BV). In both Nexin and 
MultiCaspases kits, 7-Aminoactinomycin D (7-ADD) was present to stain DNA of dead cells 
with a permeable membrane. Finally, the Tunel kit (Merck Chemicals BV) was used, where 
bromo-deoxyuridine (BrdU) was incorporated into fragmented DNA and subsequently 
labeled with a tetramethylrhodamine (TRITC)-conjugated anti-BrdU antibody. 
For the three assays, protocols recommended by the supplier were applied. Data were 
acquired and analyzed using the EasyCyte system of the CytoSoft software version 6.0.2 
(Merck Millipore, Amsterdam, the Netherlands). The results in percentage of the total cell 
population were determined independently for each category detected by the assays.
2.7 Data analysis
For the batch cultures, as it was possible to record replicates of measurements at the exact 
same time, the mean and standard error of measurements was reported on the graphs.  For 
the perfusion cultures, as practicalities made these simultaneous observations impossible, 
a linear model was adjusted on the data. The mean and 95% confidence interval (CI) of 
the mean from this linear regression were calculated as described elsewhere (47). CI is the 
interval of the mean responses conditional to the time. Briefly, CI was computed after logit 
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transformation of the data to constraint percentage value between 0 and 100%. Interval 
was then back transformed into original scale before plotting. The mean and 95% CI of 
the mean were reported on graphs to illustrate the kinetic of apoptosis.
3 Results and discussion
3.1 Cell growth and cell death in batch PER.C6® cultures
3.1.1 Performance of batch cultures
To describe cell growth and cell death dynamics of PER.C6® cultures in PERMEXCIS® 
medium, 14-day batches were conducted in triplicate. Cultures were in growth phase 
for 6 days, after which cells entered stationary phase followed by a decline phase from 
day 10 onwards (figure 1a). Culture viability measured based on trypan blue exclusion 
remained above 85% for 4 days. Viability then steadily decreased to a minimum of 
25% on day 14, when the cultures were stopped. Lactate, a by-product formed from 
inefficient metabolism of glucose, accumulated to a maximum concentration of 27.5 
mM at the moment of glucose depletion (day 4) and was afterwards consumed (figure 
1b). Both glutamine and glutamate were depleted during growth phase although a 
low residual level of glutamate was detected again from day 6 onwards (figure 1c). 
Ammonia is known for being produced during metabolism of glutamine and glutamate 
and it has a negative effect on cell growth in mammalian cell lines (48). Ammonia was 
present at a maximum of 3.5 mM at the end of the growth phase. These data describe 
a typical PER.C6® batch culture. 
Apoptosis was measured using the Tunel, MultiCaspases and Nexin assays on three 
independent samples on each sampling day for all three batch cultures. 
3.1.2 Apoptosis in batch cultures
D N A  f r a g m e n t a t i o n
The use of the Tunel assay enabled to discriminate two cell populations: TRITC positive 
cells, which presented fragmented DNA and therefore were apoptotic and TRITC 
negative cells without 3’OH DNA nick ends, which were viable. During batch PER.C6® 
cultures, accumulation of cells with fragmented DNA is very clear and reached 57% on 
day 14 (figure 2a).
R e g u l a t i o n  o f  c a s p a s e s
Monitoring of apoptosis in the same cultures with the MultiCaspases assay enabled 
discrimination of 4 populations. Cells positive for sulforhodamine-valyl-alanyl-aspartyl-
fluoromethyl-ketone (SR-VAD-FMK), which binds to active caspases, were apoptotic. 
Within this population of apoptotic cells, cells positive only for SR-VAD-FMK maintained 
their membrane integrity while activating caspases (early apoptotic), whereas cells 
positive for both SR-VAD-FMK and 7-Aminoactinomycin D (7-AAD) had active caspases 
and leaking membranes (late apoptotic). Double negative cells were considered live 
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and non-apoptotic. Finally cells only positive for 7-AAD were necrotic as they present 
permeable membranes but no active caspases. 
Results from the MultiCaspases assay showed that 93% of the total dead cells had 
active caspases at the end of the experiment (figure 2b). The portion of necrotic cells 
started at 12% of the total population and fluctuated around 25% during the first 8 days 
of culture. Early and late apoptotic cells however increased from 3 to 11% and from 3 
to 27% respectively. After day 8, during the decline phase, the portion of early apoptotic 
cells remained constant around 12% for the rest of the culture whereas late apoptotic 
cells increased to 62% and necrotic cells decreased to 4%.
P h o s p h a t i d y l s e r i n e  e x t e r n a l i z a t i o n
With the Nexin assay, three cell populations can be distinguished: double positive cells 
with externalized phosphatidylserine (PS) and permeable membranes to 7AAD that were 
dead, cells positive for Annexin V only that had externalized PS and were therefore 
apoptotic, and double negative cells that were viable non apoptotic cells. The population 
of dead cells increased from 10 to 30% in the first 4 days and further increased from 
30% to 70% in the last 6 days of the batches (figure 2c). This is consistent with the 7AAD 
staining observed in the MultiCaspases assay, when considering cells both positive and 
negative for active caspases. The percentage of Nexin apoptotic cells stayed constant at 
a low level between 5 and 9% throughout the batch runs.
Upon staining with the Nexin assay solely, it is impossible to differentiate necrotic 
from late apoptotic cells within the population of double positive dead cells. Indeed, it 
is reported in literature that Annexin V may be able to penetrate cells with compromised 
membranes integrity and stain PS on the inner layer of plasma membrane (49).
Overall, the data collected from these three assays suggested that during the growth 
and stationary phases of a batch PER.C6® culture (day 0 to day 8), both apoptosis and 
necrosis occurred at relatively low levels. However during the death phase, apoptosis 
cell death became dominant. Moreover, we showed that DNA fragmentation and active 
caspases are clear apoptosis markers in PER.C6® cultures. 
3.2 Cell growth and cell death in perfusion PER.C6® cultures
3.2.1 Performance of perfusion cultures
In the process studied here, PER.C6® cells were cultivated to high cell densities 
in perfusion mode. Perfusion enables to prevent both depletion of nutrients and 
accumulation of toxic by-products which, as shown in figure 1b and c, both occur in 
batch cultures. Typically, this perfusion process runs for 10 to 11 days, when the desired 
cell density required for the next process step is reached. 
Cell growth, viability and main metabolite concentration profiles for a representative 
perfusion run are showed in table I. The constant specific perfusion rate applied between 
day 0 and day 11 enabled to maintain the cultures in growth phase with a high cell 
growth rate between 0.017 and 0.022 h1. The  viable cell density obtained after 11 days 
of perfusion was 33-fold higher than the maximum viable cell density obtained in batch 
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Figure 1. Evolution of cell growth and main nutrient concentrations in batch PER.C6® cultures (average 
of 3 runs). a) Total (■) and viable (□) cell densities, percentage viability (●). b) Glucose (■) and lactate 
(●) concentrations. c) Glutamine (♦), glutamate (◊) and ammonia (▲) concentrations. Error bars show 
the standard deviation of the three cultures.
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Figure 2. Progression of apoptosis (average of 3 runs) in 14-days PER.C6® batch cultures. a) Tunel 
assay: percentage of non-apoptotic (●) and apoptotic (□) cells. b) MultiCaspases assay: percentage of 
viable (●), early-apoptotic (◊), late-apoptotic (♦) and dead (□) cells. c) Nexin assay: percentage of viable 
(●), apoptotic (♦) and dead (□) cells. Error bars show the standard deviation of the three cultures.
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on day 6 (figure 1a and table I). Additionally, classical process parameters such as pH, 
DO or agitation speed, were controlled at set-point during this first process phase. 
Three perfusion runs were prolonged and ran for a total of 14 days, to characterize the 
progression of apoptosis outside cultivation conditions normally applied. Extremely high cell 
densities of 367 x 106 cell mL-1 with a viability of 83% were obtained on day 14. Bioreactor 
set-up was not adapted prior to performing these extended runs to cope with such high cell 
densities. Cultivation systems therefore reached maximum capabilities as indicated in table 
I. Briefly, when cell density exceeded 100 x 106 viable cell mL-1 (around day 11), the feed 
pumps reached their maximum capacity and perfusion rate was no longer increased with 
cell density (Table I). Additionally, DO could no longer be maintained at 40% from day 12 
onwards, as the maximum capacity of the mass flow controllers supplying air and oxygen 
to the cultures was reached. Oxygen was therefore still supplied but dissolved oxygen could 
no longer be measured in the cultures (data not shown). Note that carbon dioxide did not 
accumulate after day 11, when flows of air and oxygen no longer increased with cell density, 
indicating that mass transfer was still sufficient to remove CO2 from the culture. Finally, on 
day 13, pH control was manually turned off because the amount of sodium bicarbonate 
required to maintain pH at set-point caused an increase in osmolality towards known toxic 
levels. Stopping pH control caused a decrease by 0.5 units within 2 to 3 hours.
A consequence of extending the perfusion process is nutrient limitation, as the change 
in feed regime affected evolution of main metabolite concentrations. Glucose level 
decreased from 6.0 to 4.5 mM between days 11 and 13 and was completely depleted 
on day 14. Metabolic by-products accumulated in the cultures: ammonia concentration 
doubled between day 12 and 14 from 1.4 mM to 3.1 mM, and lactate increased by almost 
8 mM over the last culture day (table I). Concurrently, cell specific growth rate decreased 
slightly from 0.022 h-1 on day 4 to 0.017 h-1 on days 10 and 11. Day-to-day growth 
rate calculated between days 11 and 14 showed large fluctuations, most likely due to 
imprecisions in sampling and cell counting. Calculations of growth rate between days 11 
and 13 and days 11 and 14 showed a trend towards slower cell growth rates (0.018 and 
0.015 h-1, respectively). Growth rate remained high after day 11, when specific perfusion 
rate was no longer maintained at set-point. The maximum perfusion rate applied at the 
end of the cultures seem to have provided sufficient nutrients at sustain high cell density at 
high viability and to support cell replication at high rates. This observation is in accordance 
with the slow decrease in main nutrients observed after day 11. 
3.2.2 Apoptosis in perfusion cultures
Apoptosis was measured for a total of 18 perfusion runs. The Nexin assay was used for all 
runs whereas MultiCaspases and Tunel assays were used for 9 and 13 runs, respectively. 
The three apoptosis markers targeted in the flow cytometry assays consistently showed 
no increase in the portion of apoptotic cells and dead cells during the standard phase 
of the perfusion process (figure 3). Apoptosis and necrosis both occurred, at a low basal 
level of around 10% each. Overall, PER.C6® cell cultivation in perfusion mode enabled to 
increase maximum cell density, maintain high viability and limited apoptosis compared 
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Figure 3. Progression of apoptosis (average of 3 runs) in 14-days PER.C6® perfusion cultures. a) 
Tunel assay: percentage of non-apoptotic (●) and apoptotic (□) cells. b and c) MultiCaspases assay: 
percentage of viable (●), early-apoptotic (◊), late-apoptotic (♦) and dead (□) cells. d) Nexin assay: 
percentage of viable (●), apoptotic (♦) and dead (□) cells. Dots are raw data; straight lines are mean 
from linear models and dashed lines are 95% confidence intervals of the mean.
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to cultures conducted in batch mode. This can be due to the supply of nutrients, or the 
removal of inhibitory metabolism by-products, or the combination of both.
Culture viability and progression of apoptosis were not drastically affected by 
perfusion process extension and suboptimal cultivation conditions. Trypan blue viability 
was maintained above 90% until day 13, after which it decreased to 83% on day 14. 
Cells positive for TRITC (TUNEL staining) increased slightly from 12% to 14% between day 
11 and day 14 (figure 3a), reflecting the small increase in apoptotic cell death. The level 
of late-apoptotic cells from the MultiCaspases assay remained constant around 13%, but 
the early-apoptotic cells increased from 6 to 12% throughout the run. Similarly to what 
was observed in batch, no increase in apoptosis was captured with the PS staining in the 
Nexin assay (figure 3d). Necrosis, determined from the population of cells positive for 
only 7AAD with the MultiCaspases assay, also marginally increased throughout the run 
from approximately 3% to a maximum of 8% on day 14 (figure 3c). Overall, data from 
the three apoptosis assays showed that under underfeeding and suboptimal cultivation 
conditions, perfusion PER.C6® cultures underwent only limited increase in cell death, 
primarily through apoptosis. The low basal level of necrosis remained constant.
Nevertheless, extended perfusion cultures beyond day 11 were clearly exposed to 
process deviation and suboptimal growth conditions. Firstly, from day 12 onwards, 
oxygen could no longer be measured in the cultures, which means that the oxygen 
uptake rate by the cells exceeded the oxygen transfer rate into the medium. Secondly, 
pH drifted by 0.5 units in a few hours after the control was turned off on day 13. Finally, 
culture density and viscosity increased with cell density, which may have resulted in 
increased shear forces. All these factors can potentially lead to necrotic cell death. For 
example, it has been showed that CHO and HEK293 cells can die of necrosis as a 
consequence of shear exposure above a certain threshold (25). However, it is difficult to 
translate the extremely unfavorable condition inducing necrosis to in vitro cultures (3). 
Based on the very small increase in cell death we observed, we conclude that the pH 
drift, oxygen deprivation and increased shear exposure underwent by the PER.C6® cells 
at the end of the perfusion did not induce necrosis.
3.3 Comparison of different methods to determine viability
Measurement of culture viability is critical for bioprocesses as viable cells represent the 
production capacity of the process. Methods commonly used to determine viability are 
based on membrane permeability, using either large molecular weight dyes such as trypan 
blue or stains that bind to DNA. Trypan blue is a negatively charged molecule that cannot 
penetrate the selective plasma membrane of viable, healthy cells. Viable cells with intact 
membranes “exclude” trpyan blue. However cells with damaged or leaking membranes are 
not able to exclude trypan blue and get stained with a characteristic blue color, detectable 
with a microscope (50,51).  Trypan blue exclusion is the primary method used to determine 
viability of PER.C6® cultures in Crucell’s processes.  Trypan blue exclusion is compared to 
7-AAD staining and Tunel labeling in figure 4 for PER.C6® batch and perfusion cultures. 
Tunel labeling and trypan blue exclusion yielded comparable viabilities throughout batch 
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cultures, except on the last culture day where they differed by 20% (figure 4a). Average 
7-AAD viabilities calculated from Nexin and MultiCaspases assays were lower than those of 
trypan blue and Tunel until day 12, with a peak of 20% divergence on day 4, in the middle 
of the growth phase. Similar observations were made from perfusion data: trypan blue and 
Tunel viabilities were similar and 7-AAD viabilities were overall lower than with the other 
two methods, both when cultures were maintained at high viability (first 11 days) and under 
suboptimal cultivation conditions (days 11 to 14) (figure 4b). 
Trypan blue and 7-AAD staining detect a late stage of cell death, when cell membrane 
integrity is lost. It is assumed that Tunel also capture a late phase of the apoptosis cascade, 
as DNA fragmentation depends on endonucleases activation by active caspases (6). The 
similarities between these two methods for viability measurement were therefore expected. 
Additionally, 7-AAD viability, which was obtained from averaging Nexin and MultiCaspases 
results, showed a larger variance compared to the other methods. This variance in reflected 
 
  
  
 
Figure 4. Comparison of viabilities from trypan blue (♦),Tunel (■) and 7-ADD (∆) from Nexin and 
MultiCaspases assays for batch (a) and perfusion (b) cultures. Nexin and MultiCaspases viabilities are 
averaged for batch cultures (a). Error bars in (a) show the standard deviation of the three cultures.
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in the error bars for batch cultures and in the spread of the data points for perfusion cultures 
(figure 4). Dyes used for flow cytometry are known for being able to penetrate live cells after 
prolonged exposure (52). This could explain on one hand the larger variation for 7-AAD, as 
the protocols for Nexin and MultiCaspases assay were different (number of cell washes and 
incubation times), and on the other hand the overall lower viability measured with this dye.
Interpretation of culture viability depends on the method chosen for the measurement. 
It is acknowledged in literature that the concept of viability is not clearly defined in the 
industry as it highly depends on the cell biological features used to determine it (53,54). 
In this study, data showed that trypan blue exclusion, the reference methods used at 
Crucell to measure viability of PER.C6® cultures, properly assessed the level of cell death 
both in batch and in perfusion. We therefore conclude that trypan blue exclusion is an 
appropriate method for routine monitoring of culture viability.
3.4 Characterization of apoptosis in PER.C6® cultures
Amongst the assays used in this study, the MultiCaspases kit offered the possibility to 
detect intermediate apoptotic state, as cells with an intact membrane and active caspases 
could be detected. However, we observed that this portion of cells positive for SR-VAD-
FMK only slowly increased from 3% to 12% throughout the batch runs and from 8 to 11% 
for the perfusion runs (figure 2b and figure 3c). Accumulation of apoptotic PER.C6® cells 
therefore occurred without a visible transition via the state where caspases are active 
and membrane integrity is not lost yet. This observation in PER.C6® cultures is different 
from that of Wei et al. (5) observed in CHO cultures. There, a peak of early apoptotic 
cells with active caspases representing up to 25% of the total cell population occurred 
between days 5.5 and 8.5 of the cultures, and these cells afterwards transitioned into a 
late-apoptotic state with permeable membranes for 7-AAD.
Likewise, externalization of PS was not captured as a marker of early apoptosis. The 
portion of cells positive only for Annexin V remained constant at a low level between 5% 
and 9% throughout the batch cultures (figure 2c). In the perfusion process, this fraction 
did not increase at all even after day 11, when process deviation occurred and caspases 
activation started to be detected (figure 3b and c). This indicates that PS is a biological 
marker of apoptosis that is not useable for PER.C6® cultures. Contradictory conclusions 
can be found in literature on whether PS exposure at the cell membrane is a universal 
phenomenon during apoptosis or not. Engeland et al. (12) stated that this phenomenon 
is universal and has been reported  not only in mammalian cells but also in insect 
and plant cells, whereas Frey (55) showed that Annexin V staining can be lacking in 
apoptotic populations of several human cell lines (namely lymphoma and hematopoietic 
cells HL60, U937 and Raji). It is therefore not possible to conclude on the occurrence 
of PS externalization in the PER.C6® apoptosis cascade. Additionally, the basal and low 
level of Annexin V positive cells throughout the batch and perfusion cultures is not due to 
non-specific binding of the dye, as Annexin V was proven to be very specific to PS (56). 
The low level of detection of cells with only externalized PS and only active caspases, 
without compromised membrane integrity can be explained by a very short duration 
76
C
haracterization of apoptosis in PER.C
6
® batch and perfusion cultures
4
of these phases during the apoptosis process. This would explain why cells did not 
accumulate in these phases. Literature on the duration of the different phases of 
apoptosis process is scarce (6,57).
4 Conclusions
With the use of three flow cytometry assays, we showed that apoptosis is the main pathway 
of PER.C6® cell death in batch cultures after depletion of main carbon sources. In high 
cell density perfusion cultures fed at a constant specific perfusion rate, both high viability 
and low apoptotic fractions were maintained. Extending this perfusion process led to 
suboptimal cultivation conditions and partial culture starvation, but with limited induction 
of cell death. In these conditions, PER.C6® cultures underwent primarily apoptotic cell 
death, while the low basal level of necrosis remained constant. Leads for potential process 
improvements have been identified based on this study. As decreasing the cell specific 
perfusion rate caused a slow decrease in nutrient levels and limited cell death, there 
may be opportunities for further optimizing the feeding regime. Similarly, interruption of 
process parameter controls such as pH and DO had slow and mild effects on the cultures, 
which suggests the possibility to optimize the current control strategy of these parameters.
Preventing or delaying cell death is a challenge in industrial bioprocesses, and 
programmed cell death through apoptosis is often believed to occur without being 
detected by classical viability measurements. Here, we show that apoptosis only occurs 
in PER.C6® cultures under starvation conditions such as the end of a batch, or suboptimal 
perfusion cultivation conditions which are far beyond how these processes are typically 
operated. Moreover, the reference viability measurement using trypan blue exclusion 
properly assesses the level of cell death in PER.C6® cultures. 
To deepen the knowledge gained from this study on PER.C6® cell growth and cell 
death dynamics, experiments in chemostat cultivations could be conducted to study 
the effect of individual process parameters. Variations in inoculation cell density of 
batch and perfusion cultures, or in process design (limitation of oxygen transfer for 
instance) could also be useful to further study the limits of the standard processes and 
equipments. Moreover, similar studies on a monoclonal producing cell line or on a 
virus production process would enable to relate the kinetics of PER.C6® cell growth and 
cell death to productivity. Nevertheless, this study on characterization of apoptosis in 
different cultivations systems enabled further fundamental understanding on PER.C6®, 
which will be helpful to support applications of this industrially relevant cell line.
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Chapter 5
Robustness of PER.C6® cell line  
for Adenovirus propagation
Abstract
Large-scale production processes are needed to cope with the increasing demand for 
production of adenoviruses (AdV) for gene therapy, cancer therapeutics or viral vaccines. 
To ensure good quality of the AdV produced, safety and quality features of the virus 
seeds and of the cells used as a substrate need to be controlled. However, it is difficult to 
characterize the quality of cells regarding virus propagation. Therefore we developed an 
assay to study the fitness of PER.C6® cells for AdV propagation, or the cells’ infectability. 
PER.C6® is an efficient and safe complementing cell line for propagation of replication-
deficient human AdV (hAdV). Infectability of PER.C6® cells was defined as their ability to 
both be infected and to replicate hAdV. On the one hand, kinetics of the infection process 
were measured by detection of intracellular hexon protein using flow cytometry. On the 
other hand, kinetics of virus production were measured through quantitative RT-PCR. 
First, kinetics of infection and of virus production were determined in exponentially 
growing and high viability cultures, to establish reference infectability data. Infectability 
was then measured on cultures exposed to various stresses as well as on cells sampled 
from a perfusion process within normal operating conditions and after a series of 
technical deviations causing suboptimal cultivation conditions. Overall, regardless of 
the effect of these stresses or perfusion process deviations on cell growth and cultures 
viability, infectability of PER.C6® cultures was not affected by any the stressors applied. 
These results show that PER.C6® is a robust cell platform for hAdV production.
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1 Introduction
Adenoviruses (AdV) are versatile delivery vectors for applications ranging from gene 
therapy to cancer therapeutics to viral vaccines (1-3). As the number of clinical trials for 
AdV-based products increases and the commercialization of these products is nearing, 
there is a need for efficient and robust large-scale production processes for these vectors 
(4-6). Platform processes developed for production of AdV aim at yielding consistent high 
virus titers. For these processes to be reliable and economically competitive, performance 
and yield must be not only high, but also repeatable and predictable. To achieve this, 
robustness of the substrate cell line for virus propagation therefore needs to be ensured. 
Efficiency of infection processes are often related to process conditions during the virus 
production step. Parameters such as cell density at the moment of infection, cultivation 
conditions and medium composition and refreshment have been shown to be of importance 
(7-11). Definition and characterization of the optimal physiological state of substrate cells 
that relate to their ability to propagate viruses are however less widely published. In this line, 
increased osmotic pressure from 250 to 410 mOsm during the growth phase of HEK 293 
cultures showed to improve AdV-5 productivity by 11-fold (12). Ferreira et al. showed that 
changing properties of HEK 293 cultivation medium influenced intracellular pH, which in 
turn affected specific AdV-5 productivity (13). Finally, decrease of culture temperature from 
37°C to 33°C during the growth phase of E1-tranformed cell lines showed to increase AdV 
productivity 2 to 3-fold (14). Cellular responses to changes in growth conditions are complex 
and the effects in turn on virus production are not clearly elucidated in these studies. 
Process changes can potentially be reflected at different levels of cell physiology and 
can in turn affect cell ability to propagate viruses at highest yields. Cell cycle distribution 
has showed to be of importance for AdV titers in HEK 293 (15,16), where increased 
portion of cells in the S phase improved virus production. A higher level of expression 
of receptors specifically binding AdV has also showed to increase HEK 293 cell-specific 
AdV productivity (17). Changes in HEK 293 cell metabolism are also known to occur 
upon infection with AdV (18-20), which suggests that the metabolic state of the cells at 
the moment of infection could be relevant for efficiency of virus replication. 
The development of effective and productive AdV production processes could benefit 
from a better understanding of the effect of cultivation conditions to cell physiology and to 
productivity. Several methods have been developed to monitor effectiveness and efficiency 
of virus propagation. Kinetics of infection at the cell population level can be measured using 
flow cytometry and specific staining to discriminate between infected and non infected cells 
(21-23). An alternative is to quantify virus production over time upon infection (8,24), which 
can be done with quantitative real-time polymerase chain reaction (RT-PCR) (25-28). In the 
applications published, the aim was to either compare cell lines for replication of a virus, 
or to compare the replication behavior of different virus strains in one cell line, but never to 
focus on capturing the quality features of cells for virus production.
An interesting cell line for AdV production is the human PER.C6® cell line. PER.C6® 
was immortalized by transformation with adenoviral E1 genes (29,30), and is therefore 
a productive platform for propagation of replication-deficient AdV (11,31-33). In the 
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present work, the fitness and robustness of PER.C6® cells for AdV propagation were 
assessed under various normal and stressed culture conditions. The fitness of the PER.
C6® cells was defined as their infectability, which includes cells’ ability to both be infected 
by and replicate AdV. A multi-level assay was developed to measure the infectability of 
PER.C6® cells for AdV propagation. Kinetics of the infection process were measured by 
detection of intracellular hexon protein and kinetics of virus production were based on 
quantitative RT-PCR measurements. Infectability was firstly assessed for exponentially 
growing PER.C6® cultures exhibiting high viabilities. The resulting data were used to 
characterize reference infectability behavior for standard PER.C6® cultures. Infectability 
was secondly measured for cells cultivated in perfusion bioreactor both under normal 
operating conditions and after process extension, which yielded suboptimal process 
control conditions. The aim was to compare the fitness for AdV replication of PER.C6® 
cells cultivated in perfusion mode in bioreactor to that of reference cultures growing 
exponentially and with high viability, and to assess whether the perfusion cultivation 
could be extended while maintaining cells’ fitness. Finally, infectability was measured 
on PER.C6® cultures exposed to severe osmolality, pH and starvation stresses, as these 
parameters were suspected to affect cells’ ability to replicate AdV.
2 Materials and methods
2.1 Cell line and growth conditions
PER.C6® cells (Crucell, Leiden, the Netherlands) were thawed and cultivated in Crucell’s 
proprietary and chemically defined PERMEXCIS® medium (Lonza, Verviers, Belgium) 
supplemented with 4 mM L-Glutamine (Invitrogen, Paisley, UK), referred to as “supplemented 
PERMEXCIS® medium” in the rest of this article. Seed trains were propagated twice per 
week with an inoculum density of 0.25 x 106 viable cells mL-1 in 850 cm2 roller bottles 
(Corning Costar Inc., Amsterdam, the Netherlands) at 250 mL working volume. Cell counts 
and culture viability were measured using a Vi-CELL® XR counter (Beckman Coulter Inc., 
Woerden, the Netherldands). Main metabolites concentrations (glucose, lactate, glutamine 
and ammonium) were measured on a NOVA Bioprofile 400 (LA Biosystems BV, Waalwijk, 
the Netherlands). Cultivation bottles were rolled at 2 rpm in Cellroll systems (Micronic BV, 
Lelystad, the Netherlands) in humidified incubators at 37 °C in 10% CO2. 
2.2 Bioreactor perfusion cultures
Perfusion PER.C6® cultures were inoculated in 13 L glass bioreactors (B. Braun Biotech, 
Melsungen, Germany) at 0.5 x 106 viable cells mL-1. Temperature was controlled at 
37°C by a heating blanket. Dissolved oxygen (DO) was controlled at 40% by sparging 
air and pure oxygen. The pH was controlled at 7.3 by addition of CO2 to the gas inlet 
or sodium bicarbonate to the cultures. The same medium was used for inoculation and 
feed. An alternating tangential flow (ATF) filtration system (Refine, Pine Brook, NJ, USA) 
equipped with a 0.2 µm hollow fiber (GE Healthcare, Breda, the Netherlands) ensured 
cell retention during perfusion. Spent medium was extracted continuously while fresh 
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supplemented PERMEXCIS® was supplied to hold a constant working volume. Cultures 
were sampled daily except on day 5 for cell counting, viability determination and 
measurement of main metabolites concentration and osmolality as described above. A 
constant specific perfusion rate (m3 cell-1 s-1) was applied throughout the process until 
cell density exceeded 100 x 106 viable cells mL-1. At this point, a maximum feed rate was 
reached and maintained constant for the remainder of the culture duration. 
2.3 Culture stresses
Two PER.C6® cultures were maintained in roller bottles for 7 and 10 days respectively 
without medium refreshment. For all other stresses, a PER.C6® seed train was split into 
four 850 cm2 roller bottles (Corning Costar Inc., Amsterdam, the Netherlands). One 
culture was used as a control and grown for 4 days as described above. The other 
cultures were grown for 2 days as described above and thereafter independently exposed 
to several stresses as follows. Osmolality was increased from 290 to 430 mOsm by 
adding 5 M NaCl (Sigma-Aldrich, Zwijndrecht, the Netherlands). The pH was decreased 
by approximately 0.4 pH units by adding 4 M HCl (Sigma-Aldrich, Zwijndrecht, the 
Netherlands). One culture was exposed to 42 °C for 30 min in a water bath before 
being placed back in an incubator at 37 °C. Cultures were maintained under stressing 
conditions for another 2 days. Before and after exposure to the stresses, cell density and 
main metabolites concentration were measured as described above, osmolality was 
measured using a Gonotech Osmomat 030 (Salm en Kipp, Breukelen, the Netherlands) 
and pH was measured using an ABL5 (Radiometer, Zoetermeer, the Netherlands). 
2.4 Measurement of infectability
2.4.1 Infection conditions
Cells from roller bottles or bioreactor perfusion cultures to test for infectability were 
medium-exchanged by centrifugation at 300 g for 5 min and resuspended in fresh 
supplemented PERMEXCIS® medium. 125 mL shaker flasks were inoculated at a working 
volume of 15 mL and at a target density of 1 x 106 viable cells mL-1. Agitation was set to 
100 rpm on an IKA KS 260 shaker plateau (VWR, Amsterdam, the Netherlands).
Cultures were infected with two human AdV (hAdV) serotypes, hAdV-A and hAdV-B. 
Both vectors are expressing different proteins. The same crude seeds of hAdV-A and 
hAdV-B were used for the entire study and their total viral particles concentration was 
determined using HPLC. For each cell source tested for infectability, shaker flask cultures 
were infected at two multiplicities of infection (MOI) for each virus, as described in 
figure 1. The MOI for each vector are given in table 1. Samples were taken from each 
shaker flask culture at regular time intervals post infection (p.i.).
2.4.2 Detection of infected cells by flow cytometric analysis
Samples from infected cultures containing 3-4 x 105 cells were fixed as follows. Cells were 
first washed twice in phosphate buffer saline (PBS, Life Technologies, Gent, Belgium) and 
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Figure 1. Schematic representation of the infectability assay.
incubated in 250 µL 1X CellFix (BD, Breda, the Netherlands) diluted in distilled water for 20 
min at 4 °C. Cells were then washed again twice with PBS and stored at 4 °C until staining.
Intracellular viral capside protein hexon was specifically stained. Cells were first 
permeabilized in 700 µL of 1X Perm/Wash (BD, Breda, the Netherlands) diluted in distilled 
water (Life Technologies, Gent, Belgium). 1X Perm/Wash was used as a washing and dilution 
buffer for all subsequent steps. Cells were incubated for 30 min at 4 °C in 100 µL of a mouse 
anti-hexon monoclonal antibody (MAB8051, Merck Millipore, Amsterdam Zuidoost, the 
Netherlands) diluted to a concentration of 1 µg mL-1. After two washes, cells were incubated 
for 30 min at 4 °C in 100 µL of a R-PE goat F(ab’)2 anti-mouse IgG (I.T.K. Diagnostics, 
Uithoorn, the Netherlands) diluted to a concentration of 1 µg mL-1. After two final washes, 
cells were resuspended in 250 µL of 1X CellFix and stored at 4 °C in the dark until analysis.
Flow cytometry analyses were performed on a Guava PCA (Merck Millipore, Amsterdam 
Zuidoost, the Netherlands) using the Express module of the EasyCyte system with the 
CytoSoft software version 6.0.2 (Merck Millipore, Amsterdam Zuidoost, the Netherlands). 
Single cells were gated based on the forward light scatter. The fluorescence of 1500 single 
cells was analyzed. A negative control consisting of mock infected cells was used to gate 
non infected cells and cells outside of this gate were considered infected.
2.4.3 Virus particles titration by quantitative RT-PCR
Crude infected samples were lysed in 1% triton-X100 (Sigma-Aldrich, Zwijndrecht, the 
Netherlands) to release all virus particles from cells. DNA that was not encapsidated 
or DNA from incomplete virus particles was digested by DNAseI (Roche Diagnostics, 
Almere, the Netherlands) during a 15 min incubation with 5 µL of a solution at a final 
concentration of 10 mg mL-1. Quantitative RT-PCR were carried out using the Applied 
Biosystems® TaqMan® Gene Expression master mix (Life Technologies, Gent, Belgium) 
with a total reaction volume of 15 µL. The primers and probe designed to amplify the 
hAdV promoter (Life Technologies, Gent, Belgium) were used at a final concentration 
of 667 mM and 6.67 µM, respectively. 5 µL of the sample DNA was added to 10 µL 
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of reaction mix. Each sample was tested in triplicates. Purified hAdVA and hAdV-B with 
known virus titers were used as a standard. A 10-fold dilution series was performed and 
5 µL of each standard dilution was analyzed in triplicate to obtain a 7-points standard 
curve. A negative control reaction contained 5 µL of dilution buffer. Thermal cycling was 
performed using a ViiA7 RT-PCR system (Life Technologies, Gent, Belgium) with first an 
incubation at 95 °C for 8 min followed by 35 cycles of 95 °C for 10 s and 60 °C for 30 s. 
The number of DNA copies in the samples was calculated using the standard curve and 
the average of the triplicates was expressed in log10 virus particles (VP) mL
-1. 
Cell-specific virus productivity was calculated by firstly subtracting the input virus 
from the mean estimate maximum virus titer and secondly dividing this number by the 
viable cell density at the moment of infection. 
2.5 Data analysis
First, specifications were set using reference data on the two infectability responses, 
namely kinetics of population infection and kinetics of virus production. A four-parameter 
logistic regression (4PL) model was found suitable for the analysis of such kinetics. Two 
global 4PL models with covariates for hAdV serotype and MOI were thus estimated on 
the two responses and the 95% prediction intervals (PI) were computed using simulations. 
The interpretation of such an interval is that 95% of future individual measurements with 
similar kinetic behavior should be found within the interval. Then, new data coming from 
test experiments (stressed cultures and perfusion cultures) were added to the graphs of the 
reference models, and were compared to the 95 % PI obtained using the reference data. 
Equivalence was accepted if most of the new individual data (ideally, 95%) was found 
within the reference interval. All results were obtained using SAS 9.3 for Windows 7.
3 Results and discussion
3.1 Characteristics of infectability of PER.C6® cultures
3.1.1 Establishment of reference infectability data
In order to characterize the infectability behavior for standard PER.C6® cultures, infectability 
was measured on 6 independent PER.C6® cultures with high viability (above 90%) and 
in exponential growth phase. The level of cell population infection was determined by 
measuring intracellular hexon protein, and the dynamics of virus production were determined 
by quantification of full DNA copies from complete encapsulated virus particles. The mean 
estimates of these two infectability responses and the corresponding 95% prediction intervals 
(PI) are shown in figure 2. Note that the 95% PI could not be determined for hAdV-B virus 
titer at high MOI because the parameters from the 4PL model were highly correlated for this 
particular condition, given the number of replicates available. 
The range of the 95% PI for the two infectability responses for these standard PER.C6® 
cultures represents the variation of the biological assay. To capture variation related to 
cell source, these 6 standard cultures originated from 4 development PER.C6® cell banks, 
which all had different passage numbers from the master cell bank. However the variation 
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measured in this dataset was not caused by the cell bank of origin and the number of 
doublings of the cultures at the moment of measuring infectability (data not shown). 
The two aims here were first to capture the variation from the individual biological 
responses and to represent a prediction of where future measurements will fall, and 
second to assess whether the infectability measurements obtained after process change 
were in the same range as the reference measurements. Therefore PI are presented 
rather than confidence intervals (CI). Indeed, CI would only reflect the uncertainty 
around the estimation of the mean kinetic of each cultivation condition. On the other 
side, PI describe the individual data instead of their mean and additionally include the 
variation of the measurements. Obviously, the PI are larger than CI, standard deviation 
or standard error, that are generally presented in other publications studying kinetics of 
viral infection in different cell lines (23,24,35,36). 
3.1.2 Effect of variation of MOI on kinetics infection and virus production
For infectability measurements, PER.C6® cultures were infected with two hAdV serotypes 
at two MOI each: 100 and 900 VP cell-1 for hAdV-A and 1 and 70 VP cell-1 for hAdV-B. 
The main characteristics of infectability in reference PER.C6® cultures for hAdV-A and 
hAdV-B at high and low MOI given are summarized in Table 1, which is directly derived 
from figure 2. MOI is known to influence kinetics of cell infection (6,21,23). Two MOI 
(high and low) per hAdV serotype in the infectability assay were included to increase 
the assay resolution by challenging the cells with different virus inputs. During the 
development of the infectability assay, high and low MOI for each hAdV serotype were 
screened to match the kinetics of cell population. Therefore the high and low MOI values 
for the two hAdV serotypes are very different (Table 1).
Cultures infected with low MOI of hAdV-A and hAdV-B were both fully infected after 
60h p.i. and cultures infected with high MOI of hAdV-A and hAdV-B were fully infected 
after 24h and 26h p.i., respectively. For both hAdV serotypes, the onset of population 
infection was earlier at high MOI than at low MOI, respectively 0 vs 20 h p.i. for hAdV-A 
and 13 vs 25 h p.i. for hAdV-B. Similar to studies conducted with other cell lines (6,21,23), 
increased MOI of hAdV accelerated the progression of infection in PER.C6® cultures. 
For both hAdV-A and hAdV-B, similar maximum titers were obtained at the two MOI. 
A plateau in virus titers was captured for the two high MOI conditions, whereas titers still 
increased at 100 h p.i. for the two low MOI. Full population infection was therefore only 
completed for the high MOI conditions. Cell-specific virus productivity was calculated for 
each infection condition (Table 1) and was on average 19-fold higher for hAdV-B than 
for hAdV-A. This difference can be related to serotype-specific replication features and 
to expressing of the transgenes present in the two hAdV constructs. 
3.2 Infectability of perfusion PER.C6® cultures
After establishing reference infectability data for standard PER.C6® cultures in 
exponential growth phase and with high viabilities, infectability of cells cultivated in 
perfusion bioreactor both under normal operating conditions and under suboptimal 
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process control conditions was measured. The aim of this study was to asess whether 
the operating conditions applied to cultivate seeds of PER.C6® cells are optimal for virus 
production, and also to evaluate  whether these conditions could even be extended to 
generate more cells, to potentially increase the yield of the perfusion process.
Under normal operating conditions of the perfusion process, a constant specific 
perfusion rate enables a fast exponential cell growth. The process generally ends after 
10 or 11 days, when the cell density required to start the subsequent virus production 
process is reached. In a first experiment, infectability of cells from 3 perfusion cultures 
was measured on day 4, 7 and 10 of the process. In a second experiment, 3 perfusion 
runs were extended in order to study cells’ fitness beyond normal operating conditions. 
A representative cell growth and viability profile for an extended perfusion run is shown 
in figure 3. A maximum total cell density of 307 x 106 viable cells mL-1 was obtained 
on day 14 at a viability of 83%. For the extended runs, the bioreactor set-up was the 
same as for standard cultures terminated on day 10 or 11, meaning that the systems 
were not specifically modified to support cell densities beyond the normal operating 
range. Upon process extension, nutrients and mass transfer requirements for the culture 
exceeded the capacities of the control system to maintain optimal conditions, which led 
Figure 2. Infectability of reference PER.C6® cultures in exponential growth phase and with high 
viabilities above 90%. Time courses of infected cells and virus titer upon infection with hAdV-A (a and 
b) and hAdV-B (c and d) at  low MOI (grey lines) and high MOI (black lines). Mean model estimates 
are shown by bold lines. Dashed lines represent 95% PI. Dots represent the raw data and squares the 
input virus concentration at t=0.
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to suboptimal process control and cultivation conditions. On day 11, perfusion rate no 
longer increased with cell density but was maintained constant. On day 12, disolved 
oxygen (DO) could no longer be controlled at setpoint as maximum capacity of the mass 
flow controller supplying air to the system was reached. Finally on day 13, pH could 
no longer be controlled at setpoint because the volumes of base required to maintain 
pH became critical for the osmolality of the culture, which ultimately resulted in the 
abortion of the experiment. During this second experiment, cell samples were taken for 
infectability measurements within normal operating conditions on day 7 and 10, as well 
as beyond normal operating conditions on day 12 and 13. 
Infectability profiles of cells from the perfusion process are plotted against the estimate 
of the mean infectability and the 95% PI of the reference cultures previously described 
(Figure 4). The kinetics of infection and of virus production of cells from the perfusion 
process were very similar among each other. Only 11 data points out of the 648 shown 
in figure 4 fell outside of the 95% PI, which is well below the expected 1 data point out of 
20 outside these PI. Data from figure 4 were further analyzed to evaluate if culture day in 
the perfusion process affected infectability (data not shown). As we did not observed any 
trend based on this parameter, data points are not represented by specific symbols in the 
figure. The extremely high cell density reached in prolonged perfusion runs, as well as the 
decreased specific feed rate and interruption of both DO and pH controls were expected 
to affect the fitness of PER.C6® cells for hAdV replication. Nevertheless, infectability of PER.
C6® cells was maintained even under these suboptimal conditions.
3.3 Infectability of stressed batch PER.C6® cultures
In order to test the robustness of the PER.C6® cell line for hAdV production when 
cultivated under defined and severe stress conditions, infectability was measured 
after exposure of cultures to several isolated cultivation stresses. Instead of perfusion 
cultures we now used batch PER.C6® cultures exposed to high osmolality, low pH, high 
Figure 3. Cell growth profile for a perfusion PER.C6® cell expansion culture. Total (■) and viable (□) 
cell concentrations and viability (♦) are showed for a representative run for 14 days. Arrows show 
when samples were taken for infectability measurements.
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Figure 4. Comparison of infectability of reference PER.C6® cultures and cultures from perfusion 
expansion process on day 4, 7, 10, 12 and 13 (●).Time courses of infected cells and virus titer upon 
infection with hAdV-A (a, b, c and d) and hAdV-B (e, f, g and h) at low MOI (a, c, e and g) and high 
MOI (b, d, f and h). Mean model estimates are shown by bold lines. Dashed lines represent 95% PI.
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temperature and starvation stresses, as these parameters have shown to affect hAdV 
productivity of HEK-293 (10,13,14,18-20). Cell growth and metabolism parameters 
of control and stressed cultures immediately before infectability measurements are 
presented in table 2. Osmolality increase was the most drastic stress as it caused a 
10% loss in viability and a stop in cell growth. The 7-days and 10-days cultures were 
exposed to depletion of glucose and glutamine and to higher concentrations of lactate 
and ammonia. Cell density of the 10-days culture reached levels at which PER.C6® cells 
are at the end of the exponential growth phase. Oppositely, pH stress did not affect 
culture growth rate nor viability. Temperature stress caused a 30% decrease in growth 
rate compared to the control culture, while viability was maintained. Concentration of 
main metabolites in these two stress conditions mainly varied in relation to cell growth. 
Note that the higher glucose concentration in the culture with pH stress, reaching 138% 
of that of the control, is an exception which could not be fully explained. This could be 
either due to analytical variation or to an effect of pH stress, resulting in more efficient 
use of other nutrients as carbon sources than glucose (e.g. amino acids).
Infectability profiles of stressed cultures were compared to those of the reference 
cultures (Figure 5). Note that for the kinetics of cell population infection, the first data 
point at 12 h p.i. is missing because of a technical error for all stressed cultures with the 
exception of the 7-days culture (for the two virus serotypes at the two MOI) and for the 
culture with temperature stress with hAdV-B at MOI 70VP cell-1. The kinetics of infection 
and of virus production of stressed cultures were overall very similar among each other. 
The majority of the data points (141 data points out of the 145 shown) fell within the 
95% PI of the reference cultures or in a near neighborhood. This shows that infectability 
of stressed and starved PER.C6® cultures was maintained. The only data points falling 
outside the 95% PI are the last point of the infection kinetics (at 96.5 h p.i.) for all stressed 
cultures infected with hAdV-B at high MOI, except for the 7-days culture (Figure 5f). The 
reasons for this decrease in percentage of infected cells at the end of the infection process 
are unclear and this was not reflected in the virus productivity of these cultures (Figure 5h). 
Several groups have investigated changes in cell physiology during growth phase prior 
to AdV virus production, with the aim of improving virus yields. Cultivation of HEK-293 
cells under hyperosmotic stress yielded increased AdV titers. On the contrary, a decrease 
in intracellular pH of these same cell line reduced AdV productivity (12,14). As pH and 
temperature stresses did not drastically affect the physiological characteristics of PER.
C6® cultures, it was not expected that infectability would be affected by these stressors. 
Oppositely, the drastic effects of osmotic stress on cell growth and culture viability were 
expected to affect cells’ fitness for hAdV propagation. Yet in our experiments, the changes 
in PER.C6® cultivation conditions did not affect productivity in any way, positive or negative.
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Figure 5. Comparison of infectability of reference and stressed PER.C6® cultures. Time courses of 
infected cells and virus titer upon infection with hAdV-A (a, b, c and d) and hAdV-B (e, f, g and h) 
at low MOI (a, c, e and g) and high MOI (b, d, f and h). Mean model estimates are shown by bold 
lines. Dashed lines represent 95% PI. Stressed cultures: () 10-days culture, (□) 7-days culture, (∆) 
temperature stress, (◊) pH stress, () osmolality stress.
97
4 Conclusions
In this study, a broad range of stressors was applied to PER.C6® cultures in order to mimic 
a variety of aberrant processing conditions. The stressors induced several complex effects 
at the cellular level, from physico-chemical environmental changes (osmolality increase 
and pH decrease), to metabolic activity changes (reflected in the different metabolites 
concentrations measured in the cultures). In all cases, regardless the effect of these 
stresses or of these process deviations on cell growth and cultures viability, the resulting 
infectability profiles were comparable to those of optimally growing reference cells. 
We did this work to study whether the cells grown in perfusion prior to hAdV infection 
were prone to variation in quality attributes that could affect the subsequent virus 
infection process. This study clearly shows that cells at all stages of normal operation 
and even when subjected to severe stressors retain their ability to be infected by and 
propagate hAdV. Robustness of the cell line used as a substrate for virus production is 
key to develop high performing platform processes suitable for large scale processes for 
late stage clinical testing or product commercialization. Overall, this study shows that 
PER.C6® is a robust cell platform for hAdV production.
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Chapter 6
PAT tools for a perfusion PER.C6® 
cultivation process: dielectric  
and near-infrared spectroscopy
Abstract
Cell cultivations are the most complex operation units of a bioprocess to produce 
biological therapeutics. In these processes, good process performance and good product 
quality can be ensured by online monitoring of critical process parameters. These can be 
used in real-time for process control, as suggested by the Process Analytical Technology 
(PAT) initiative. Today, solutions for real-time monitoring of critical parameters such as 
concentrations of cells, main nutrients and metabolism by-products are developing, but 
their applications in industrial settings are still limited. We evaluated in this study the use 
of dielectric spectroscopy (DS) and near-infrared spectroscopy (NIRS) as PAT tools for 
a PER.C6® cell expansion perfusion process, defining the optimal calibration strategy 
for these two tools. With DS and NIRS, accurate predictions of viable cell density and 
of glucose and lactate concentrations were achieved. We show that DS and NIRS are 
complementary PAT tools for monitoring of a perfusion PER.C6® cultivation process. 
We also show that the perfusion stream offers great opportunities for non invasive, 
yet frequent process monitoring. With the current trend towards more continuous 
bioprocesses, accurate online monitoring of critical process parameters with PAT tools is 
contributing to the continuous effort to increase control of process output.
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1 Introduction
Mammalian cell cultivations for the production of biological therapeutic products 
are complex. In order to ensure good process performance and consistent product 
quality, process parameters should be monitored online and used in real-time for 
process control. The US Food and Drug Administration advises (bio)pharmaceutical 
companies to use Process Analytical Technology (PAT) for better control of bioprocesses 
in order to consistently deliver high quality products (1). In applications of PAT to cell 
cultivation processes, parameters such as pH, temperature or dissolved oxygen are 
often controlled using data from well established classical sensors (2,3). Solutions for 
real-time monitoring of other relevant analytes such as concentrations of cells, main 
nutrients and metabolic by-products (glucose, glutamine, lactate, etc.) are also being 
developed, but their applications in industrial settings are still limited. 
Among the established methods for online biomass monitoring, dielectric 
spectroscopy (DS) measuring permittivity provides the most direct information on 
biomass concentration (2,4). DS measures the capacity of the cells to store electrical 
charges. This measurement is therefore related to both the density of viable cells with 
intact cytoplasmic membranes, and the electrical properties of the membranes (5,6). 
Applications of DS for cell culture monitoring have been reviewed in several publications 
(5,7-9). DS has been used for mammalian and insect cell lines to establish correlations 
between permittivity and viable cell volume and to develop prediction models for cell 
density (4,10-13). Direct translation of permittivity into cell densities is only possible 
when variations in cell diameter are small throughout the process (4,14,15). However, 
in most fed-batch and perfusion processes cell diameter is not constant. Assessing 
whether the accuracy of viable cell density predictions could be improved by accounting 
for changes in cell diameter in such processes has not been reported yet. 
Another interesting tool for online monitoring of cell cultivations is near-infrared 
spectroscopy (NIRS). NIRS is a non-invasive and non-destructive vibrational spectroscopy 
technique capturing real-time measurements of multiple variables in one single measurement 
(16,17). The use of NIRS for cell cultivation has been established for over a decade for 
predictions of total or viable cell density and concentrations of main metabolites (mainly 
glucose and lactate), which are parameters routinely monitored off-line (18-22). To obtain 
these predictions, multivariate models are calibrated to correlate variations in NIRS spectra 
with changes in concentration or level of the parameters to monitor. Partial least squares (PLS) 
regressions are the most widely used multivariate technique for NIRS calibration (23,24). 
The co-linearity among process variables due to metabolic stoichiometry during cell growth 
causes in turn challenges for accurate NIRS calibrations. This is often overcome by the use 
of semi-synthetic calibration samples to break the correlations (25,26). Accurate predictions 
of mammalian cell density and main metabolites concentrations have been shown from 
at-line NIRS measurements using samples extracted from the bioreactor cultures (27-29) 
and also from online NIRS measurements using in situ probes submerged in the cultures 
(19-22,26,30). In all these studies, batch or fed-batch processes were monitored. Here we 
report the application of NIRS on a high density perfusion culture of PER.C6® cells.
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Figure 1. Representative cell growth (a) and main metabolite concentrations (b) during the perfusion 
PER.C6® cell expansion process. Total (■) and viable (□) cell densities, viability (♦), glucose (▲) and 
lactate (●) concentrations.
PER.C6® is an industrial human cell line used for the production of several vaccines 
(31-33), which can be grown to densities exceeding 150 x 106 viable cells mL-1 in 
perfusion (34,35). In perfusion systems optimal growth conditions are maintained 
because nutrients required for cell division are continuously supplied and by-products 
inhibiting cell growth are removed. Application of PAT on a perfusion process therefore 
aims at monitoring and controlling the process parameters to ensure optimal cell growth.
The objective of this study was to evaluate both DS and NIRS as PAT tools for a 
PER.C6® perfusion process. The focus was on defining the optimal calibration strategy 
for these two tools. Accurate predictions of viable cell density and of glucose and lactate 
concentrations were achieved using a combination of DS and NIRS. The possibilities this 
creates to use these PAT tools to further improve process control are discussed.
2 Materials and methods
2.1 Perfusion cultures and sampling methods
PER.C6® (Crucell, Leiden, The Netherlands) perfusion cultures were inoculated in 13 L glass 
bioreactors at 0.5 x 106 viable cells mL-1 in a 10 L working volume. PERMEXCIS® medium 
(Lonza, Verviers, Belgium) supplemented in house was used. Temperature, pH, dissolved 
oxygen (DO) and stirrer speed were controlled at set-point. Perfusion was operated with 
an alternating tangential flow (ATF) system (Refine, Pine Brook, NJ) equipped with a 
0.2 µm hollow fiber (GE Healthcare, Breda, the Netherlands). Cells were retained in the 
bioreactor vessel while filtrate of spent medium was continuously extracted. Fresh medium 
was added at a constant specific feed rate to maintain a constant working volume. A total 
of 35 perfusion bioreactors were used as a support for this study.
In this perfusion process, total cell density typically increases exponentially, reaching 
approximately 75 x 106 cell mL-1 on day 10 (Figure 1a). Although perfusion starts 
immediately after inoculation, main metabolite concentrations evolve similarly to a 
batch culture during the first 4 days, with glucose consumption and lactate accumulation 
(Figure 1b). From day 4 onwards, metabolite concentrations are maintained constant.
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Bioreactor samples were obtained by direct sampling of bioreactors (Figure 2). These 
samples contained cells and all other components of the cultures. Permeate samples 
were collected from the permeate line of the ATF, after filtration through the hollow fiber. 
2.2 Off-line reference analyses
Cell density, viability and mean cell population diameter were measured using a ViCell Counter 
XR (Beckman Coulter Inc., Woerden, The Netherlands). Glucose and lactate concentrations were 
measured on a NOVA BioProfile 400 (LA Biosystems BV, Waalwijk, the Netherlands).
2.3 Dielectric spectroscopy (DS)
2.3.1 Online DS measurement
Capacitance was measured online with a Fogale iBiomass 465 system and directly 
converted into permittivity (Applikon, Delft, The Netherlands). Measurements were taken 
every 12 minutes as described elsewhere (11). The frequency scans were obtained 
between 1 and 10 MHz. 
2.3.2 DS data analysis
Two analysis strategies were applied. Firstly, a linear regression was used to directly 
correlate viable cell density (VCD) and permittivity (∆ε) (Equation 1). The intercept was 
constrained to zero as permittivity is assumed to be zero when no cells are present. 
  (1)
Secondly, changes in mean cell population diameter were used to predict VCD from 
permittivity. For that, viable cell volume (VCV) was calculated from VCD and mean cell 
diameter measured off-line (with a ViCell Counter XR), using the formula of a sphere 
Figure 2: Procedure for sample collection for NIRS measurements on a perfusion cell culture process. 
Samples were collected both directly from the bioreactor (bioreactor samples) as well as from the 
permeate line of the ATF. These samples were analyzed at-line using an MPA FT-NIR analyzer. Online 
NIRS measurements were done by a Matrix F FT-NIR analyzer using an in situ probe. 
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volume (Equation 2), where V is the culture volume (in L). Then permittivity was correlated 
to VCV using a linear regression with the intercept also constrained to zero (Equation 3). 
Changes in cell population mean diameter ( ) over time (t) during the cultivation process 
were described using a linear regression (Equation 4) (c represents the intercept). The 
resulting estimation of mean cell diameter over process time was used to calculate VCD 
from VCV, also using the formula of a sphere volume (Equation 2).
 (2)
  (3)
  (4)
2.4 Near-infrared spectroscopy (NIRS)
2.4.1 NIRS spectra acquisition
Bioreactor samples and samples from the permeate waste line were measured at-line 
(Figure 2). To enlarge the ranges of metabolite concentrations and to break correlations 
naturally occurring because of the PER.C6® metabolism, semi-synthetic samples were 
generated by spiking glucose (Lonza, Breda, The Netherlands) and lactate (Sigma-
Aldrich, Zwijndrecht, The Netherlands) from stock solutions of known concentration. 
At-line NIR spectra were measured in triplicate with a multipurpose analyzer (MPA) 
Fourier transform near-infrared (FT-NIR) analyzers from Bruker Optics (Delft, the 
Netherlands). Samples were homogenized and pre-heated at 30°C in glass disposable 
cuvettes of 8 mm optical path length.
Online NIRS analyses were performed in situ using a FT-NIR Matrix-F equipped with a 
transflectance probe with a path length of 2 mm (Bruker Optics, Delft, the Netherlands) 
that collected both transmitted and reflected light every 8s. The dataset was reduced 
prior to further analysis to one spectrum every 4 hours because this time period is 
sufficient to capture dynamics of a mammalian cell cultivation process.
Each spectrum, at-line or online, was an average of 16 scans with 8 cm-1 of spectral 
resolution recorded in the wavenumber range of 4 000 to 12 000 cm-1, resulting more 
than 2 000 points for each spectrum. A single background spectrum was used with every 
sample spectrum to set up the baseline intensity. 
2.4.2 NIRS data analysis and chemometric approach
M o d e l  c a l i b r a t i o n
The saturated regions due to absorption of water, between 4000 and 5340 cm-1 
and between 6430 and 7200 cm-1, were removed as they add noise add noise and 
unnecessary complexity to spectra (36). Several mathematical pretreatments of the 
spectra were used: standard normal variation (SNV), multiplicative scatter correction 
(MSC) and first derivative, as described by Næs et al. (37).
For at-line bioreactor samples, two types of partial least squares (PLS) calibration 
techniques were used: PLS type 1 (PLS1) and PLS type 2 (PLS2). With PLS1, parameters 
108
PAT tools for a perfusion PER.C
6
® cultivation process
6
are predicted individually and models can be fully optimized to obtain the most 
accurate predictions. Oppositely, with PLS2 all parameters of interest can be predicted 
simultaneously with one global model, but the modeling settings are applied for all 
parameters to predict. As optimal NIRS regions were better identified with PLS1 than 
PLS2, the PLS2 model was constrained to only use the NIRS regions identified with 
PLS1. For at-line permeate samples from the permeate line of the ATF and for online 
measurements, only PLS1 models were calibrated. The number of spectra and the origin 
of the samples used to calibrate all models are given in table 1.
M o d e l  v a l i d a t i o n
For at-line models, a cross-validation was first used to identify the optimal number of 
latent variables (LV), spectral pretreatment techniques and NIRS regions to be used. 
Best models displayed the lowest root mean square error of cross-validation (RMSECV), 
calculated as described elsewhere (38). Secondly, a test set validation was performed. 
The predictive ability of the models was evaluated using the correlation coefficient R2 
between reference and predicted values and the root mean square of prediction (RMSEP), 
calculated as described elsewhere (38). RMSEP was also expressed in percentage of the 
calibration range, by dividing the RMSEP values by the calibration range and multiplying 
by 100. Best prediction models presented the lowest RMSEP (in initial unit or in % of 
calibration range) and the closest R2 to 1.
For online models, only a cross-validation was possible as reference values were 
not available for other spectra than those used in the calibration data set. Best models 
displayed the lowest RMSECV.
S o f t w a r e
PLS1 modeling was done using OPUS Quant2 (OPUS 6.5, Bruker, Germany). PLS2 
modeling was done using SIMCA 13.0 (Umetrics AB, Kinnelon, NJ).
Table 1. Composition of calibration and prediction datasets for multivariate prediction models built 
from bioreactor and permeate NIRS spectra.
Measurement 
and modeling 
technique
Sample 
type Dataset
Number of spectra Number of 
bioreactor runs 
included
from natural  
samples
from semi-synthetic 
samples
At-line
(PLS1 and PLS2)
Bioreactor Calibration 231 30 10
Prediction 84 15 5
Permeate Calibration 279 30 16
Prediction 216 15 11
Online
(PLS1)
Bioreactor Calibration 12 0 1
Prediction 80 0 1
PLS: partial least square.
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3 Results and discussion
3.1 Dielectric spectroscopy to monitor viable cell density
Online permittivity using dielectric spectroscopy (DS) and off-line cell density, viability and 
metabolite concentrations were measured in 6 perfusion runs. Two modeling strategies 
were compared to predict viable cell density (VCD) from permittivity, either using a direct 
prediction or accounting for changes in cell diameter. For the first strategy, the model was 
built based on the correlation between permittivity and VCD (Figure 3a). For the second 
strategy, correlation between permittivity and viable cell volume (VCV) (Figure 3b) and 
changes in mean cell population diameter over process time (Figure 3c) were both used. 
Predictions of VCD were done using the two models on 5 independent perfusion runs 
(Figure 4). The two models accounting or not for changes in cell diameter closely fitted 
the data, with RMSEP of 6.8% and 7.2% of the calibration range, respectively and a R2 
between predicted and measured values of 0.96 in both cases.
These data showed that permittivity measured by DS can be modeled with simple 
linear regressions to monitor VCD in a PER.C6® perfusion process with very high 
cell concentrations above 90 x 106 viable cells mL-1. When including changes of cell 
diameter to the prediction model, prediction accuracy did not change considerably. 
Mean diameter of the PER.C6® population increased during the perfusion process from 
approximately 15.5 to 17.5 µm (Figure 3c). These limited variations in cell diameter 
were expected as mammalian cell diameter is known to vary over cell cultivation process 
time due to changes in growth conditions, substrate concentrations or osmotic pressure 
(39). Including an additional variable in a model (in this case cell diameter) should be 
considered with caution, as it increases the complexity of the final model, increasing in 
turn the risk to over fit the original data. Here we showed that accounting for limited 
changes in cell diameter is not needed to obtain accurate VCD predictions.
The RMSEP achieved were low considering that the intermediate precision of the 
reference method (ViCell cell counter) is ± 6% according to the manufacturer. To our 
knowledge, the lowest standard error on prediction reported for the growth phase of 
mammalian cultures are of 0.135 x 10^6 viable cells mL-1 or 2.2% of the calibration 
range (0.35 to 4 x 106 viable cells mL-1) with a linear regression (10). In the present 
study, the best prediction model yields a standard error of prediction of 6.8 % of the 
calibration range, which is close to the 6% reported for the off-line method used a 
reference to build the model. Different modeling techniques suggested in other studies 
could potentially increase further the accuracy of VCD prediction, for instance using 
multivariate modeling or the Cole-Cole empirical model, which relates permittivity to 
the dielectric properties of the cell suspension (10,40,41). 
3.2 NIRS to monitor cell and metabolite concentrations
The process parameters predicted from NIRS spectra in this study were total cell density 
and glucose and lactate concentrations. It has been shown that glutamine and glutamate 
are poorly predicted from NIRS, especially when their concentration range was small 
(21,26,42). These two metabolites were thus not considered for predictions here. 
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Figure 3. Calibration of DS models for direct prediction of viable cell density. Correlations between viable 
cell density and permittivity (a), between viable cell volume and permittivity (b) and between mean cell 
population diameter and process time (c) for 6 perfusion runs. The solid lines represent linear regression.
Figure 4. Prediction of viable cell density from DS. Comparison of viable cell density measured with 
reference method (♦) and predicted from online permittivity model including changes in cell diameter () 
for a model predicting viable cell density directly (a) or taking into account changes in mean cell population 
diameter (b). Data are shown for one representative run but RMSEP and R2 were calculated from the 5 
independent runs used to validate the models. Calibration range was 0.6 - 90.2 x 106 viable cells mL-1.
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Additionally, because of the strong correlation between viable and total cell density (R2 
> 0.999) in the perfusion process (Figure 1a), it was not possible to predict accurately 
both parameters. As DS enabled to monitor viable cell density, we decided to restrict the 
NIRS predictions to total cell density only. 
3.2.1 Comparison between PLS1 and PLS2 modeling
Unlike DS, NIRS raw data cannot be directly correlated to the process parameters to 
monitor. Multivariate calibration using PLS is needed. To compare the performance of 
the two modeling techniques, PLS1 and PLS2 models were calibrated with at-line spectra 
measured from bioreactor samples (containing both cells and metabolites, figure 2) from 
10 perfusion runs. The calibration dataset included 231 spectra from natural samples 
and 30 spectra from semi-synthetic samples spiked with known concentration of glucose 
and lactate, in order to break natural correlations between these metabolites (Table 1). 
The calibration and prediction summary of these models is given in table 2. Regarding 
the calibration, the PLS2 model was rather simple as it had similar number of LV as PLS1 
models and required no data pretreatment. For all three parameters to predict, the 
RMSEP of the PLS2 model was 1.6 to 1.7-fold higher than those of PLS1 models. Lactate 
predictions were particularly poor with PLS2, with a RMSEP of 23% of the calibration 
range. R2 for the prediction of glucose and lactate concentrations also decreased in the 
PLS2, from 0.78 to 0.56 and from 0.69 to 0.25, respectively. An exception is seen for 
TCD, for which the same R2 of 0.99 was achieved with both PLS1 and PLS2 models. This 
is most likely due to the fact that the spectral regions used for the calibration of the PLS2 
model included all the specific regions required to predict TCD identified with PLS1 (5361 
to 5489 cm-1 and 6144 to 6464 cm-1). As a consequence, TCD was very well predicted 
with the PLS2 model. However, the PLS2 model also used additional spectral regions 
that were not necessary to predict glucose and lactate concentrations. Therefore noise 
was introduced for the prediction of these parameters and model accuracy decreased. 
Model optimization is less flexible with PLS2, which leads to lower prediction 
performance for some process parameters of interest. Even though PLS2 presents the 
advantage that only one global model is needed, the data presented here showed that 
PLS1 modeling provides the most accurate predictions. Therefore to predict multiple 
process parameters accurately, several PLS1 models should be preferred over one 
overarching PLS2 model for these parameters.
3.2.2 Comparison of predictions from several types of samples from 
perfusion cultures
E f f e c t  o f  s a m p l i n g  a n d  m e a s u r e m e n t  p r o c e d u r e  o n  r a w  N I R S  s p e c t r a
NIRS spectra were collected in three different ways from the perfusion process: online 
with an in situ probe and at-line from the bioreactor vessel and from the permeate line 
of the ATF (Figure 1). The differences in sample types (bioreactor and permeate) and 
measurement methods (online versus at-line) were reflected in the corresponding raw 
NIRS spectra (Figure 5). Spectra from bioreactor samples presented a clear shift in baseline 
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Table 2. Calibration and prediction summary of PLS1 and PLS2 models from at-line bioreactor NIRS 
spectra.
Modeling 
technique Parameter
Calibration Prediction
Pretreatment
Spectral 
regions (cm-1)
Number 
of LV RMSECV
RMSEP  
(% calibration 
range) R2
PLS1 TCD  
(.106 cells mL-1)
None 5361-5489
6144-6464
3 2.3 2.0 (2.2%) 0.99
Glucose  
(mM)
First derivative 5732-6063
7301-8131
5 4.7 2.4 (10%) 0.78
Lactate  
(mM)
SNV 5774-6102
8127-11834
8 4.6 3.4 (14%) 0.69
PLS2 TCD  
(.106 cells mL-1)
None 5361-5489
5732-6464
7301-11834
5 3.8 4.7 (5%) 0.99
Glucose  
(mM)
None 5361-5489
5732-6464
7301-11834
5 4.5 4.0 (17%) 0.56
Lactate  
(mM)
None 5361-5489
5732-6464
7301-11834
5 3.8 5.7 (23%) 0.25
PLS: partial least square; LV: latent variable; RMSECV: root mean square error on cross validation; 
RMSEP: root mean square error on prediction; R2: correlation coefficient; TCD: total cell density; 
SNV: standard normal variation. Calibration ranges for TCD, glucose and lactate concentrations 
were 0.76 to 91.62 x 106 cells mL-1, 7.4 to 31.5 mM and 1.9 to 27.1 mM, respectively.
absorbance with increased time and therefore increased cell density. This shift was caused 
by the light scattering from the cells and associated cell debris. Oppositely, spectra from 
the cell free permeate samples overlapped perfectly, which means that the extracellular 
environment during perfusion culture was constant. Online and at-line spectra from 
bioreactors also presented differences with absorbance values between 0.5 and 2.5 units 
lower for online spectra than at-line. These differences were caused by the measurement 
technique itself (measurement mode in transmission for at-line and transflectance for 
online, use of optical fibers to transmit the signal for online NIRS, or path length) (38). 
P r o c e s s  m o n i t o r i n g  f r o m  t h e  p e r f u s i o n  p e r m e a t e  l i n e
To study whether glucose and lactate concentrations in a perfusion process can be 
monitored using the external waste line of a cell retention device, PLS1 models were 
calibrated from NIRS spectra measured at-line from bioreactor samples and from 
samples taken on the permeate line of the ATF (Figure 2). Model performance was 
compared for the calibration and prediction of glucose and lactate concentrations 
(Table 3). The glucose and lactate models calibrated from at-line NIRS on permeate 
sample had similar complexity in terms of number of LVs and spectral regions used as 
models built from bioreactor samples. The glucose predictive ability from bioreactor and 
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Figure 5. Overlay of 27 at-line NIRS spectra from bioreactor (a) and permeate (b) samples and of 12 
online NIRS spectra (c), representative of an entire perfusion cell cultivation process. Spectral regions 
bordered by dashed lines correspond to the high absorption regions caused by water, which were 
excluded from the analysis.
permeate samples was comparable with RMSEP of 10 and 12% of the calibration range 
and R2 of 0.73 and 0.78, respectively. Lactate predictions were more accurate with the 
model from permeate samples, as the RMSEP over the calibration range decreased 
from 14% to 10% and the R2 increased from 0.69 to 0.89. Precision of reference 
methods were of 6% and 5% for TCD measured on ViCell and for glucose and lactate 
concentrations measured on NOVA Bioprofile 400, respectively. In the case of the 
metabolite concentrations, at-line NIRS RMSEP over the calibration range is higher (10 
to 14%) than its reference counterpart (5%). Nevertheless, this is believed acceptable for 
an at-line measurement that can be replicated with no additional sample preparation 
and treatment, allowing for instance higher frequency of measurement.
Here, we showed that similar accuracy of prediction for glucose and lactate 
concentrations can be obtained from samples collected from the permeate line of a 
perfusion system. The continuous permeate stream obtained after a 0.2 µm filtration 
offers a great potential for process monitoring. Although the medium flow rate was 
low at the beginning of the process, when cell density was low, samples collected from 
the permeate line had a chemical composition close to that of bioreactor samples 
throughout the process, with R2 of 0.82 and 0.98 for glucose and lactate concentrations, 
respectively (data not shown). Moreover, despite the variation in flow rate in the permeate 
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line, prediction accuracy did not vary over process time. Therefore we present here a 
novel non invasive alternative for perfusion cell cultivation monitoring by measuring 
NIRS outside the sterile containment of the process. 
O n l i n e  i n  s i t u  m o n i t o r i n g
NIRS predictions models for TCD, glucose and lactate concentrations from online and 
at-line bioreactor samples are also compared in table 3. The calibration ranges for 
TCD, glucose and lactate concentrations varied because two different sets of perfusion 
runs were used. Validation of the models from online NIRS could not be done using an 
independent prediction dataset, as reference data was not available for other spectra 
than those used to calibrate the models. The cross-validation step already indicated that 
the models from at-line and online samples performed similarly, with RMSECV of the 
same order of magnitude for all three parameters. 
Evaluation of the predictive ability of the online models was done by plotting 
predictions from online spectra every 4h and process parameters measured daily 
with off-line reference methods (Figure 6). The exponential cell growth was accurately 
predicted by NIRS (Figure 6a). Negative values were predicted during the first day of the 
process, probably due to the small increase of TCD by 0.5 x 106 cells mL-1 on that first 
day of culture. Between days 2 and 6, measured and predicted TCD values were similar. 
When cell density exceeded 20 x 106 cells mL-1, the discrepancy between measured and 
predicted values increased exponentially. This could be caused either by fouling of the 
online transflectance probe during the process, or by the use of the light scattering to 
calibrate TCD from NIRS, which is caused both by the cells and by other impurities also 
accumulating throughout the process. Glucose and lactate concentrations were predicted 
by online NIRS very closely to the values measured by the reference method (Figure 6b 
and c). As reference data was available only once per day, it was not possible to assess 
whether the small variations of +/- 2-3 mM predicted between day 5 and day 10 are 
real fluctuations of metabolites concentration or noise from online NIRS measurements. 
It is important to note that online NIRS was measured on one perfusion run, for which 
12 samples have been analyzed with reference methods. The experiment could not be 
repeated for practical reasons. The online model therefore does not account for run to 
run variability. For routine application, the calibration model should be trained with a 
much higher number of spectra from several experimental runs, as was done with at-line 
models. We expect that the predictive ability for TCD and metabolites concentration 
would consequently be lower than those we present here. 
The main benefit of predictions from online NIRS is clearly depicted in figure 6: 
accurate monitoring of the cell cultivation process can be delivered much more 
frequently (on minute scale) than the traditional daily samples. Here, we chose to predict 
cell cultivation parameters every 4 h as we estimated that this time frame was sufficient 
to monitor the 10-days process and to take corrective actions in case of a deviation. 
Online spectra were actually collected as often as every 8 s, which offers the possibility 
for an even closer monitoring of the process. 
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Online NIRS measurements were performed in situ for the present study, which 
enabled to monitor information related to cell density. Based on the similar performance 
of the at-line NIRS prediction models from the permeate line of the perfusion system, 
we conclude that an ideal monitoring of this process should be done online and on the 
permeate line of the ATF retention device. 
4 Conclusions
This paper shows that for perfusion processes, a combination of online in situ DS and 
online NIRS measured on the perfusion stream would be ideal to monitor cell density 
and main metabolites concentrations. The perfusion stream offers a great opportunity for 
safe process monitoring without the need for invasive probes or frequent sampling of the 
bioreactor contents. Moreover, daily samples, besides being laborious and causing risks of 
culture contamination, may not be sufficient to capture all relevant dynamics of a process 
where cells double every 20 to 30 h. Online monitoring is therefore a major advance 
compared to the current daily sampling regime. Accurate online monitoring of key process 
parameters with PAT tools such as DS and NIRS is clearly where the bioprocessing industry 
is moving towards in a continuous effort to increase control of process output. 
The primary aim of DS or NIRS applications published for cell cultivations is process 
monitoring. Although efforts focus on controlling the processes based on these advanced 
 
Figure 6. Comparison of total cell density (a), glucose (b) and lactate (c) concentrations measured 
with reference method (♦) and predicted with PLS1 models calibrated from online NIRS spectra on 
bioreactor samples ().
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PAT tools, this is only seldom reached. An example is given by Dowd et al. (43), where 
the perfusion and feed rate of CHO cultures was automatically adjusted based on the 
cell concentration information extracted from online DS. Although several examples are 
published for microbial cultivations (44-46), to our knowledge, NIRS is not yet used to 
actively control mammalian cell cultivation processes. 
DS and NIRS could also be used to not only monitor the perfusion process studied here, 
but also to improve the control strategy. Online predictions of viable cell density from DS 
could be connected to the control loop driving feed and perfusion rate, in order to ensure a 
tight control of the specific perfusion rate. Monitoring of glucose and lactate concentrations 
in real-time with NIRS could serve to confirm that cell metabolism and cell environment 
are constant, and could also be used in the control loop of the feed and perfusion flows. 
Given the recent trend in the industry to move towards more continuous manufacturing 
processes using perfusion, the need for continuous real time information on critical process 
parameters will become a crucial aspect of modern biopharmaceutical manufacturing.
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1 Introduction
Process analytical technology (PAT) is “a system for designing, analyzing, and controlling 
manufacturing through timely measurements (i.e., during processing) of critical quality 
and performance attributes of raw and in-process materials and processes, with the 
goal of ensuring final product quality” (1). All critical quality attributes (CQAs) of a (bio)
pharmaceutical product, which contribute to its safety and efficacy once administered into 
patients, need to be identified and controlled (shown in green in Figure 1). Shortly after 
the PAT initiative, additional guidelines were released inviting the (bio)pharmaceutical 
industry to adopt Quality by Design (QbD) (2,3). QbD promotes the definition of a 
process design space in which process parameters can vary without affecting product 
quality (shown in purple in Figure 1). QbD is therefore a modern approach to process 
design based on scientific understanding of the process and strong risk management 
strategies. As a result of PAT and QbD, product quality must be built in the process and 
ensured during its production rather than relying on post-manufacturing testing. 
In this thesis, critical parameters for the quality of PER.C6® cells in a perfusion culture used 
for Adenovirus infection were studied and how these parameters are best monitored was 
addressed. In this chapter, the growing interest of the biopharmaceutical industry to develop 
continuous and perfusion manufacturing processes and the opportunities and challenges 
associated with implementation of QbD and PAT on such processes are discussed.
Figure 1. Roles of QbD and PAT-based process control for biopharmaceutical productions.
2 PAT for continuous cell cultivation
2.1 Continuous bioprocessing
Several industries from petrochemical, chemical, food and pharmaceutical, have 
developed intensified production processes by switching from classical batch-wise 
operation to continuous manufacturing (4-6). Across these different industries, continuous 
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manufacturing presents a series of similar advantages ranging from high volumetric 
productivity to small equipment and facility size and to reduced capital expenditure (7). 
The biopharmaceutical industry follows a similar path and is now rapidly developing 
more continuous processes. 
Cell cultivation processes can be run in different modes to operate either batch-wise 
or continuously (Figure 2). Batch and fed-batch processes are both used for batch-wise 
productions. These processes are very dynamic and process parameters and control 
output vary continuously. Cell environment is never constant and it even deteriorates 
towards the end of the runs, as cells die and toxic metabolic by-products accumulate. 
In continuous processes, the aim is to provide a constant favorable environment 
for the cells to grow at high rates and for the quality attributes of the product to be 
maintained, for as long as possible. Chemostat is the simplest continuous system, with 
incoming feed of unconcentrated medium that equals the outgoing bleed containing 
cells and spent medium. In chemostat, most process conditions are maintained 
constant: nutrient levels, cell density, gas flows, etc. However because cell densities are 
usually rather low (lower than in batch) and product is continuously washed out, this 
system is not very often used in manufacturing for cell cultivation, except for the most 
fragile products (8). Perfusion is a modified chemostat in which the cells are partially 
or fully retained in the system, usually by a filter system. Perfusion therefore combines 
the increased cell densities of the fed-batch with the continuous refreshment of the 
bioreactor contents of the chemostat. Because of that, this system is mostly considered 
for continuous biopharmaceutical manufacturing.
Several technologies have been developed to run perfusion cell cultivation processes 
and demonstrations of the resulting high productivity have been published (9-13). 
Several leading biotechnology companies such as Janssen, Genzyme, Merck-Serono, 
Boehringer Ingelheim and Bayer have implemented these processes in manufacturing 
settings for years (14). Because the aim of continuous processes is to have most process 
conditions maintained constant, control strategies for these processes are simpler 
Figure 2. Schematic representation of the main cell cultivation modes. For perfusion processes, bleed is 
optional and cell separation and retention device can be external (1) or internal (2) to the bioreactor vessel.
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than for batches or fed-batches, where all controller outputs vary continuously. These 
constant conditions are an advantage for PAT implementation. Moreover, with increased 
volumetric productivity and culture longevity, perfusion processes require smaller 
reactor volumes than batch or fed-batch processes to reach the same product yield. This 
decreases development costs and increases flexibility in manufacturing plants. However, 
with fewer runs per year compared to other (fed-batch) processes, the capital at stake 
for each batch is higher and failures are more expensive. For this reason, there is a 
special incentive for PAT and QbD for continuous processes. This combined with the 
fact that continuous processes are more efficient and easier to keep under control make 
them particularly interesting for investing in PAT tools.
2.2 PAT for perfusion cell cultivation: status and challenges
Efforts to implement PAT on cell cultivation steps have been widely published over the 
last decade (15-18). This process step is of particular importance in bioprocessing 
because the quality features of a product are often related to the process step where the 
product is formed, namely during cell cultivation (19). Therefore proper control of cell 
cultivations is required to ensure product quality. 
In perfusion cultures, cell growth rate and nutrient concentrations are key process 
parameters that need to be controlled at constant levels and therefore should ideally 
be monitored online. Several techniques enable the monitoring of cell density online, 
such as capacitance measurements, soft-sensors for computation of oxygen uptake rate, 
automated flow cytometry or in situ microscopy probes (20-23). Metabolite concentrations 
can be measured at-line in cell cultures using for example high performance liquid 
chromatography, near-infrared spectroscopy or multi-functional analyzers coupled 
with automated sampling systems (24-26). Implementation of these tools on industrial 
continuous cultivations is not widely published, most likely because of the protection of 
companies’ intellectual property and know-how. An example was presented recently 
at a conference (23rd European Society for Animal Cell Technology (ESACT) Meeting, 
2013) by Nanjegowda et al., where online capacitance was used to measure cell density 
in a perfusion culture and in the permeate stream, to monitor performance of the cell 
retention device (27). These measurements were also used to indicate time of switch of 
new cell retention filters and to control perfusion rates. 
Overall, monitoring and control of cell density and metabolite levels is relevant in any 
cell cultivation process, regardless of the operation mode (batch or continuous). PAT tools 
for cell cultivations are therefore globally universal, and the applications that are most 
widely published on batch and fed-batch processes can largely be leveraged to continuous 
perfusion processes. Yet process control strategies to implement are largely dependent on 
operation mode. The major challenge for PAT implementation on continuous cell cultivations 
is therefore not essentially on the identification of the appropriate tools, but more importantly 
on defining the most appropriate utilization of these tools for optimal process control.
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3 PAT for PER.C6® perfusion cultivation
The process studied in this thesis is a perfusion cell expansion process, which aims at 
generating high density PER.C6® cultures to seed virus production bioreactors. In this 
case, perfusion is run with an alternating tangential flow (ATF) filtration system, which 
continuously retains the cells in the cultivation vessel. The main reason for using ATF 
is that this system prevents fouling of the hollow fiber filter and enables very short 
residence times outside the bioreactor. Cell densities above 300 x 106 cells mL-1 can in 
this way be achieved (Chapters 4 and 5). 
3.1 Exploitation of historical process data
PAT starts with understanding the underlying biological reactions taking place during 
the bioprocess that leads to the formation of the product and of the cellular biomass. 
Therefore the first logical step to increase understanding of an existing process is to 
explore the data already available. Cell cultivation processes yield particularly complex 
datasets, and because of the co-linearity among the dynamic process variables 
monitored, multivariate statistics are the most appropriate tool for exploring these 
data. Chapter 2 reviews the applications of multivariate data analysis (MVDA) for cell 
cultivation processes. This review shows that when applying MVDA, most information 
can be extracted from datasets that are complete and originate from series of well-
designed experiments. Unfortunately this is not always the case, especially not for 
early development data.  Chapter 3 shows the actual application of MVDA on a set of 
early development PER.C6® perfusion runs. Despite the fact that these datasets were 
incomplete and did not originate from well-designed experiments, MVDA proved to 
be very useful to expand understanding on the process. Causes for batch-to-batch 
variation and sensitivity of the process to scale were identified, whereas these findings 
were previously undetected using traditional data analysis techniques. In this chapter, 
the limitations of the dataset available were also shown, suggesting that some relevant 
information on the process (input, output or process variables) was most likely lacking. 
3.2 Identification of product CQAs
In continuous cell cultivation processes, a number of process parameters are controlled 
at set point and these stable conditions should be maintained as long as possible. 
Perfusion mode enables to operate under constant metabolite concentrations, pH and 
culture viability for example. However parameters such as cell density, culture viscosity, 
shear stress, gas flows, etc. continuously increase during these processes. A challenge 
for application of PAT principles in such a process is to make sure that the product 
quality remains optimal throughout the process despite variation of certain parameters. 
In Chapters 4 and 5 we studied the biological dynamics taking place during the 
perfusion process and the effect on the quality of the end product. 
In chapter 4, several phases of programmed cell death through apoptosis were 
measured at different time points of the PER.C6® perfusion process. Unlike in batch 
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mode, where nutrients depletion and accumulation of metabolic by-products induce 
apoptotic cell death, this study shows that perfusion enabled to maintain apoptosis at a 
very low level. This is a clear benefit of this cultivation mode over for instance fed-batch, 
where cell death typically increases towards the end of the culture. Chapter 5 focuses on 
the features of PER.C6® cultures that could influence their suitability to be infected with 
viruses and propagate these viruses at high yields. An assay was developed to capture 
the infectability of PER.C6® cultures for Adenovirus replication. We showed that cells’ 
fitness for virus propagation is maintained throughout the perfusion process. Overall, 
the conclusions from Chapters 4 and 5 are that the quality features of perfusion PER.C6® 
cultures were maintained throughout the culture time. We therefore conclude that the 
main CQA of the high density PER.C6® cells obtained from perfusion is the cells’ viability.
3.3 PAT tools and online process monitoring
Besides attributes related to product quality, indicators of process performance are also 
relevant in PAT implementation, to assess the capability and efficiency of the process. 
Here, cells’ viability was identified as the main CQA of the perfusion PER.C6® cultures. 
Moreover, cell growth rate is a key performance attribute of the process, as ideally high 
cell densities should be reached in the shortest process time possible. The PAT tools to 
monitor and control this process therefore need to capture accumulation of viable cells. 
Chapter 6 shows how dielectric spectroscopy (DS) and its permittivity measurements 
can accurately predict online viable cell density. The signal measured informs not only 
about the amount of viable cells generated at a certain time-point in the process, but it 
also enables to calculate cell specific growth rate, the key performance attribute of the 
process. Additionally, near-infrared spectroscopy (NIRS) was used for accurate online 
predictions of cell density and glucose and lactate concentrations. Online monitoring of 
metabolites level is of great importance during a perfusion process, since the aim is to 
maintain these parameters constant. 
As shown in Chapter 6, the filtrate perfusion stream presents a great opportunity for 
monitoring and possibly controlling the process from outside the sterile containment of 
the vessel. This stream has similar physical-chemical contents to the main cultivation 
broth, but without the noise created by cells and debris. This is particularly true when 
high perfusion flow rates are used, as the residence time of spent medium in the waste 
line is then relatively short. Using online analytical tools on this stream therefore enables 
an accurate non-invasive and external monitoring of the process. This strategy would 
also be beneficial from a good manufacturing practices (GMP) perspective since the 
sensors are physically separated from the product and the implementation of these tools 
would not require any modification or revalidation of the production vessel itself. 
In conclusion, for industrial perfusion cultivations there is a clear possibility to demonstrate 
that the steady state is maintained by using online PAT tools that monitor and control the 
CPPs or process outputs (28). DS and NIRS are suitable PAT tools in that respect.
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4 Outlook of PAT and QbD for cell cultivations
4.1 Online process monitoring to replace culture sampling
Data generated by online PAT tools should ultimately substitute daily sampling that is 
usually done on mammalian cell cultivations. Relying on samples taken only once per 
day presents a series of disadvantages. If a process deviation is only at its initial stage 
at the moment of sampling, the sample taken the following day could come too late to 
take corrective actions on the deviation. Chapter 6 showed that accurate predictions of 
key process parameters such as viable cell density and concentrations of glucose and of 
lactate can be obtained from online PAT tools. In the examples provided in this chapter, 
glucose and lactate concentrations were predicted every 4 h from NIRS. This significantly 
increased the sampling resolution compared to the daily off-line measurements. In 
principle the technique even allows for continuous monitoring at time intervals as small 
as a few minutes. Similarly, in this chapter predictions of viable cell density are shown 
only every 24 h, but DS could yield measurements every 12 min. Overall, online process 
monitoring presents the advantage of collecting direct information on CQAs and CPPs 
and at a high frequency. These two points are beneficial to optimize process control.
4.2 Beyond process understanding: process control
The goal of PAT and QbD is real-time control of product quality and ultimately real-time 
product release based on online process control. QbD submissions to regulatory agencies 
are far from standard. To date, only one case of process control based on a design space 
has been submitted and approved by the FDA (http://qbdworks.com/qbd-biologics-
gazyva-design-space/). This approval demonstrates that the pharmaceutical industry and 
authorities can reach the implementation of this new, science-based approach to quality 
on complex biopharmaceuticals. However to our knowledge, this approved design space 
relied only on classical process control, without including additional PAT tools. 
Reaching PAT-based process control, without considering a design space from QbD, 
is also difficult as shown by the limited number of publications exposing this stage 
(Chapter 2). Applications of PAT tools used for process control found in literature are 
mostly on microbial cultures run in batch or fed-batch modes (29-32). In these examples, 
advanced analytical tools such as mid- or near-infrared spectroscopy, dielectric 
spectroscopy or radio frequency impedance measurement are used for online control of 
viable cell density or concentration of metabolites or product. What is achieved in these 
examples is still far from the ideal real-time product release based on PAT tools and on 
process control within a pre-defined design space. 
A great number of steps need to be taken before real-time product release of a complex 
biopharmaceutical can be envisioned solely based on in-process control within a design 
space and using PAT tools. Gaining scientific understanding on the processes needs to 
become a main focus during development. Process monitoring and control strategies need 
to be defined with robust datasets and using reliable advanced analyzers and modeling 
tools. Finally, criteria for product release need to be defined based on the data available and 
the process knowledge. In this thesis and in most publications on PAT, the principles were 
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implemented on one process step. The major challenge in the future will be to demonstrate 
that QbD and PAT principles can be implemented on a complete bioprocess line, where high 
product quality will be ensured from thawing of a cell bank to storage of the finish product.
5 Investments and challenges for implementation  
of QbD and PAT
Despite the obvious benefits of QbD and PAT, which mainly lie in the increase in product 
quality, and the fact that the adoption of these initiatives were recommended by the FDA 
over 10 years ago, these concepts are not embraced by all biopharmaceutical companies 
yet. The reasons for this include underestimation of the increased flexibility brought by a 
QbD- and design space-based process control, resistance to change in quality mindset 
in some organizations, strong pressure on time-to-market and competition between 
business priorities and QbD and PAT implementation (33). 
A major change to process development that is required to implement QbD and PAT 
is the amount of data generated to define the relations between process output, process 
input and process parameters and to explore the process design space. It is indeed 
acknowledged that process characterization for the submission of a design space requires 
a larger number of small scale development runs than classical approaches (34). The way 
the data are generated is also substantially different, with more investment in the early 
phases of product and process development, and with the use of statistical tools such 
as Design of Experiments (DoE) or MVDA, in order to gain strong scientific knowledge 
from experimental work (35). Although early process development is often driven by 
short timelines to deliver clinical trial material, stronger understanding of the process 
in an early stage increases the chances of success of the later process development. 
Finally, the way these data are used is also fundamentally different. With the traditional 
approach, submission files consist of detailed descriptions of process steps and their 
control strategies, whereas with QbD and PAT, the focus is to use the knowledge gained 
during the development of the process to explain why each process step is needed, how 
the objectives of these process steps are reached, and finally to demonstrate that the 
performance of these steps can be fully controlled and predicted (36).
The implementation of QbD and PAT and of the associated changes is slower than 
technical innovations in the field, but this process should be accelerated by the exposition 
of the benefits in terms of product quality, process efficiency and costs of goods. More 
examples from the companies that dare to pioneer in this field will continue to show the 
return on investment from QbD and PAT.
Conclusions
QbD and PAT principles for bioprocesses can be defined as systematic and structured 
approaches for applying common sense rules. The focus lies first on the quality requirements 
of the end product, and then shifts towards the design of the most apporpriate process 
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that ensures control of all critical sources of variation, to guaranty product quality. These 
principles are therefore strongly relying on the use of scientific knowledge to design 
manufacturing processes. In this line, this thesis gives a demonstration of the efforts 
that need to be deployed to identify the CQAs of a product and to understand how 
they are affected by process parameters. A structured approach to experimental design 
and to data analysis is required in the early phases of the clinical development of a 
drug candidate. Gaining this fundamental understanding on the process and on the 
interactions between process and product are absolute must-haves before further QbD 
and PAT steps can be taken and proper process control can be designed. 
With the increasing number of successful demonstrations of QbD and PAT implementation, 
these concepts will become the common quality standard in industry in the coming years. 
The most important benefit from QbD and PAT will be that the biopharmaceutical industry 
delivers the safest, most efficacious and most affordable high-quality products to patients. 
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Summary
Process Analytical Technology (PAT) is an initiative introduced by the American Food 
and Drug Administration (FDA) in the early 2000s. (Bio)Pharmaceutical companies are 
encouraged by the PAT guideline documents to improve process monitoring and control 
of the quality of the product manufactured. PAT aims at monitoring and controlling 
all critical process parameters (CPPs) that affect the critical quality attributes (CQAs) 
of the end product or the process performance. The ultimate objective is to ensure 
consistent and high product quality during manufacturing, based on the use of scientific 
understanding of the production process to control all interacting CPPs. 
Since its release, the PAT initiative has been largely embraced by the small molecule 
pharmaceutical world, where the manufacturing processes are overall simpler and the 
relations between product and process are generally well understood and characterized. 
Implementation of PAT for bioprocesses, and in particular the cell cultivation step of 
these process, is more challenging. First, biopharmaceutical molecules are larger and 
more complex in nature than small molecules (e.g. entire organisms or subunits), and 
therefore understanding the interactions between the manufacturing process and the 
quality of these complex molecules is more difficult. Secondly, cell cultivations are of 
particular importance in the manufacturing of biopharmaceuticals, as it is in this process 
step that the product formation actually takes place.
The research described in this thesis focuses on applying PAT principles to a perfusion 
PER.C6® cell cultivation process for viral vaccine production. The aim of this process is to 
expand PER.C6® cultures to high cell densities in perfusion mode, to seed the following 
process step of virus production. Variation in quality of these high density cultures was 
hypothesized to cause variation in performance of the subsequent virus production 
process. Therefore, a research project was started to identify which process parameters 
would affect the quality and suitability of these cells for virus production. However, the 
quality features, or CQAs, of substrate PER.C6® cells for virus propagations are not 
well defined, and the effect of variation in PER.C6® cell quality on virus attachment, 
infection, and propagation are also not fully understood. The objectives of this thesis 
were therefore to identify the CQAs of the PER.C6® cells used for virus production and to 
implement the most appropriate analytical tools for optimal monitoring of the perfusion 
cell cultivation process.
First, the most appropriate data analysis tool for transforming the large, multi-factorial 
and multi-collinear datasets generated during cultivations into relevant process 
information needed to be identified. Multivariate data analysis (MVDA) is a statistical 
tool able to explore these elaborate datasets to deepen process understanding and study 
the relations between process parameters and process outcome. The importance of 
MVDA for industrial (bio)pharmaceutical data was shown, particularly for cell cultivation 
processes where MVDA-based models are useful to characterize and build stronger 
understanding on the processes. MVDA therefore is a key element in for successful PAT 
and QbD implementations. 
137
Multivariate analysis was used to explore the available data of the PER.C6® perfusion cell 
cultivation process. This process had been routinely run as part of early development of 
vaccine production processes; therefore data from these historical runs was available for 
further analysis. Principal component analysis (PCA) and partial least squares (PLS) are 
the two MVDA techniques used to exploit these early process development data, which 
were not generated from statistically designed experimental sets and contained data gaps. 
Nevertheless, the systematic and structured analysis of these data increased the understanding 
of the process studied. New process insights were revealed, such as root causes for batch 
deviations and process sensitivity to scale. MVDA helped to identify knowledge gaps and 
incentives for further monitoring of process parameters and of process responses.
Next, the research focused on understanding the biological dynamics taking place 
during the perfusion cell cultivation process and to assess the quality of the cells used for 
virus propagation. Biological and cellular parameters that were expected to reflect the 
cell’s suitability for virus attachment, infection and replication were studied in order to 
identify the CQAs of PER.C6® cells. First, dynamics of PER.C6® cell growth and cell death 
were compared during perfusion and batch cultures. Flow cytometry assays were used 
to measure three phases of the apoptosis cascade. This showed that in batch mode, 
nutrients depletion and accumulation of metabolism waste products induced apoptotic 
cell death. However, in perfusion cultures apoptosis was kept at a constant low level. 
Having established this, the next step was to evaluate parameters that could influence 
the suitability of PER.C6® cells to be infected with viruses and propagate these viruses 
to high yields. A novel assay was developed to capture the fitness of PER.C6® cells for 
Adenovirus propagation, shortly referred to as “infectability”. In this assay both kinetics 
of the infection process and kinetics of virus production were measured. Infectability 
measurements were compared from exponentially growing and high viability cultures 
and from cells sampled from a perfusion process within normal operating conditions 
and under suboptimal cultivation conditions. This study showed that infectability of 
PER.C6® cultures with adenoviruses is very robust throughout the perfusion cultivation 
and under suboptimal process conditions. 
Overall, these studies on the CQAs of PER.C6® cells showed the robustness of the PER.C6® 
cells in the perfusion process. It was therefore postulated that the main CQA of the high 
density PER.C6® cells obtained from perfusion can be assessed by the measurement of 
culture viability. Consequently, the last step was to identify the most relevant online PAT 
tools to monitor this process. In addition to capturing information related to the cells’ 
CQAs, PAT tools should also monitor key performance attributes of the process, related 
to business capacity and efficiency of the process. Specific growth rate was identified 
as a key performance attribute as sufficient cell densities to inoculate the subsequent 
virus production process should be reached in the shortest time possible. Dielectric 
spectroscopy (DS) and near infrared spectroscopy (NIRS) are two advanced PAT tools that 
can be used complementarily to monitor the product CQAs and the key performance 
attributes of the perfusion PER.C6® cultivation process. The models developed enabled 
accurate predictions of viable cell density and of glucose and lactate concentrations from 
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DS and NIRS data, respectively. In addition, this study showed that the perfusion stream 
closely reflects the actual cellular matrix and thus provides an excellent opportunity to do 
on line measurements without using invasive probes or excessive sampling. 
This thesis gives a demonstration of the structured and systematic approach needed to 
apply PAT principle on a perfusion cell cultivation process. The identification of the CQAs 
of the PER.C6® cells and the evaluation of PAT tools for process monitoring enabled to 
gain fundamental understanding on the process and the cell line studied. These efforts 
are an absolute must before further QbD and PAT steps can be taken and proper 
process control can be designed.
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Samenvatting
‘Process Analytical Technology’ (PAT) is begin jaren 2000 een door de Amerikaanse 
Food and Drug Administration (FDA) geïntroduceerd initiatief. (Bio)Farmaceutische 
bedrijven worden aangemoedigd om de kwaliteit van hun producten te verbeteren en 
te monitoren met behulp van PAT toepassingen. PAT richt zich op het monitoren en 
controleren van alle kritische proces parameters (CPPs), die een effect hebben op de 
kritische kwaliteitseigenschappen (CQAs) van het eindproduct of het proces. Het ultieme 
doel is om constante en hoge product kwaliteit al tijdens de productie te waarborgen, 
gebaseerd op wetenschappelijk inzicht in het productie proces.
Sinds de start is het PAT initiatief grotendeels omarmd voor laag-moleculaire 
geneesmiddelen waarvoor de productie processen veelal simpeler zijn en de 
relaties tussen product en proces vaak beter begrepen en gekarakteriseerd zijn. Het 
implementeren van PAT voor bio-processen, en in het bijzonder voor de celkweek stap 
van het process, geeft meer uitdagingen. Allereerst zijn biofarmaceutische moleculen 
van nature groter en complexer dan kleine moleculen (bijvoorbeeld hele organismen 
of sub-units van eiwitten). Dit maakt het begrijpen van de interacties tussen het 
productieproces en de kwaliteit van deze complexe moleculen moeilijker. Ten tweede is 
de celkweek stap van van bijzonder belang, aangezien dit de stap is waar het product 
daadwerkelijk wordt gemaakt. Celkweek is een bijzonder ingewikkeld proces, met vele 
parameters die interactie hebben met elkaar. 
Het onderzoek beschreven in dit proefschrift richt zich op het gebruik van de PAT principes 
op een PER.C6® celkweek perfusie proces voor productie van virale vaccins. Het doel 
van dit proces is om PER.C6® culturen te laten groeien tot een hoge celdichtheid met 
behulp van perfusie. Omdat deze cellen vervolgens worden gebruikt om de volgende 
stap in het virus productie proces te starten, wordt onderzocht welke proces parameters 
de kwaliteit en geschiktheid van deze cellen voor virus productie beïnvloeden. Deze 
kwaliteitseigenschappen (of CQAs) waren vooralsnog niet gedefinieerd voor PER.C6® 
cellen, die dienen als substraat voor virus productie. Daarnaast is het effect van variatie 
van de kwaliteit van deze cellen op virus infectie en proliferatie niet volledig begrepen. De 
doelstellingen van dit proefschrift zijn dan ook om de CQAs van PER.C6® cellen gebruikt 
voor virus productie vast te stellen en om de meest geschikte analytische instrumenten 
(PAT) voor het optimaal controleren van perfusie cel cultuur processen te implementeren. 
Allereerst moest de meest geschikte data analyse tool worden geselecteerd om de 
uitgebreide, multi-factoriale en mulit-collineaire datasets, gegenereerd tijdens celkweek, 
om te zetten in relevante proces informatie. Multivariate Data Analysis (MVDA) is een 
statistische methode, waarmee dit soort datasets kunnen worden geanalyseerd om 
het begrip van het proces te verbeteren en om relaties tussen proces parameters en 
product eigenschappen te bestuderen. MVDA is van groot belang voor industrïele (bio)
farmaceutische data, met name voor celkweek processen, waarin op MVDA gebaseerde 
modellen gebruikt kunnen worden om processen te karakteriseren en beter te begrijpen. 
MVDA is daarom een sleutelstuk voor het succesvol implementeren van PAT en QbD.
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MVDA is gebruikt om de beschikbare data van het PER.C6 perfusie celkweek proces te 
onderzoeken. Dit proces werd routineus gedraaid als onderdeel van de beginfase van 
de ontwikkeling van vaccin productie processen; hierdoor was er data van historische 
runs beschikbaar voor verdere analyse. Twee MVDA technieken zijn gebruikt om deze 
data uit te diepen: Principal Component Analysis (PCA) en Partial Least Squares (PLS). 
Hoewel de data niet voortkwam uit statisch ontworpen experimenten en daardoor niet 
altijd compleet en gestructureerd was, vergrootte deze systematische analyse van de 
data het begrip van het bestudeerde proces. Nieuwe inzichten in het proces werden 
verkregen, zoals de oorzaak van batch deviaties en de gevoeligheid van het proces voor 
de schaal waarop het uitgevoerd wordt. MVDA hielp de kennisgaten en drijfveren voor 
het controleren van procesparameters en -gedrag te identificeren.
Vervolgens heeft het onderzoek zich gericht op het begrijpen van de biologische dynamiek, 
die plaats vindt gedurende het perfusie cel cultuur proces, en om de kwaliteit van de cellen 
gebruikt voor virus propagatie vast te stellen. Eerst zijn de dynamiek van de PER.C6® 
celgroei en afsterving in perfusie en batch culturen vergeleken. Flow cytometrie analyses 
zijn gebruikt om 3 fases van de apoptose cascade te meten. Deze analyses lieten zien dat 
nutrient depletie en de accumulatie van metabolieten apoptotische celdood induceerde 
in batch culturen. In perfusie culturen bleef apoptose echter op een constant laag niveau. 
Nadat dit vast gesteld was, was de volgende stap om de parameters, die de bruikbaarheid 
van  PER.C6® om virus tot een hoge opbrengst te kunnen propageren, te evalueren. 
Een nieuwe test werd ontwikkeld om de geschiktheid van PER.C6® (de “infectability”) 
voor adenovirus propagatie te meten. In deze test worden zowel de kinetiek van het 
infectie process als de kinetiek van de virus productie gemeten. Iinfectability metingen 
zijn vergeleken tussen exponentieel groeiende batch culteren met een hoge viabiliteit en 
perfusieculturen met standaard en substandaard celkweek condities. Deze studie liet zien 
dat de infectability van PER.C6® zeer robuust is gedurende het hele standaard cultivatie 
proces alsook onder substandaard condities. Deze studies over de CQAs van PER.C6® 
cellen toonden de robuustheid van de cellen in het perfusie proces aan. Daarom is 
aangenomen dat de belangrijkste CQA voor PER.C6® cellen bij een hoge celdichtheid 
verkregen uit een perfusie celkweek de viabiliteit van deze cultuur is. 
Vervolgens werd gekeken wat de meest relevante online PAT tools om het proces te 
monitoren zijn. Naast het verzamelen van informatie over de CQAs van de cellen, 
moeten PAT tools ook de ‘key performance attributes’ kunnen monitoren, die 
gerelateerd zijn aan de economische performance en efficiency van het proces. 
Dielectric Spectroscopy (DS) en Near Infrared Spectorscopy (NIR) zijn twee geavanceerde 
PAT tools, die gebruikt kunnen worden om zowel de CQAs van het product alsook 
de ‘key performance attributes’ van het PER.C6® perfusie celkweek proces te kunnen 
monitoren. De modellen die ontwikkeld zijn hebben het mogelijk gemaakt om vanuit 
DS en NIRS data nauwkeurige voorspellingen te doen van respectievelijk de dichtheid 
van levende cellen, en de concentratie van glucose en lactaat. De studie liet verder 
zien dat de filtraat vloeistofstroom uit het perfusieproces een goede weerspiegeling is 
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van de daadwerkelijke cellulaire matrix. Hierdoor geeft deze stroom een uitstekende 
mogelijkheid om online metingen te doen zonder de kweek zelf te bemonsteren of 
gebruik te maken van invasieve probes. 
Dit proefschrift beschrijft de gestructureerde en systematische aanpak, die nodig is om 
het PAT principe toe te passen op een perfusie celkweek proces. De identificatie van 
de CQAs van de PER.C6® cellen en de evaluatie van de PAT tools om processen te 
monitoren maakte een fundamenteel begrip van het proces en de bestudeerde cellijnen 
mogelijk. Deze pogingen zijn van cruciaal belang om verdere QbD/PAT stappen te 
kunnen maken en om goede proces controle te kunnen ontwerpen. 
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Process Analytical Technology (PAT) est une initiative qui a été présentée par l’instance 
américaine de réglementation des produits alimentaires et de santé (Food and Drug 
Administration, FDA) au début des années 2000. Cette initiative encourage les industries 
pharmaceutique et biotechnologique à améliorer le suivi des procédés de production et 
le contrôle qualité des produits issus de ces industries. PAT a pour objectif de contrôler 
tous les paramètres opérationnels de production critiques (critical process parameters, 
CPPs) ayant un effet sur la qualité des produits (critical quality attributes, CQAs) ou sur 
le rendement des procédés de fabrication. Le but final est d’assurer de façon constante 
la bonne qualité des produits, et ce durant la totalité du procédé de fabrication. Pour ce 
faire, le concept PAT s’appuie sur les connaissances fondamentales et scientifiques des 
procédés de production ainsi que sur le contrôle de tous les CPPs.
Depuis la présentation de PAT par la FDA, cette initiative a été largement adoptée par 
l’industrie pharmaceutique classique (chimique), pour laquelle les procédés de fabrication 
sont globalement plus simples que ceux de l’industrie biotechnologique. De plus, l’impact 
de ces procédés sur la qualité des produits est généralement bien compris et caractérisé. 
La mise en œuvre de PAT pour les procédés de biotechnologie, et en particulier pour 
l’étape de culture cellulaire de ces procédés, est plus délicate. Les biomolécules produites 
sont beaucoup plus grosses et de nature plus complexe que les produits chimiques, 
puisqu’elles peuvent être par exemple des micro-organismes entiers ou des sous-unités de 
ces organismes. Comprendre et caractériser l’influence des procédés de production sur 
ces biomolécules complexes est donc plus difficile. De plus, l’étape de culture cellulaire est 
d’une importance particulière dans les procédés de production des biomolécules puisque 
c’est lors de cette étape que se forment les produits d’intérêt.
Le projet de recherche décrit dans cette thèse se concentre sur l’application des principes 
de PAT en biotechnologies, et plus particulièrement à un procédé de culture de cellules 
PER.C6® opéré en perfusion pour la production de vaccins viraux. Cette opération unitaire 
a pour objectif de cultiver les cellules PER.C6® en perfusion jusqu’à atteindre une très haute 
densité cellulaire. Ces cellules sont alors utilisées comme substrat pour la production de 
virus au cours d’une seconde opération unitaire. Une hypothèse a été formulée quant 
au lien entre la fluctuation de la qualité de ces cultures PER.C6® à haute densité et le 
rendement de l’étape suivante de production de virus.  Par conséquent, un projet de 
recherche a été initié afin d’identifier les paramètres du procédé de culture cellulaire en 
perfusion affectant la qualité des cellules PER.C6® ainsi que l’aptitude de ces cellules à 
produire des virus. Cependant, les caractéristiques qui déterminent la qualité des cellules 
PER.C6® pour la production de virus (en d’autres termes les CQAs) ne sont pas clairement 
définies. De plus, l’influence de la qualité des cellules PER.C6® sur l’attachement des 
virus à ces cellules, sur le processus d’infection et sur la réplication des virus n’est pas 
entièrement comprise. Les objectifs de cette thèse sont donc d’identifier les CQAs des 
cellules PER.C6® utilisées pour la production de virus et de mettre en place les outils de PAT 
les plus appropriés pour un suivi optimal du procédé de culture cellulaire en perfusion.
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Les procédés de culture cellulaire génèrent des ensembles de données qui sont 
particulièrement denses, complexes, multi-factoriels et multi-colinéaires. L’identification 
d’un outil d’analyse capable de transformer ces ensembles de données en information 
pertinente a été un prérequis à cette étude. L’analyse multivariée de données (multivariate 
data analysis, MVDA) est un outil statistique capable d’explorer ces ensembles de 
données complexes pour approfondir la compréhension des procédés et pour étudier 
les relations entre les paramètres opérationnels et les réponses du procédé (qualité du 
produit et rendement). L’importance de la MVDA pour analyser les données des industries 
pharmaceutique et biotechnologique est présentée dans cette thèse, en particulier pour 
les procédés de culture cellulaire pour lesquels des modèles issus de la MVDA sont très 
utiles pour acquérir une compréhension plus approfondie des procédés. La MVDA est 
donc un élément-clé pour la réussite de la mise en œuvre des principes de PAT.
Une analyse multivariée MVDA a été utilisée pour étudier les données disponibles sur 
le procédé de culture de cellules PER.C6® en perfusion. Ce procédé  a été exécuté 
régulièrement pendant les phases précoces de développement  pour la production de 
vaccins. Par conséquent, de plus en plus de données historiques étaient disponibles pour 
de plus amples analyses. Les analyses des composantes principales (principal component 
analysis, PCA) et des moindres carrés (partial least squares, PLS) sont les deux techniques 
de MVDA qui ont été utilisées pour modéliser les ensembles de données disponibles. 
Ces derniers n’avaient pas été générés à partir de plans d’expérience conçus avec des 
outils statistiques et contenaient des données manquantes. Néanmoins, l’utilisation de la 
MVDA pour une analyse systématique et structurée de ces données a permis d’améliorer 
la compréhension du procédé étudié. De nouvelles informations ont été révélées, comme 
les causes de déviation du procédé et la sensibilité du procédé à l’échelle à laquelle il 
est exécuté. La MVDA a permis d’identifier ces lacunes et a mis en évidence le besoin 
d’améliorer le suivi des paramètres opérationnels et des réponses du procédé. 
Le projet de recherche a ensuite porté sur la compréhension des processus dynamiques 
qui ont lieu au cours du procédé de culture de cellules PER.C6® en perfusion, et sur 
l’évaluation de la qualité de ces cellules utilisées pour la production du virus. Les 
paramètres biologiques et cellulaires qui affectent  l’aptitude des cellules PER.C6® à 
fixer les virus, à être infectées et finalement à répliquer les virus ont été étudiés afin 
d’identifier les CQAs de ces cellules. Tout d’abord, les cinétiques de croissance et de mort 
des cellules PER.C6® ont été comparées au cours de procédés de culture en perfusion et 
en batch. La cytométrie de flux a été utilisée pour détecter trois étapes différentes dans 
le processus d’apoptose des cellules. Cette étude a montré que lors des cultures en 
batch, l’épuisement des nutriments et l’accumulation des déchets métaboliques  induit la 
mort cellulaire par la voie de l’apoptose. En revanche, dans des cultures en perfusion, 
l’apoptose est constante et à un faible niveau. L’étape suivante a ensuite consisté à 
évaluer les paramètres pouvant influencer la capacité des cellules PER.C6® à être 
infectées par des virus et à propager ces virus à des rendements élevés. Un test innovant 
a été mis au point pour capturer l’aptitude des cellules PER.C6® à répliquer l’Adénovirus, 
en d’autres termes leur “infectabilité”. Lors de ce test, les cinétiques des processus à la 
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fois d’infection de la population cellulaire et de production de virus ont été mesurées. 
Les mesures d’infectabilité ont été comparées pour des cellules en phase de croissance 
exponentielle et avec une viabilité élevée, et pour des cellules cultivées en perfusion 
dans des conditions de fonctionnement soit normales, soit sous-optimales. Cette étude a 
montré que l’infectabilité des cellules PER.C6® par des Adénovirus est très robuste tout au 
long de la culture en perfusion et même sous des conditions de culture sous-optimales.
Dans l’ensemble, ces études sur les CQAs des cellules PER.C6® ont montré la robustesse 
de ces cellules lorsqu’elles sont cultivées en perfusion. Il a donc été postulé que le 
principal CQA des cultures de cellules PER.C6® à haute densité obtenues par un procédé 
en perfusion peut être évalué par la simple mesure de la viabilité de ces cultures. La 
dernière étape de ce projet de recherche a finalement consisté à identifier les outils 
PAT les plus pertinents pour suivre en ligne le procédé de culture en perfusion. En plus 
de collecter des informations relatives aux CQAs des cellules, ces outils PAT doivent 
également permettre de suivre les paramètres rendant compte de la performance 
du procédé (key performance attributes, KPAs), qui sont liés à la productivité et au 
rendement économique du procédé. Le taux de croissance cellulaire spécifique a été 
identifié comme étant un KPA du procédé de culture en perfusion. En effet, les hautes 
densités cellulaires nécessaires avant d’entamer l’opération unitaire de production 
virale doivent idéalement être atteintes en un minimum de temps. La spectroscopie 
diélectrique (dielectric spectroscopy, DS) et la spectroscopie proche infrarouge (near-
infrared spectroscopy, NIRS) sont deux outils PAT qui peuvent être utilisés pour suivre les 
CQAs des cultures PER.C6® ainsi que les KPAs du procédé de culture en perfusion. Des 
modèles statistiques ont été développés pour prédire précisément la densité cellulaire 
et les concentrations en glucose et en lactate. De plus, cette étude a montré que le flux 
de perfusion reflète étroitement les conditions de culture présentes dans un bioréacteur 
et donc offre une excellente opportunité de suivre les cultures en ligne sans besoin de 
sondes additionnelles ou d’échantillonnage excessif. 
Pour conclure, cette thèse apporte une démonstration de l’approche structurée et 
systématique à suivre pour appliquer le principe de PAT à un procédé de culture de cellules 
en perfusion. L’identification des CQAs des cellules PER.C6® et l’évaluation des outils PAT 
pour le suivi de leur procédé de culture a permis d’acquérir des connaissances et une 
compréhension fondamentales sur le procédé et sur la lignée cellulaire étudiée. Ces efforts 
sont absolument indispensables avant que la mise en œuvre plus approfondie du concept 
PAT puisse être envisagée et que la stratégie de contrôle du procédé puisse être optimisée.
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